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Abstract 
Type 2 diabetes mellitus (T2DM) is a complex disease involving various 
physiological factors, hormones and metabolites. Over expression of key 
gluconeogenic enzymes, such as PEPCK, cause features of T2DM including obesity 
and insulin resistance. Previous studies showed intravenous administration of 
corticotropin releasing factor (CRF) and sauvagine in rats cause marked 
hyperglycaemia, which is adrenal dependent. The 11-β hydroxylase inhibitor 
metyrapone augmented this hyperglycaemia raising important questions about the role 
of known and unknown corticosteroids in hepatic carbohydrate metabolism.  
The goal of this project was to identify and characterise the gluconeogenic activity of 
adrenal corticosteroids secreted under basal and stimulated conditions. This was 
accomplished by establishing a rapid, sensitive and robust multi-well assay for 
measurement of PEPCK activity in the hepatocyte cell line H4-II-E-C3. A sensitive 
fluorescent method for assay of glucose production by these cells was also developed. 
Extracts of media samples from adrenal glands incubated with sauvagine and 
metyrapone significantly increased hepatocyte glucose production (HGP) despite low 
corticosterone concentrations. HPLC characterisation of these extracts revealed 
increases in 11-deoxycorticosterone (DOC) and other unidentified peaks. However, 
none of these individual fractions significantly affected HGP in culture. 
Commercially available corticosterone, which contains DOC as an impurity, had 
greater gluconeogenic effect compared to purified corticosterone alone. Based on 
these observations and discrepancies in the literature, the effect of DOC on hepatic 
carbohydrate metabolism was characterised. Surprisingly, DOC suppressed the 
activity of gluconeogenic enzyme PEPCK in fed rat hepatocytes and enhanced insulin 
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stimulated glycogen stores in cultured hepatocytes at higher glucose concentrations 
(25 mM) over a 24 hour period.  In serum-starved, fasted hepatocytes these effects 
were not significant, suggesting the need for a detailed investigation of the signalling 
pathways and regulatory control of DOC on GK, GS, G6Pase and PEPCK. 
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Chapter 1 
          General Introduction 
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1.1 Overview 
Type 2 diabetes mellitus (T2DM) is a complex and heterogeneous disease with a 
poorly understood aetiology. It is characterised by impaired beta cell function and 
varying degrees of insulin resistance leading to reduced tissue uptake of glucose and 
varying degrees of hyperglycaemia (Gerich, 1998). It is generally considered that 
there is a strong genetic predisposition, which becomes evident when exposed to a 
sedentary western lifestyle.  
Since 2006 many studies have been published based on High-Throughput genome 
wide association (GWA) studies. These studies have uncovered new genetic loci 
linked to diabetes. Five large studies were conducted using a two-stage strategy 
consisting of a GWA screen in an initial cohort of unrelated cases and controls 
followed by replication of the most significant findings in additional sets (Florez et 
al., 2007; Hanson et al., 2007; Hayes et al., 2007; Rampersaud et al., 2007; Salonen 
et al., 2007). From these studies at least fifteen loci emerged as being consistently 
associated with T2DM across multiple studies. Three of these (TCF7L2, KCNJ11, 
and PPARG) have already been linked with T2DM. The other 12 represent potential 
new T2DM genes (Table 1.1).  
T2DM has increased rapidly over the past 30 years. According to the World Health 
Organisation (WHO), the numbers of cases worldwide are around 170 million and the 
number is expected to rise to 350 million by 2025 (Wild et al., 2004). The 
predominant reasons for the global rise in T2DM are obesity, physical inactivity and 
the increasing number of elderly people. Of the existing diabetes worldwide, 95% 
suffer from T2DM.  
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Gene 
Symbol 
Cellular Function OMIM 
Number 
Odds 
Ratio 
Frequency of 
Risk Allele 
NOTCH2 Regulator of cell differentiation 600275  1.13 0.11 
THADA Unknown 611800 1.15 0.90 
ADAMT
S9 
Proteolytic enzyme regulating 
extracellular matrix 
605421 1.09 0.76 
PPARG Transcription factor receptor for TZDs 
and prostaglandins 
601487 1.17 0.85 
IGF2BP2 IGF2 mRNA-binding protein 2 608289 1.14 0.29 
CDKAL1 Presumed regulator of cyclin kinase 611259 1.0-
1.20 
0.31 
JAZF1 Zinc-finger protein of unknown 
function 
606246 1.10 0.50 
SLC30A8 Zinc transporter 8 611145 1.18 0.65 
CDKN2A 
CDKN2B 
Cyclin-dependent kinase inhibitor 2A 
and 2B 
600431 1.20 0.83 
CDC123 
 
Required for S phase entry of the cell 
cycle 
 1.11  0.18 
CAMK1
D 
Mediator of chemokine signal 
transduction in granulocytes 
607957   
IDE 
 
Neutral metallopeptidase that can 
degrade many peptides 
146680 1.13 0.53 
HHEX 
 
Homeobox transcription factor 604420   
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KIF11 Kinesin related motor in microtubule 
& spindle function 
148760   
TCF7L2 High mobility group transcription 
factor 
602228 1.31-
1.71 
0.26 
KCNJ11 Inwardly rectifying potassium channel 600937 1.14 0.47 
TSPAN8 Cell surface glycoprotein 600769 1.09 0.27 
LGR5 Orphan G protein receptor 606667   
FTO 58kD protein with nuclear localization 
signal 
610966 1.27 0.38 
 
Table 1.1: Genetic loci in “common variety” in T2DM (Doria et al., 2008). 
WHO estimates that there are also 1.6 billion people who are overweight and around 
400 million are obese worldwide. Obesity is a major concern as there is clear 
evidence of an association with the risk of developing T2DM (Gruber, 2006). 
Sedentary lifestyle, lack of exercise, consumption of foods rich in saturated fat and 
sugar lead to an increase in obesity (Swinburn et al., 2004), resulting in insulin 
resistance and subsequent T2DM (Caterson et al., 2002). Although there is a strong 
association between excess body fat and T2DM, not all obese and overweight subjects 
develop diabetes. The relationship to the risk of T2DM is closer in subjects with 
abdominal obesity (Bordier et al., 2009). This is also consistent with increased 
visceral fat being linked to insulin resistance and dyslipidaemia; two characteristics of 
the metabolic syndrome and T2DM. The majority of patients with T2DM suffer from 
hypertension, as well as microvascular and macrovascular diseases which result in a 
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high incidence of cardiovascular disease, blindness, amputation and renal failure 
(2008). 
The aetiology of type 2 diabetes primarily involves peripheral insulin resistance and 
impaired insulin secretion, but several other defects contribute to the development and 
progression of type 2 diabetes. These include increased hepatic glucose production, a 
lack of glucagon suppression, impaired incretin signalling, and increased expression 
and activity of renal glucose transport proteins (Tahrani et al., 2009). Together, all of 
these factors contribute to hyperglycaemia; in turn, the resulting glucotoxicity 
worsens all of these defects. Increased hepatic glucose production due to 
dysregulation of gluconeogenesis and glycogen metabolism and decreased glucose 
uptake can cause hyperglycaemia (Clore et al., 1992; Krssak et al., 2004). In T2DM 
this hyperglycaemia is not controlled because of defects in insulin secretion and 
action. It is now well recognised that in addition to the defects in secretion of insulin 
and tissue sensitivity to the actions of insulin, there are a number of other hormones 
that potentially play a role in development and progression of T2DM. 
As the molecular defects causing diabetes are still largely unknown the factors 
triggering insulin resistance or deficiency as a primary defect still need to be resolved. 
Steroids derived from the adrenal gland are well known glucose modulators with 
glucocorticoids closely linked with hyperglycaemia and T2DM (McMahon et al., 
1988). However research of various clinical conditions exhibiting insulin resistance or 
hyperglycaemia raise interesting questions about adrenal abnormalities that may 
underline T2DM.  
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1.2 Pathophysiology of type 2 diabetes mellitus 
1.2.1 Abnormalities in insulin secretion 
T2DM involves impairments in both insulin secretion and insulin sensitivity 
(DeFronzo et al., 1989). Insulin sensitivity is determined by the ability of insulin to 
promote glucose uptake and utilization. Normally insulin displays rapid variations in 
blood concentrations with early secretory peaks every 5 – 10 min and larger 
oscillations every 60 – 120 min. However in patients with overt T2DM these 
secretory peaks are found to be reduced or absent (O'Rahilly et al., 1988; Polonsky et 
al., 1988). In experimental models normal insulin secretion in response to intravenous 
glucose is characterised by an early peak after 3 – 5 min followed by a slower and 
more progressive phase that lasts as long as the glucose infusion. In T2DM this first 
phase is abolished, and the late phase is reduced and delayed (Cerasi et al., 1967; 
Fujita et al., 1975). This early phase insulin secretion suppresses hepatic glucose 
production during the transition stage from fasting to the fed state (Luzi et al., 1989). 
Specific immunoassays have shown that insulin deficiency in T2DM is often masked 
by unprocessed circulating pro-insulin. These prohormones may account for more 
than 40% of circulating insulin immunoreactivity in T2DM compared to 5% in non-
diabetics (Temple et al., 1990). Insulin secretory capacity is decreased by 50% at the 
time of diagnosis with a further decrease of 15% six years later (UKPDSG, 1995). 
This progressive reduction has been attributed to glucotoxicity (Rossetti et al., 1990), 
lipotoxicity (Unger, 1995), advanced glycation of the insulin promoter gene 
(Matsuoka et al., 1997), and excess reactive oxygen species causing β-cell apoptosis 
(Butler et al., 2003; Sakuraba et al., 2002). Overall a 20 – 40% reduction in β-cell 
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mass is present in T2DM in contrast with β-cell hyperplasia observed in insulin 
resistant states associated with non diabetic obesity (Biarnes et al., 2002). 
TCF7L2 is a gene that was found to predict high susceptibility to T2DM; accounting 
for 20% of cases (Grant et al., 2006). This gene was found to be associated with 
alterations in insulin secretion with severely impaired insulin secretion in carriers of 
the susceptibility variants (Saxena et al., 2006). Low birth weight has also been 
associated with decreased β-cell mass and an increased chance of developing 
impaired glucose tolerance (IGT) and T2DM during adulthood (Hales et al., 1991). 
There is a hyperbolic relationship between insulin secretion and sensitivity (Weyer et 
al., 1999). β-cells in non-diabetics adapt their secretion rate according to the level of 
insulin sensitivity. If this compensation is impaired it results in hyperglycaemia. 
1.2.2 Insulin resistance and endogenous glucose production 
In addition to the deficiency of insulin some of the earliest studies showed variations 
in the responses of diabetic patients to insulin, suggesting the role of insulin 
insensitivity as the biochemical defect. This was supported by radioimmunoassay data 
that showed that subjects with adult (onset) T2DM had more than average circulating 
levels of insulin (Yalow et al., 1960). Although a high proportion of this circulating 
insulin was later reported to be pro-hormones (Temple et al., 1990).  
Insulin resistance can be explained as an increased hepatic glucose production and 
decreased glucose uptake by skeletal muscle. A primary defect in insulin signalling 
pathways and dysfunction in adipose tissue further contributes to insulin resistance. 
Individuals who develop T2DM proceed through a phase of impaired glucose 
tolerance IGT (Tuomilehto et al., 1992) as a result of defects in insulin secretion and 
action. As the tissues become more and more resistant to insulin, pancreatic β cells 
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secrete more insulin to compensate for this resistance. However, progressive β cell 
failure leads to an inability to compensate for insulin resistance which results in post-
prandial hyperglycaemia, and eventually the fasting hyperglycaemia of the diabetic 
state. The risk of progressing from IGT to T2DM is known to vary depending on the 
population, ethnicity, obesity and other cardiovascular risk factors (Alberti, 1996). As 
long as pancreatic β cells compensate for the insulin resistance the disease never 
progresses from IGT to T2DM. A number of trials have shown a greater than 50% 
reduction in progression of IGT to T2DM by lifestyle measures which include 
moderate exercise and diet (Tuomilehto et al., 2001). 
The transition from a pre-diabetic state to T2DM is characterised by three major 
changes 
a) A reduction in insulin secretion by pancreatic β cells. 
b) Overproduction of glucose by the liver. 
c) Insulin resistance in the skeletal muscle  
The manifestation of insulin resistance in T2DM is generally attributed to decreased 
glucose transport and metabolism in fat cells and skeletal muscle. Inability to suppress 
hepatic glucose output is also a major factor (DeFronzo, 2004). So, insulin resistance 
in the liver contributes to hepatic glucose production causing hyperglycaemia. 
Although the general assumption is that insulin resistance results in increased 
endogenous glucose production, there is also a possibility of a change in the hepatic 
metabolic flux that can lead to insulin insensitivity. Some studies showed that 
increases in the gluconeogenic regulator fructose 2,6-bisphosphate can overcome 
insulin resistance in T2DM (Wu et al., 2006). 
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1.2.3 Insulin sensitivity and glucose transport 
Obesity is characterised by insulin resistance. Eighty percent of all subjects with 
T2DM are obese. Also, obese individuals with T2DM are more insulin resistant than 
those without diabetes (DeFronzo et al., 1996). In T2DM hepatic glucose production 
is uninhibited and peripheral glucose uptake is reduced in response to insulin. This 
indicates that both liver and peripheral tissues are involved in insulin resistance. 
Skeletal muscle is the major tissue responsible for insulin-mediated glucose uptake. It 
was quickly established that insulin resistance in skeletal muscle and liver did not 
result from a defect in the insulin receptor number but from a defect in the insulin 
signalling pathway (Garvey et al., 1993). Furthermore, it was clearly demonstrated 
that insulin resistance in skeletal muscle is due to defects in insulin-dependent glucose 
transport (Bell et al., 1993). Due to the hydrophilic nature of glucose it cannot 
penetrate the lipid bi-layer of cell membranes and needs specific transporter proteins 
to facilitate its diffusion. This is mediated by two distinct families of hexose transport 
proteins: facilitative glucose carriers [glucose transporters (GLUTs)] and sodium 
glucose carriers (SGLTs) (Bell et al., 1993). Within the facilitative glucose 
transporters, class I transporters (GLUT 1, GLUT 3, and GLUT 4) have a high 
affinity for glucose and the level of these proteins on the cell surface greatly influence 
the rates of glucose uptake into cells. Of the three Class I GLUTS, GLUT 4 mediates 
insulin-stimulated glucose uptake by skeletal muscle, heart, white and brown adipose 
tissues by a mechanism involving translocation between cellular compartments. 
Insulin increases the cell surface expression of this protein by increasing the rate of 
externalisation and decreasing the rate of internalisation (Jhun et al., 1992). The 
fundamental role of GLUT4 was demonstrated in animal models where muscle 
specific over expression significantly improved insulin action and reduced blood 
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glucose levels (Leturque et al., 1996; Rencurel et al., 1996). Several other studies 
have also shown that insulin increases glucose uptake in cells by stimulating the 
translocation of glucose transporters (GLUT4) to the cell surface from intracellular 
sites. Up to 75% of insulin dependent glucose disposal occurs in the skeletal muscle, 
whereas adipose tissue accounts for only a small fraction of this (Klip et al., 1990). 
However, mice with an insulin receptor knockout in muscle had normal glucose 
tolerance (Bruning et al., 1998), and those with knockout of insulin sensitive glucose 
transporter in fat developed impaired glucose tolerance (Abel et al., 2001). This 
highlights the important role of adipose tissue in regulating glucose metabolism. It is 
also interesting to note that exercise causes an increase in AMPK in muscle, which in 
turn increases GLUT4 translocation in response to insulin (Goodyear et al., 1998). 
As the molecular defects causing diabetes are still largely unknown the factors 
triggering insulin resistance or deficiency as a primary defect still need to be resolved. 
Skeletal muscle, adipose tissue and the liver are all involved in the development of the 
disease state but, the most important site of insulin resistance is still the subject of 
debate (DeFronzo, 2004). Apart from insulin resistance and sensitivity, endogenous 
glucose production and dysregulation of gluconeogenesis are considered to be the key 
areas of inadequate understanding in T2DM, with excess hepatic glucose production 
being a major contributor to both fasting and postprandial hyperglycaemia in T2DM. 
Promising biological targets being investigated include those leading to insulin 
sensitization (11β-HSD-1 inhibitors, and antagonists of glucocorticoid receptor), 
reducing hepatic glucose output (antagonist of glucagon receptor, inhibitors of 
glycogen phosphorylase and fructose-1,6-biphosphatase), and finally increasing 
urinary elimination of excess glucose (SGLT inhibitors).  
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1.2.4 Adrenocortical dysregulation. 
Adrenal glucocorticoids are increasingly implicated in the pathogenesis of metabolic 
syndrome (MS). Increased adrenal corticosteroid production represents an important 
pathogenic pathway in MS, T2DM, Cushing’s syndrome and other disease states such 
as Polycystic ovary syndrome (PCOS), which exhibit insulin resistance and 
hyperglycaemia (Vassiliadi et al., 2009). Alterations in carbohydrate metabolism 
occur in adrenalectomised animals. Administration of adrenal extracts raise blood 
sugar levels and liver muscle glycogen in both adrenalectomised and normal animals 
(Long et al., 1940). The most interesting finding linking the adrenal gland with the 
diabetic state is that adrenalectomy in obese Zucker rats prevents hyperinsulinaemia 
(Freedman et al., 1986). Similarly, in diabetic (ob/ob) mice, adrenalectomy reduces 
plasma insulin and glucose levels (Makimura et al., 2000). Animal models of 
lipoatropic diabetes have elevated glucocorticoids. Adrenalectomy in these models 
decreased the blood glucose, serum insulin, and glycated hemoglobin levels (Haluzik 
et al., 2002). These mice also showed improved insulin sensitivity in both muscle and 
liver after adrenalectomy. 
Although it is generally assumed that adrenalectomy simply eliminates the metabolic 
actions of corticosterone, such studies are not specifically aimed at investigating the 
effects of specific glucocorticoids and thus do not eliminate a role for other adrenal 
steroids and metabolites. The defects observed in adrenalectomised animals were not 
due to impaired cAMP production or subsequent signalling pathways. Freedman in 
his observations quoted that the "nature of the defect following adrenalectomy is 
elusive and not easily reproducible". This was based on the observations that 
adrenalectomy of obese Zucker rats improved insulin resistance (Freedman et al., 
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1986). The hypothalamic pituitary-adrenal axis (HPA) plays an important role in the 
tight regulation of the circulating levels of glucocorticoids. However, glucocorticoid 
levels are locally enhanced in the liver and adipose tissue by the enzyme 11β-HSD1 
(Tomlinson et al., 2004). Transgenic mice with over expression of 11β-HSD1 either 
in adipose tissue or the liver exhibited components of MS (Masuzaki et al., 2001). 
It is now well accepted that glucocorticoids generally mobilise substrates for 
gluconeogenesis by stimulating the release of amino acids from skeletal muscle, fatty 
acids and glycerol from adipose tissue, and have a direct effect on gluconeogenic 
enzymes like phosphoenolpyruvate carboxykinase (PEPCK) (Gunn et al., 1975). 
They also stimulate glycogen synthesis by activating glycogen synthase and 
inactivating the glycogen-mobilizing enzyme glycogen phosphorylase. 
There has been an association between enlarged adrenal glands and T2DM in obese 
patients (Godoy-Matos et al., 2006). Adrenal gland weight is also higher in rats fed a 
high-fat diet (Pitts et al., 1977). From these observations it is important to look in 
more detail the role of adrenal corticosteroids in the collective effect on glucose 
homeostasis both in vivo and in vitro. 
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Figure 1.1 Overview of the pathogenesis of T2DM. 
Current theories on T2DM include insulin resistance of muscle, dysfunction of 
adipocytes, and dysfunction of pancreatic β cells, obesity, excess hepatic glucose 
output, and genetic predisposition.  
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1.3 Adrenal corticosteroids 
The adrenal cortex synthesises and secretes steroids while the medulla produces 
catecholamines and neuropeptides (Delarue et al., 2001). The zona glomerulosa is 
specialized in the production of aldosterone whereas the zona fasciculata and zona 
reticularis synthesise glucocorticoids (Stewart et al., 1972). In humans and other 
primates the zona reticularis and to a lesser extent the zona fasciculata produce C19 
androgens including large amounts of precursor’s dehydroepiandrosterone (DHEA) 
and DHEA-sulphate (Rainey et al., 2004). Glucocorticoids and C19 steroids secretion 
are mainly controlled by adrenocorticotropic hormone (ACTH), whereas aldosterone 
secretion is mainly regulated by angiotensin II (ANG II). However, in physiological 
conditions, all adrenal steroids may also be regulated by a complex interaction of 
several systemic or paracrine factors (Ehrhart-Bornstein et al., 1998). 
1.3.1 Corticosteroid receptors 
Mineralocorticoids (aldosterone, deoxycorticosterone) and glucocorticoids 
(corticosterone, cortisol) bind to corticosteroid receptors which belong to the large 
superfamily of 48 nuclear receptors proteins that are involved in eukaryotic gene 
expression. The corticosteroid receptors are mineralocorticoid receptor (MR) and the 
glucocorticoid receptor (GR). Detailed biochemical studies of these receptor proteins, 
which were partially purified, revealed that their domain structure (N terminal, central 
DNA binding domain and the C-terminal) is very similar within the family of receptor 
proteins. 
The progesterone and androgen receptors share many structural and functional 
features with MR and GR. 
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1.3.2 Structural domains of corticosteroid receptors 
There are three main domains that are described as part of these receptors: 1) N-
terminal region, 2) the central DNA binding domain, and 3) C-terminal region. 
N-terminal region  
This region differs the most among the receptor types in size and amino acid 
sequence. It contains the ligand independent activation function 1 (AF1) region. It is 
considered that this region acts as a docking platform for the recruitment of chromatin 
remodelling proteins (Warnmark et al., 2003).  
DNA binding domain 
The central DNA binding domain is the most conserved between the receptor types. 
This region confers the specificity for the recognition of the hormone response 
element in gene promoter regions. It is also considered that the hinge region between 
the DNA binding domain and the C-terminal region contains nuclear localization 
signal motifs (Tyagi et al., 1998). 
C-terminal region 
This region serves as the ligand binding domain of the receptor and serves many 
essential functions. It contains the specific binding pocket for the steroid hormone. 
Crystal structure studies have shown that the ligand binding induces a conformational 
change in the α-helix of the C-terminal region. This leads to a protein surface that 
allows interactions with transcriptionally active proteins. This surface is called the 
ligand-dependent activation function 2 (AF2).  
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1.3.3 Variants of corticosteroid receptors 
The genes coding for GR and MR have similar DNA sequences composed of 9 exons.  
For both GR and MR, several different transcripts that differ in the 5´-untranslated 
region give rise to the same identical receptor proteins (Patel et al., 1989; Turner et 
al., 2005). 
The human GR receptor has 3 splice variants that result in two distinct mRNAs and 
proteins namely GRα and GRβ. In GRβ, the 50 C-terminal amino acids are lacking. 
This makes it transcriptionally inactive, which has led to suggestions that it acts as a 
dominant negative transcription factor (Yudt et al., 2003). Both the MR and GR 
receptors have different translation variants which differ in their transcriptional 
capacities and are expressed in a tissue-dependent manner (Yudt et al., 2002). From 
these studies it suggests that MR or GR receptors are a set of closely related and 
possibly functionally different proteins that may differ in hormone sensitivity and 
intrinsic activity. 
1.3.4 Expression of the corticosteroid receptors 
Of the two receptors the GR is present in almost all tissues. It is highly expressed in 
the immune system, bone, lungs, liver, adipose tissue and the brain. These expression 
levels reflect the main clinical use (anti-inflammatory) and side effects (hepatic 
glucose output) of synthetic glucocorticoids. MR expression was initially shown by 
immune-histochemistry in kidney (Krozowski et al., 1989; Lombes et al., 1990). MR 
expression was also detected in the colon (Lombes et al., 1984), lung (Krozowski et 
al., 1981), sweat glands (Kenouch et al., 1994), liver (Duval et al., 1974) and in the 
inner ear (Teixeira et al., 2006).  In the brain both the MR and GR are co-localised in 
the hippocampus. 
34 
 
1.3.5 Selectivity of the corticosteroid receptors 
The MR is capable of binding mineralocorticoids (aldosterone, 11-
deoxycorticosterone), glucocorticoids (corticosterone, cortisol) and progesterone with 
high affinity. Aldosterone is considered to be the main primary ligand for MR in vivo 
in most tissues. In some tissues cortisol may be the primary ligand for MR.  
1.3.6 Mechanism of action of corticosteroid receptors 
1.3.6.1 General mechanism of action of Glucocorticoids 
In general corticosteroids enter the cells through passive diffusion across the cell 
membrane and bind to the steroid receptors in the cytoplasm. The corticosteroid 
receptors are located predominantly in the cytoplasm as multiprotein complexes 
including heat-shock proteins (HSP), immunophillins and other kinases (Gustafsson 
et al., 1987; Pratt et al., 2006). This combination of ligand and the receptor causes 
steric changes in the receptor, which leads to the dissociation of the HSPs and other 
factors. This dissociation of the GR results in its translocation from cytoplasm to the 
nucleus within minutes of glucocorticoids binding to its receptor (Buttgereit et al., 
2009). This dissociation uncovers nuclear localization motifs of the receptor. These 
motifs are recognized by the transport machinery of the cells and members of the 
importin family proteins direct the ligand activated receptor to gated channels of the 
nuclear membrane. Within the nucleus, the GR interacts with the DNA (with or 
without transcription factors) to regulate gene expression (Hager et al., 2000).  
Normally, ligand activated steroid receptors are considered to modulate the initiation 
rate of transcription (Sabbah et al., 1998). However, it is also proposed that many 
rapid random transcriptionally unproductive complexes are formed in conjunction 
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with the association of the appropriate factors at specific DNA sites. These initial 
random interactions have been proposed to be essential in scanning the whole genome 
before the sequential and ordered recruitment of the co-regulator proteins at high 
affinity binding sites (Fletcher et al., 2002).  
Although glucocorticoids have pleiotrophic effects, the target genes are mostly cell 
specific (So et al., 2007). The co-regulator protein recruitment is a major determinant 
to this effect. These proteins mediate the transduction of the signal from the DNA 
bound steroid receptors to the transcription machinery. Co-regulator proteins are 
enzymatically active and they reorganize the chromatin environment after recruitment 
by the ligand activated receptor. They exist in multi component complexes supplying 
the promoters with the variety of enzymatic activities and forming specific blocking 
platforms for the recruitment of other co-regulator proteins. Activation of the 
glucocorticoid receptor can result in either the stimulation or repression of the target 
gene (Figure 1.2). Stimulation typically involves the direct binding of GR to specific 
DNA sites called the glucocorticoid responsive elements (GREs) and subsequent 
recruitment of co-regulator proteins, most of the transactivation through DNA binding 
requires dimerisation of the GR. 
Repression is brought about by direct interference of the activated GR with other 
transcriptional factors such as activated protein 1 (AP-1) and nuclear factor kappa B 
(NFB). Transcription of the genes can also be inhibited by the direct interaction 
between activated GR and negative GREs such as alpha fetoprotein and prolactin 
genes (Sakai, 1985). It is also been suggested that glucocorticoids suppresses 
transcription of IL-1 and IL-2 via negative GREs. In general it takes hours or days 
before changes can occur on cellular tissue or organism level. However, some of the 
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immunosuppressive, anti-inflammatory and anti-allergic effects of glucocorticoids 
occur too fast to be explained by the classical genomic mechanisms of action 
(Buttgereit et al., 2002; Falkenstein et al., 2000).  
1.3.6.2 Mechanism of action of non-genomic effects of Glucocorticoids: 
At least three different mechanisms have been proposed to explain the rapid non-
genomic effects of glucocorticoids (Figure 1.3).  
Non specific interaction of glucocorticoids with cell membranes: 
It was shown that at high concentration of glucocorticoids interchelate into the cell 
membranes.  This changes the physiochemical properties of the membrane and also 
affects the activities of the membrane associated proteins (Buttgereit et al., 2002). 
This results in reduced calcium and sodium cycling across cell membranes of immune 
cells. This contributes to the rapid immunosupression and a reduction in the 
inflammatory processes (Buttgerit and Scheffold, 2002). In addition to these effects 
glucocorticoids are suggested to increase mitochondrial proton leaks resulting in 
impaired ATP production. As ATP is important for housekeeping activities of the 
immune cells it affects the functions such as cytokine synthesis, phagocytosis etc.  
Non-genomic effects caused by the cytosolic ligand activated glucocorticoid 
receptors: 
The unligated cGR is located in the cytoplasm as a multi protein complex consisting 
of HSPs and several kinases including the MAP kinases (MAPKs). Due to the 
glucocorticoids ligand binding the cGR is dissociated from these kinases. Certain 
signalling molecules like the Src are released from the GR multi protein complex. 
These Srcs are responsible for certain rapid effects observed (Croxtall et al., 2000). 
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Arachidonic acid (AA) is essential for metabolic and inflammatory reactions in 
producing prostaglandins. AA is released from the cell membrane associated 
phospholipids and is controlled by different mediators such as MAPK and lipocortin-
1. This release of AA is inhibited by glucocorticoids in a cGR dependent mechanism 
(Croxtall et al., 2000). These studies show that cGR is not only important in the 
genomic effects but also involved in the non-genomic effects.  
Non-genomic effects caused by the membrane bound glucocorticoid receptors: 
The existence of the membrane bound glucocorticoid receptor (mGR) was shown 
initially in the amphibian neuronal membranes and lymphatic cells (Gametchu et al., 
1999). These mGRs were later identified in human peripheral blood mononuclear 
cells using immunofluorescent staining (Buttgereit et al., 2004). Using this sensitive 
method it was shown that over expression of cGR did not increase the mGR 
expression on the cell surface. Hence, it is considered that the mGR is not just a cGR 
that has been transported to the cell surface. It is suggested that, it could be a splice 
variant of the GR. In patients with rheumatoid arthritis an increased number of mGR 
positive monocytes and lymphocytes correlate with higher disease activity scores 
(Buttgerait et al., 2005). Many other correlations in inflammatory diseases suggest 
that mGR may play a role in pathogenesis of chronic inflammatory disease.  
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Figure 1.2 General genomic mechanism of action of Glucocorticoids 
The glucocorticoids (GC) diffuse into the cell and bing to cytoplasmic  glucocorticoid 
receptor (cGR). This induces conformational changes causing disassociation of the 
chaperone proteins. Subsequently the receptor translocates into the nucleus and 
either induces or represses gene expression. 
 
1.3.7 Mineralocorticoid Receptor: 
Mineralocorticoid Receptor (MR) like the GR is located in cytoplasm and was cloned 
and characterized in many species. It is now regarded as a crucial transcription factor 
involved in many important physiological processes and pathological disorders 
(O'Malley, 2007). The ligand binding domain (C-terminal region) of MR contains a 
ligand dependent activation factor 2 (AF-2) consisting of helices H3, H4, H5 and 
H12. Once the ligand is bound to the MR a rearrangement of the ligand binding 
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domain (LBD) occurs forming a hydrophobic cleft on the surface. These changes are 
essential for the activation of MR transcriptional activity. Like the GR, the MR 
interacts with a variety of proteins such as HSPs, Immunophillins, etc., in its non-
liganded state. Once the mineralocorticoid binds to the MR these proteins are 
dissociated and the MR undergoes nuclear translocation. Inside the nucleus this acts 
as transcription factor by binding to specific Hormone Responsive Elements (HRE) in 
target genes. These HREs are located up to 10Kb upstream or downstream of the 
transcription start site (So et al., 2007). When the MR binds to the HREs it recruits 
chromatin remodelling complexes to release the nucleosome structure and also brings 
in the transcriptional machinery to activate transcription. In mineralocorticoid 
sensitive epithelial tissue (kidney and colon) MR regulates salt balance and water 
homeostasis by stimulating the expression of ionic transporters (ENaC, Na
+, 
K
+
-
ATPase
 
pump).  
1.3.6.1 Non genomic effects of Mineralocorticoids: 
Non genomic effects of mineralocorticoids, especially aldosterone have been 
described on various target organs like smooth muscle, endothelial cells (Wehling, 
1994), skeletal muscles, lymphocytes, cardiac myocytes (Sato et al., 1997), colonic 
epithelial cells (Doolan et al., 1996) and kidney cells (Gekle et al., 1997).  A specific 
membrane MR (mMR) has been proposed based on several studies. High affinity 
binding sites for aldosterone have also been described and the most commonly 
reported second messenger response is an increase in intracellular calcium 
concentration  (Gekle et al., 1996). It was also demonstrated that epidermal growth 
factor receptor (EGFR) is used by aldosterone to stimulate MAPK signalling cascade 
(Gekle et al., 2002). This was also shown in M1 kidney cell line. These studies 
suggest that a rise in intracellular calcium and MAPK phosphorylation may be 
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general mediators of the rapid aldosterone effects. It is also suggested that there could 
be an interaction integrating both genomic and non-genomic aspects of 
mineralocorticoids (Losel et al., 2003). Firstly, steroid hormones elicit rapid 
activation of protein kinases such as PKAs and MAPKs through non-genomic 
mechanisms and these kinases in turn phosphorylated transcription factors and co-
factors activating early genomic responses.  
 
 
Figure 1.3 Non-genomic mechanism of action of corticosteroids 
1.4 The diverse role of glucocorticoids 
Glucocorticoids (cortisol/corticosterone) exert widespread actions in the body which 
are essential for the maintenance of homeostasis and enable the organism to prepare, 
respond and cope with physical and emotional stress (Sapolsky et al., 2000). They 
promote the breakdown of carbohydrate and protein, and exert complex effects on 
lipid deposition and breakdown. They are also important regulators of immune and 
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inflammatory processes and are required for numerous processes associated with host 
defence system. These properties underlie many of the stress-protective actions of the 
steroids as they quench the pathophysiological responses to tissue injury and 
inflammation and, thereby, prevent them proceeding to a point where they threaten 
the survival of the host (Munck et al., 1992). This is also why they are used as anti-
inflammatory and immunosuppressive drugs. Glucocorticoids also have other actions. 
They raise blood pressure and have aldosterone-like effects in some cases. These 
actions were suggested to be due to their ability to alter the sensitivity of tissues to 
catecholamines. Glucocorticoids also have an effect on bone growth. In the central 
nervous system (CNS), glucocorticoids affect the growth and development of neurons 
and glial cells. During development they help in the organization of the brain and 
during adulthood they contribute to neuronal plasticity. They are also associated with 
complex changes in mood and behaviour. They affect food intake, body temperature, 
pain perception and neuroendocrine function (Brown, 2009). 
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Figure 1.4 Principal pathways for the biosynthesis of adrenocorticosteroids. 
Cholesterol, the precursor to all steroid biosynthetic pathways, is converted to a 
variety of steroid molecules in a series of reactions catalyzed by several cytochrome 
P450 (cyp 450) enzymes. 
1.4.1 Glucocorticoids and the hypothalamo-pituitary axis. 
All glucocorticoids are synthesised from cholesterol in the adrenal cortex and are 
released into the systemic circulation in a distinct circadian pattern. Serum 
glucocorticoid concentrations vary 3–5 fold over a 24 h period. In humans, plasma 
cortisol/corticosteroid concentrations are maximal around dawn and decline thereafter 
to reach a low phase early in the sleep phase. Glucocorticoids are also released in 
response to physical and emotional trauma. This ‘stress response' is superimposed 
over the existing circadian tone and varies in magnitude according to the nature, 
intensity and duration of the stimulus and the individual's previous experience 
(Buckingham et al., 1996). 
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The circadian and stress-induced secretion of glucocorticoids is governed by the 
hypothalamo-pituitary axis (HPA). The hypothalamus receives monitors and 
integrates information from many sources, and acts as a sensor of changes in the 
external and internal environment. Using this information, the hypothalamus responds 
to adverse physical or emotional changes by activating the pathway for glucocorticoid 
synthesis. The first step is the release of two hypothalamic neurohormones, 
corticotropin-releasing factor (CRF) and arginine vasopressin (AVP), from 
parvocellular neurones that project from the paraventricular nucleus to the median 
eminence. CRF and AVP travel from the hypothalamus via the hypophyseal–portal 
blood vessels to the anterior pituitary gland where they act synergistically via specific 
receptors [type 1 corticotropin-releasing factor receptor (CRF-R1) and type 1b 
vasopressin receptor, respectively] to trigger the release of adrenocorticotrophic 
hormone (corticotrophin, ACTH) from the corticotrophs into the systemic circulation. 
ACTH in turn acts on the adrenal cortex via type 2 melanocortin receptors to initiate 
the synthesis of cortisol/corticosterone, which is released immediately into the 
systemic circulation by diffusion. The sensitivity of the hypothalamo-pituitary-
adrenocortical (HPA) axis to incoming stimuli is modulated by a negative feedback 
(servo) system through which the sequential release of CRF/AVP and ACTH from the 
hypothalamus and anterior pituitary gland are suppressed by the glucocorticoids 
themselves. The magnitude of the HPA response to stress thus depends upon the pre-
existing glucocorticoid tone (Buckingham et al., 1996). 
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Figure 1.5 Inverse relationships between the effects of insulin (green arrows) and 
glucocorticoids (orange arrows) on key enzymes regulating hepatic glucose 
metabolism. 
1.4.2 Glucocorticoids and regulation of hepatic glucose metabolism 
The liver is a key organ in the control of mammalian glucose homeostasis. 
Glucocorticoids control many aspects of the hepatic energy metabolism. During 
fasting, free fatty acids or amino acid precursors are channelled into the 
gluconeogenic pathway that comprises various biochemical steps converting pyruvate 
to glucose. The main regulatory enzymes are pyruvate carboxylase (PC), which 
converts pyruvate into oxaloacetate, phosphoenolpyruvate carboxykinase (PEPCK) 
promoting decarboxylation of oxaloacetate to phosphoenolpyruvate, and finally 
glucose-6-phosphatase (G6Pase) hydrolysing glucose-6-phosphate into free glucose 
(Figure 1.4). PC catalyses the ATP dependent carboxylation of pyruvate to 
oxaloacetate, which may be utilised in the synthesis of glucose, fat, some amino acids 
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or their derivatives and several neurotransmitters. T2DM and hyperthyroidism 
increase the level of expression of pyruvate carboxylase in the long term, while its 
activity in the short term is controlled by the intra-mitochondrial concentrations of 
acetyl-CoA and pyruvate (Wallace et al., 1998). 
PEPCK expression is controlled by a variety of physiological stimuli including 
dietary carbohydrates, hormones and cellular intermediates (Hanson et al., 1994). 
Over expression of PEPCK in the liver during diabetes is a major factor in the 
elevated hepatic glucose production that is characteristic of T2DM. The first 
convincing evidence for the role of PEPCK in T2DM came from studies performed 
on transgenic mice carrying a rat PEPCK mini-gene. This showed that over 
expression of PEPCK led to fasting hyperglycaemia, decreased glycogen storage, and 
altered glucose tolerance test: all features of T2DM (Valera et al., 1994). Additional 
research showed hypoglycaemia in fasted animals treated with 3-mercaptopicolinic 
acid, which is a PEPCK inhibitor (DiTullio et al., 1974). PEPCK is adaptively 
regulated at the transcriptional level in a manner that correlates with gluconeogenic 
flux (Cimbala et al., 1982; Granner et al., 1983), with most evidence indicating the 
importance of PEPCK in the pathophysiology of T2DM. PC and pyruvate kinase (PK) 
were suggested to play a greater role in gluconeogenesis than PEPCK (Groen et al., 
1986). 
The pathways involved in hepatic energy metabolism are regulated by multiple 
mechanisms. Since PEPCK catalyses a reaction at the intersection of several 
fundamental pathways, the absence or over expression of this might have 
unpredictable effects on the accumulation of specific metabolites in disease states. 
PEPCK activity is reduced in the fed state whilst its activity is increased in the fasted 
animals (Granner et al., 1990). PEPCK mRNA is not significantly expressed in livers 
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of fed rats, but its expression increases dramatically in fasted rats (Yoon et al., 2001). 
Peroxisome proliferator-activated receptor (PPAR) gamma coactivator-1 (PGC-1α) 
plays a key role in regulating lipid and carbohydrate metabolism. PGC1-α knockout 
mice showed diminished hepatic gluconeogenesis and lowered glucose production, 
highlighting the importance of this co-activator (Burgess et al., 2006; Chevalier et al., 
2006). 
Uncontrolled gluconeogenesis contributes significantly to hyperglycaemia in T2DM 
patients (Consoli, 1992). This is largely due to the induction of gluconeogenic gene 
expression by glucocorticoids (Jones et al., 1993). Mice carrying a liver specific 
mutation of the glucocorticoid receptor (GR) gene displayed fasting hypoglycaemia 
due to reduced expression of gluconeogenic genes (Opherk et al., 2004). These 
studies suggest a role of glucocorticoids in the induction of gluconeogenesis under 
insulin resistant diabetic conditions. Indeed liver GR antagonism with A-348441 (a 
liver specific analogue of RU486) and antisense oligonucleotides is sufficient to cause 
substantial improvement of hyperglycaemia and dyslipidaemia in animal models of 
T2DM (Jacobson et al., 2005; Liang et al., 2005). Also GR has been found to be over 
expressed in hepatocytes of diabetic rodent models (Liu et al., 2005). 
The PEPCK gene expression is increased not only in diabetes but also in 
hyperthyroidism and various nutritional states (Hanson et al., 1997). The transcription 
of PEPCK is altered by hormones. PEPCK catalyses the conversion of oxaloacetate 
(OAA) to phosphoenol pyruvate (PEP). Its activity is only controlled at the 
transcriptional level as there are no known allosteric modifiers (Hanson et al., 1994). 
During fasting, hormones like glucagon and glucocorticoids enhance the transcription 
of PEPCK. Insulin dominantly represses hormone induced expression. The 
transcription of PEPCK is also enhanced by retinoic acid and thyroid hormone.  
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1.5 PEPCK promoter response units 
There are five major hormone response units in the PEPCK promoter region.  
1) Glucocorticoid response units (GRU) 
2) Retinoic acid response units (RARU) 
3) Cyclic AMP response units (CRU) 
4) Thyroid hormone response units (TRU) 
5) Insulin response units (IRU) 
The following figure shows the arrangement of the various response units in the 
promoter region (Figure 1.6). 
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Figure 1.6 PEPCK gene promoter: response elements and the binding proteins. 
dAF2, distant accessory factor element 2; dAF1, distant accessory factor element 1; 
SRE, sterol response element; RARE1, retinoic acid response element 1; AF1, 
accessory factor element 1; AF2, accessory factor element 2; GRE1, glucocorticoid 
response element 1; GRE2, glucocorticoid response element 2; RARE2, retinoic acid 
response element 2; TRE, thyroid response element; AF3, accessory factor element 3; 
CRE, cyclic AMP response element; PPARα, peroxisome proliferator activated 
receptor α; SREBP, sterol response element-binding protein; HNF-4α, hepatic 
nuclear factor-4α; HNF-3β, hepatic nuclear factor 3β; COUP-TF, chicken 
ovalbumin upstream transcription factor; GR–G, glucocorticoid receptor–
glucocorticoid; RAR–RXR, retinoic acid receptor–retinoid receptor; TR–T3, thyroid 
receptor–thyroid hormone; C/EBP, CAAT enhancer-binding protein; HNF-1, hepatic 
nuclear factor 1; NF-1, nuclear factor 1; CREB, cyclic AMP response element 
binding protein; CEBPβ, CAAT enhancer-binding protein β; PGC-1α, peroxisome 
proliferator-activated receptor – γ coactivator-1α; TORC2, transducer of regulated 
CREB activity 2; CBP, CREB-binding protein 
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1.5.1 Glucocorticoid response units (GRU) 
The GRU of the PEPCK consists of two non-consensus glucocorticoid response 
elements (GRE) GRE1 and GRE2; three accessory factor (AF) elements AF1, AF2 
and AF3 and cyclic AMP response elements (CRE). A series 5’ deletion mutants of 
the promoter before the transcription start site defined the regulatory elements 
responsible for the response to glucocorticoids (Imai et al., 1990). There had initially 
been a discrepancy between the boundary of functional GRU domain and the actual 
GREs. These studies led to the discovery of accessory factor elements. The cGR 
poorly binds to the GRE1 and GRE2 compared to a consensus GRE. It was shown 
that AF1 and AF3 create a high binding environment for cGR to bind to GRE1 and 
GRE2 (Stafford et al., 2001). When AF1 and AF2 positions in the promoter regions 
are swapped the response to glucocorticoid is reduced (Wang et al., 1999) this 
indicates that the exact positions of the accessory factor elements are necessary for 
full response. Also, any combination of two mutations of the AF1, AF2 and AF3 
completely abolishes the glucocorticoid response (Scott et al., 1996). So, it can be 
said that the PEPCK GR1 and GR2 are inactive in the absence of at least two 
accessory elements. 
Hepatic nuclear factor 4 (HNF4) or chicken ovalbumin upstream promoter 
transcription factor (COUP-TF) was shown to serve as accessory factors for the 
induction of PEPCK by glucocorticoids via the AF1site (Hall et al., 1995). Members 
of the hepatic nuclear factor 3 (HNF3) and CCAT enhancer binding protein (CEBP) 
bind to the AF2 element (O'Brien et al., 1994). It appears that CEBP functions as an 
accessory factor for the GREs through the CRE (Yamada et al., 1999). Distal 
accessory factors dAF1 and dAF2 were shown to be also important in the 
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glucocorticoid regulation of PEPCK (Cassuto et al., 2005). For the complete response 
of the PEPCK gene to glucocorticoid response requires AF1, AF2, AF3, CRE and the 
two GREs (GR1 and GR2) along with the steroid receptor complexes. Of the two 
GREs GR1 is quantitatively more important than GR2 (Scott et al., 1998). 
It is interesting to note that the PEPCK gene transcription is positively regulated by 
glucocorticoid in the liver and negatively regulated in adipose tissue (Hanson et al., 
1994). Liver enriched transcription factors HNF3 and HNF4 serve as AF1 and AF2 
respectively. These factors are not present in adipose tissue; this possibly explains 
differential regulation in different tissues. So, the whole of GRU allows for a graded 
response and it is also suggested that GRU is part of a much more complex assembly 
called metabolic controlled domain.  
1.5.2 Retinoic Acid response unit (RARU): 
In addition to their role in GRU, AF1 and AF3 elements also function as retinoic acid 
response element RARE1 and RARE2 by binding to a heterodimeric complex 
consisting of retinoic acid receptor (RAR) and 9-cis-retinoic acid receptor (RXR). So 
the RAR binding to the RARE1 enhances the PEPCK gene expression (Hall et al., 
1992). RARE2 supports the function of the RAR and RXR heterodimer. The DNA 
binding elements of GRU and RARU are overlapping and suggest the existence of 
functional co-operativity. The combination of dexamethasone and retinoic acid has a 
synergistic effect on PEPCK expression in both primary hepatocytes and H4IIE cells 
(Wang et al., 2004a).  
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1.5.4 Cyclic AMP response units (CRU) 
The CRU is composed of one CRE, three CAAT enhancer binding proteins (CEBP) 
and one AP-1 site. The CRE is present in number of other promoter region genes 
whose transcription is induced by cAMP (Short et al., 1986). The transcription factor 
binding to this CRE was cloned and identified as CRE binding protein (CREB) 
(Montminy et al., 1987). The CRE with CREB and a co-activator CREB binding 
protein (CBP) is not enough to explain the liver specific response of PEPCK gene to 
cAMP. A distal region in the promoter spanning from -320 to -230 showed a 
distinctive liver specific binding pattern. Liver enriched transcription factor called the 
CEBP bound specifically to three sites in this distal region along with binding to the 
CRE (Park et al., 1990). An AP-1 binding site was also identified later in the same 
region. A mutation in any of these cis-elements (CRE, CEBP and AP-1) significantly 
reduces the degree of cAMP response (Liu et al., 1991). Unlike the glucocorticoid 
response unit rearrangement of these elements did not have any effect (Roesler et al., 
1994). It is interesting to note that CEBPβ when bound to CRE acts as an accessory 
factor in the GRU of the PEPCK promoter (Yamada et al., 1999).  
1.5.5 Thyroid hormone response units (TRU): 
In the presence of thyroid hormone, the thyroid hormone receptor (TR) binds to its 
response element as a hetero dimer with RXR. P3(I) is another site which binds to 
CEBP. It was shown that CEBPβ along with TR mediates thyroid hormone 
induction of PEPCK transcription. The P3(I) site is involved in the induction of 
PEPCK by both T3 and cAMP. Interestingly, CBP which is involved in cAMP 
induction also enhances PEPCK transcription by thyroid hormone. It is shown to 
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interact with steroid receptor coactivator (SRC-1) which is recruited by the ligand 
activated TR.  
1.5.6 Insulin response units (IRU): 
Many gene regulatory proteins mediating the actions of insulin have been identified 
but the actual insulin response units (IRU) have not yet been clearly established. The 
AF-2 element in the GRU mediates the inhibition of insulin using a heterologous 
thymidine kinase promoter (O’Brian et al., 1990). Insulin triggers the dissociation of 
the transcription initiation complex formed on the promoter in response to 
glucocorticoids (Hall et al., 2007). CEBP dependent transcription is enhanced by 
FOXO1. This transcription is inhibited by insulin although the exact mechanism is not 
known (Sekine et al., 2007). However, mutation of IRE (AF-2) did not cause any 
alterations in insulin response in H4IIE cells (Yeagley et al., 2001). Insulin seems to 
affect PEPCK transcription indirectly by affecting transcription factors and co-
activators.  Insulin increases the levels of liver enriched inhibitory protein (LIP) 
which natural inhibitor of CEBP. Insulin signalling phosphorylates CBP which 
affects the interaction of CBP with CREB.  
1.6 Hypercortisolism and adrenal dysregulation in metabolic 
syndrome and T2DM 
Although it appears that hypercortisolism is the common link between all of these 
disease states, closer examination reveals a more complex picture and shows our poor 
understanding of the mechanisms that are involved. Only mild hypercortisolism is 
observed in MS and T2DM patients compared to control subjects (Pasquali et al., 
2006; Walker, 2006). It has been suggested by a number of authors that inhibiting the  
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synthesis or actions of cortisol could provide a novel therapeutic approach for MS 
(Walker, 2006). A number of studies have reported circulating cortisol concentrations
 
to be higher in patients with MS compared with healthy subjects. This difference is 
more evident in patients
 
with MS and hypertension or IGT (Reynolds et al., 2001). 
Furthermore, weight loss normalizes cortisol
 
levels and improves insulin resistance 
(Reinehr et al., 2004). Despite the fact
 
that cortisol levels are within the normal range, 
there is evidence
 
of increased activity of cortisol in the periphery and dysregulation
 
of 
the hypothalamic-pituitary-adrenal (HPA) axis (Sen et al., 2008; Walker, 2006). 
Cortisol clearance seems to be inversely correlated with insulin
 
sensitivity, and this 
correlation is independent of body fat (Holt et al., 2007). It is also well documented 
that glucocorticoids promote
 
the differentiation and proliferation of human adipocytes 
and
 
that their receptors are more abundant in visceral
 
adipose tissue (Rebuffe-Scrive et 
al., 1992). They also redistribute adiposity from peripheral
 
to central depots, increase 
the size and number of fat cells,
 
and activate lipolysis and the release of free fatty 
acids into
 
the circulation, which further increases insulin resistance.  
Increased cortisol levels
 
are also associated with insulin resistance (Phillips et al., 
1998; Reinehr et al., 2004; Ward et al., 2003). Higher cortisol
 
concentrations were 
related to a reduced insulin secretion,
 
a finding consistent with in vivo and in vitro 
data showing
 
that glucocorticoids regulate insulin secretion (Delaunay et al., 1997). 
However, higher insulin levels may also be compensatory to counter insulin 
resistance and raised blood glucose concentrations. Furthermore,
 
a study conducted in 
obese children with or without insulin
 
resistance showed that body weight reduction 
decreased both cortisol levels
 
and insulin resistance in the insulin-resistant group. This
 
was not shown in children without insulin resistance (Reinehr et al., 2004). 
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1.7 Dysregulation of adrenal glucocorticoids and disease. 
In certain conditions, when there are sustained and pronounced elevations in 
circulating glucocorticoids, the normal glucocorticoid effects become exaggerated and 
result in a lot of unwanted and undesirable physiological conditions. This increase in 
adrenal glucocorticoids is either due to hyper-secretion of endogenous steroids 
(Cushing's syndrome) or prolonged administration of exogenous steroids (treatment 
conditions). Increased circulating glucocorticoids result in a significant redistribution 
of fat giving rise to centripetal obesity, protein wasting, muscle weakness, 
hyperglycaemia and insulin-resistant diabetes mellitus (‘steroid diabetes'), 
hypertension, raised cholesterol, altered serum lipids, salt and water retention. Other 
adverse effects of glucocorticoids include immunodeficiency, poor wound healing, 
impaired growth and development, osteoporosis, menstrual irregularities, infertility, 
depression and, sometimes, impaired cognitive function. Conversely, insufficient 
glucocorticoid secretion, which may arise from Addison's disease (an autoimmune 
disorder causing degeneration of the adrenal cortex), the adrenogenital syndrome (an 
inherited disorder of glucocorticoid synthesis) or pituitary disease, is characterised by 
a vulnerability to stress, white blood cell excess, lymphoid tissue hypertrophy, 
hypotension, mood disturbances, weakness/lethargy, weight loss and hypoglycaemia. 
Slight changes in glucocorticoid levels and prolonged changes contribute to the 
pathogenesis of a number of common diseases, including hypertension, 
cardiovascular disease, insulin resistance, obesity and T2DM, depression, 
autoimmune inflammatory disease and reproductive dysfunction (De Kloet et al., 
1998; Gold et al., 2002; Seckl, 2004). 
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1.8 11β-hydroxysteroid dehydrogenase 
Probably the most important factor regulating the access of endogenous 
glucocorticoids to their receptors (GR or MR) is local metabolism of the steroids 
within the target cells by 11β-hydroxysteroid dehydrogenase (11β-HSD) enzymes. 
11β-HSDs catalyse the interconversion of cortisol and its inactive metabolite 
cortisone in humans (or corticosterone and 11-dehydrocorticosterone in rodents) 
(Seckl et al., 2001). Its existence was first recognised in 1953 (Amelung et al., 1953). 
In the late 1980’s studies on a case of 11β-HSD deficiency revealed that in the normal 
state intra renal 11β-HSD inactivates cortisol and, thus, allows preferential binding of 
aldosterone to mineralocorticoid receptor (MR) (Stewart et al., 1988). On the other 
hand, other tissues in which MRs are abundant (e.g. brain, heart) show little if any 
11β-HSD activity, suggesting that cortisol (or corticosterone) is the primary MR 
ligand at these sites (Edwards et al., 1996). These studies led to more research on the 
effects of interconversion of active and inactive glucocorticoids. 
Initially 11β-HSD was purified from rat liver and complementary cDNA was 
prepared that hybridised with a product expressed in the kidney (Agarwal et al., 1989; 
Stewart et al., 1991). A second enzyme 11β-HSD2 was purified and cloned from 
human placenta (Albiston et al., 1994; Brown et al., 1993). This enzyme is highly 
expressed in aldosterone sensitive tissues like kidney, colon and sweat glands. It 
converts active cortisol into cortisone, thus preventing nonspecific binding to 
mineralocorticoid receptors (Whorwood et al., 1992) 
11β-HSD1 differs from 11β-HSD2 in many regards. It is expressed mainly in the 
liver, lung adipose tissue (particularly omental) and brain, but is also found in other 
tissues (Stewart et al., 1999). It is subject to regulation by a variety of factors 
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including glucocorticoids, stress, sex steroids, cytokines and perioxisome proliferator-
activator receptor ligands (Hermanowski-Vosatka et al., 2000; Jamieson et al., 1999). 
11β-HSD1 is a low-affinity NADP(H)-dependent enzyme, which in vitro shows 
bidirectional activity (i.e. both dehydrogenase and reductase). However, in vivo it 
appears to function solely as a reductase, relying on hexose-6-phosphate 
dehydrogenase (with which it is co-localised in the endoplasmic reticulum) to 
generate NADP(H) (Draper et al., 2003). 11β-HSD1 thus serves to regenerate 
biologically active cortisol/corticosterone from inert cortisone/11-
dehydrocorticosterone.. 
As 11β-HSD1 is found mainly in tissues in which the high-affinity MR is sparse but 
the low-affinity GR is abundant, it has been argued that principal role of 11β-HSD1 is 
to amplify the local concentration of active glucocorticoids in those tissues in which 
the steroids have a key regulatory role, for example, the liver (Seckl et al., 2001). The 
support for this hypothesis emerged from a number of studies, including phenotypic 
analysis of 11β-HSD1-null mice (Kotelevtsev et al., 1997). These mice have raised 
corticosterone levels (due to impaired glucocorticoid feedback) but are resistant to the 
hyperglycaemia normally induced by stress or overfeeding. In addition, they show 
raised high-density lipoprotein cholesterol, with reduced low-density lipoprotein 
cholesterol and blood triglycerides (Harris et al., 2001). The metabolic responses 
appear to be driven by key changes, which, by preventing amplification of the local 
corticosterone concentration, reduce gluconeogenesis and β-oxidation of lipids in the 
liver and possibly also attenuate glucocorticoid-dependent functions in visceral 
adipose tissue. 
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Interestingly, when placed on a high fat diet, 11β-HSD1-null mice gain less weight 
than their wild-type counterparts and tend to deposit fat in subcutaneous rather than 
the visceral sites associated with metabolic disease (Kershaw et al., 2005). 
Furthermore, fat-specific 11β-HSD1 transgenic mice, which have enzyme activity 
increased to a similar extent to that seen in obese humans, develop visceral obesity 
with insulin and leptin resistance, dyslipidaemia and hypertension (Masuzaki et al., 
2001). In adipocytes, both antidiabetic PPARγ agonists and LXRα agonists 
significantly reduce 11β-HSD1 mRNA and enzyme activity, suggesting that 
suppression of 11β-HSD1 in adipose tissue may be one of the mechanisms by which 
these drugs exert beneficial metabolic effects (Masuzaki et al., 2003). 
1.9 Polycystic ovary syndrome 
Polycystic Ovary Syndrome (PCOS) is defined by: (i) clinical and/or biochemical 
hyperandrogenism, (ii) chronic anovulation, and (iii) exclusion of related disorders. 
PCOS displays a strong association with metabolic syndrome (T2DM, obesity, and 
cardiovascular diseases) (Baillargeon, 2005). It is already known that 
hyperandrogenism is the main clinical feature of PCOS (Azziz et al., 2006). This 
feature correlates positively with hyperinsulinaemia and it is agreed that adrenal 
androgens contribute to PCOS (Dunaif, 1997).  
In PCOS, it is well known that altered cortisol clearance is associated with enhanced 
steroid 5α-reductase activity and that insulin is likely to increase the 5α-reduction of 
steroids (Stewart et al., 1990; Tsilchorozidou et al., 2003). Earlier these 5α 
metabolites were presumed to be inactive, but recent evidence suggests that these 5α 
metabolites and not the 5β metabolites bind and activate the glucocorticoid receptor 
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(GC) (McInnes et al., 2004). GR is preferentially expressed in the zona reticularis of 
the adrenal cortex and this suggests a possible role of glucocorticoid metabolites in 
regulating adrenal steroid biosynthesis (Paust et al., 2006). Metformin is an anti-
diabetic drug that increases glucose utilization in insulin-sensitive tissues. As PCOS 
and T2DM share some altered parameters-such as abnormal glucose: insulin ratio, 
altered lipid metabolism and insulin-resistance syndrome, the use of metformin has 
become increasingly accepted and widespread in the treatment of PCOS. These 
observations suggest that local steroid metabolism might be dysregulated or defective, 
giving rise to novel steroids that have an effect on blood glucose regulation. 
1.10 Hyperglycaemia induced by corticotropin releasing factor 
family of peptides 
Intravenous administration of corticotropin releasing factor (CRF) or sauvagine cause 
a pronounced and long-lasting hyperglycaemia (Brown et al., 1982). Both sauvagine 
and CRF are equipotent stimulators of ACTH release through CRF-R1 receptor 
(Brown et al., 1982). So this hyperglycaemia could be a glucocorticoid response due 
to pituitary activation. However, administered in equal amounts sauvagine is more 
potent in causing hyperglycaemia than CRF. Therefore, it is most likely that this 
effect is due to a CRF-R2 receptor dependent mechanism, which implies that the 
anterior pituitary secretion of ACTH cannot account for this response.  
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1.11 Corticotropin releasing factor family of peptides 
1.11.1 CRF 
CRF is a 41-amino acid peptide abundantly expressed in neurons of the 
paraventricular hypothalamic nucleus that project to the median eminence to stimulate 
the secretion of adrenocorticotropic hormone (ACTH). CRF is the major controller of 
the basal and stress-induced activation of the HPA axis. It was observed that the only 
remarkable phenotype of the CRF knockout mouse is the pituitary–adrenal 
hyporeactivity (Muglia et al., 2000). 
The broad distribution of CRF neurons conforms to the many expected functions of 
the peptide. When injected centrally, CRF evokes autonomic responses and cause a 
widespread arousal (Koob et al., 1990) and anxiety-like behaviours (Heinrichs et al., 
1999). It activates and inhibits respectively, the sympathetic and parasympathetic 
branches of the autonomic nervous system. It stimulates cardiorespiratory functions 
(Fisher et al., 1982), as well as brown adipose tissue thermogenesis (LeFeuvre et al., 
1987), and inhibits digestive activity (Tache et al., 1990). CRF also blunts the activity 
of the reproductive system (Rivest et al., 1995) and induces anorexia (Heinrichs et al., 
1999). The view that CRF orchestrates the multiple facets of the whole animal 
response to stress has dominated the research area on CRF since the discovery of the 
peptide. However, apart from the brain, CRF like immunoreactivity was thought to be 
widely expressed in peripheral tissues, but now it seems more likely that this was due 
to cross reactivity with other structurally homologous peptides. 
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1.11.2 Urocortins 
Urocortins are peptides that are homologous to CRF and the fish peptide urotensin I. 
These peptides bind to CRF receptors and show a particularly high specificity for 
CRF-R2 (Lewis et al., 2001). Urocortin is a 40-amino acid peptide expressed in the 
mammalian brain as well as in peripheral tissues. It has 63% sequence homology with 
urotensin I and 45% with CRF (Vaughan et al., 1995). Urocortin II and urocortin III 
are also included in the urocortin subfamily of peptides. Murine urocortin II is a 38-
amino-acid peptide that selectively binds to the CRF-R2 with no appreciable affinity 
for the CRF-R1 (Reyes et al., 2001). There are still uncertainties surrounding the 
exact chemical nature of the human ortholog of murine urocortin II (Hsu et al., 2001). 
Urocortin III is a putative 38 amino acid peptide that is also referred to as stresscopin 
in humans (Hsu et al., 2001; Lewis et al., 2001). It is similar to urocortin II and 
selectively binds to the CRF-R2 receptor.  
Of the three urocortins, urocortins II and III are not likely to be physiologically 
involved in either the basal or stress-induced pituitary activation as they show little 
activity on the CRF-R1 receptor, which mediates the hypophysiotropic effect within 
the CRF system (Smith et al., 1998). Whereas, a central infusion of urocortin, which 
binds to the CRF-R1 with a high affinity, activates the HPA axis (Vaughan et al., 
1995) and elicits anxiety-like behaviours (Moreau et al., 1997). 
Because of their selectivity for the CRF-R2 urocortins II and III have been described 
as ‘stress-coping’ peptides (Hsu et al., 2001). Both peptides are capable of reducing 
anxiety, blood pressure and arousal. 
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1.11.3 Sauvagine 
Sauvagine is a 40-amino acid peptide isolated from the frog skin (Montecucchi et al., 
1980). When administered intravenously into rodents sauvagine causes an intense, 
long-lasting hypotension accompanied by tachycardia (Erspamer et al., 1980). The 
degree of hypotension was not modified by either atropine or propranolol, indicating 
the fall in blood pressure was due to vasodilator activation. Tachycardia, on the 
contrary, was partially inhibited by propranolol indicating that it was due to 
baroreceptor mediated reflex activation of sympathetic function rather than a direct 
chronotropic action. In these studies there was a reduction in urine volume 
accompanied by a decrease in GFR and an increase in tubular Na
+
 reabsorbtion. 
Sauvagine shares significant structural homology with CRF and elicits a number of 
similar biological responses. CRF and sauvagine have similar potencies in stimulating 
pituitary ACTH secretion. However, sauvagine is 5-10 times more potent than CRF 
administered within the brain to increase plasma levels of catecholamines and glucose 
and to elevate mean arterial pressure. Sauvagine is likewise more potent than CRF 
outside of the brain to increase superior mesenteric artery flow and plasma glucose 
concentrations and to decrease mean arterial pressure (Brown et al., 1982). 
Regulation of energy homeostasis is a vital function of the central nervous system 
(CNS) requiring adaptive responses to maintain and support life after stress 
perturbations. The mechanisms whereby these processes occur are, however, only 
partially understood. A major determinate of these responses is corticotropin-
releasing factor (CRF). The two CRF receptor subtypes, CRF-R1 and CRF-R2, have 
been hypothesized to play distinct roles in the alterations necessary for homeostatic 
maintenance. The function of CRFR2, in particular, has remained elusive despite its 
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presence in both the CNS and periphery. Gene deletion and pharmacological 
approaches have been used to elucidate the crucial role CRF-R2 plays in the 
regulation of regional tissue thermogenesis and adaptive physiology. 
1.12 Corticotrophin releasing factor receptors 
The CRF-R1 (Perrin et al., 1993) and the CRF-R2 (Lovenberg et al., 1995) together 
with the non-mammalian CRF-R3 receptor (Arai et al., 2001) are G-protein-coupled 
receptor types that mediate the effects of the CRF family of peptides. In addition to 
binding to two receptors, CRF and related peptides also bind to CRF-binding protein 
(Behan et al., 1989; Orth et al., 1987; Potter et al., 1992). 
1.12.1 CRF-R1 receptor 
The CRF-R1 binds CRF with high affinity (particularly ovine CRF), urocortin I with 
low affinity, and does not bind to urocortin III. CRF-R1 mRNA is broadly distributed 
in the brain with high densities of expression observed in cortical, hypothalamic, 
limbic and cerebellar regions (Potter et al., 1994; Wong et al., 1994). It is also 
markedly expressed in the pituitary and in some peripheral tissues (Dieterich et al., 
1997). Within the PVN, CRF-R1 mRNA is not detected under basal conditions but 
can be acutely induced by stressful stimuli. Glucocorticoids have been reported to 
suppress the expression of the CRF-R1 in anterior pituitary cell cultures (Pozzoli et 
al., 1996). The pituitary and PVN are among the few regions for which modulatory 
effects on the CRF-R1 gene have been reported. These modulatory effects are 
consistent with the critical role played by CRF-R1 in mediating the hypophysiotropic 
action of CRF (Smith et al., 1998). 
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Animal investigations tend to demonstrate that the CRF-R1 receptor
 
activity is 
increased in obesity. Following stressful stimuli,
 
obese rodents showed an enhanced 
activity of the HPA axis (Guillaume-Gentil et al., 1990), which is under the
 
control of 
the CRF-R1. In addition, food-deprived obese
 
Zucker rats exhibit a neurogenic-stress-
like response, which appears to be mediated by CRF receptors and
 
was associated 
with the development of obesity (Timofeeva et al., 2001; Timofeeva et al., 1997). 
This is consistent with the hypothesis that development
 
of obesity may be linked to a 
dysregulation of the HPA axis. Adrenalectomy reverses or attenuates
 
the obese 
phenotype in genetically obese (ob/ob) mice (Feldkircher et al., 1996; Yukimura et 
al., 1978) and (fa/fa) Zucker rats (Marchington et al., 1983). CRF-R1 antagonists 
have relatively mild effects on energy balance, but CRF-R1 blockade was shown to 
improve plasma variables related to metabolic syndrome in obese Zucker rats (Doyon 
et al., 2007). 
Pharmacological inhibition of CRF receptors in now considered a potential 
therapeutic target to treat depression (Grammatopoulos et al., 2002). Interestingly 
depression is also linked with raised blood glucose and insulin resistance. 
1.12.2 CRF-R2 receptor 
The CRF-R2 receptors show high affinity towards urocortins and lower affinity 
towards CRF (Reyes et al., 2001). The CRF-R2 has two splicing variants in rodents 
and three variants in humans. The three anatomically distinct splice variants are 
known as the CRF2α receptor, the CRF-R2β receptor and the CRF-R2γ receptor  (Perrin 
et al., 1999). The CRF-R2α receptor is mainly expressed in the hypothalamus and 
other areas of the brain. The CRF2β receptor is not expressed in the brain parenchyma 
and is principally expressed in the peripheral tissues including the adrenal glands 
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(Dermitzaki et al., 2007). The CRF-R2γ receptor has solely been found in human brain 
(Kostich et al., 1998). The CRF-R2 has greater affinity for the urocortins, urotensin I 
and sauvagine than for CRF itself  (Dieterich et al., 1997). There is evidence that the 
CRF-R2 mediates ‘stress-coping’ responses such as anxiolysis, ‘dearousal’ and 
hypotension (Hashimoto et al., 2001). CRF-R2-ablated mice tend to exhibit an 
increased HPA activity following restraint stress (Coste et al., 2000). In the periphery, 
the CRF-R2 mediates the inhibitory effect of CRF receptor agonists on gastric 
emptying.  
1.12.3 Other CRF receptors and CRF binding protein 
In mammals, the existence of CRF receptors other than CRF-R1 and CRF-R2 has yet 
to be described. However, the observation that CRF can produce effects in the 
absence of CRF-R1 or CRF-R2 suggests the presence of additional CRF receptors 
(Van Pett et al., 2000). In addition to binding to two receptors, CRF and its related 
peptides also bind to CRF-binding protein (CRF-BP) (Jahn et al., 2001). CRF-BP is a 
32 KDa soluble glycoprotein. It has been detected in anthropoid primates and rodents 
but not in evolutionarily earlier species suggesting that a complex regulatory 
mechanism involving CRF-BP developed later in the evolution. In the circulation and 
interstitial spaces CRF-BP binds to either CRF or UCNs with high affinity. In 
primates the CRF-BP gene is expressed in several tissues including liver, placenta and 
brain. By binding to CRF and UCNs CRF-BP reduces their bioavailability and 
consequently their activity (Tsatsanis et al., 2007). 
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1.13 CRF peptides and adrenal function. 
Accumulating evidence suggests that CRF or its related peptides also affect the 
adrenals directly, through actions within the adrenal gland where they form paracrine 
regulatory loops (Tsatsanis et al., 2007). However, very little is known about the 
physiological importance of intra-adrenal CRF and related peptides, or their receptors 
in regulating adrenal function. CRF and its related peptides, the urocortins [UCNs: 
UCN1, UCN2 and UCN3], their receptors CRF-R1 and CRF-R2 as well as CRF-BP 
are all expressed in adrenal cortical, medullary chromaffin and resident immune cells 
(Chatzaki et al., 2002). The intra-adrenal CRF-based regulatory system is likely 
complex and depends on the balance between the local concentration of CRF ligands 
and the availability of their receptors. 
Complex CRF based circuits exist within the human and rodent adrenal glands. These 
complex circuits may control adrenal cortical and medullary function, or the level of 
their interaction. An early study showed exogenous CRF enhanced adrenal 
steroidogenesis in hypophysectomised calves, indicating that CRF could have a direct 
effect independent of ACTH (Jones et al., 1992). This is supported by a report that 
CRF stimulated cortisol production from isolated human fetal adrenocortical cells 
(Sirianni et al., 2005). In addition to a direct effect, CRF enhances the adrenal 
response to ACTH; when a sub-maximal dose of CRF with a sub-effective dose of 
ACTH caused a marked increase in the release of corticosterone levels in rat adrenals 
in vitro (Andreis et al., 1991). 
Consistent with the pivotal role of the hypothalamus and pituitary in regulating the 
HPA axis, adult CRF (-/-) mice have low basal corticosterone and impaired 
glucocorticoid responses to stress. Histological examination showed marked atrophy 
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of the zona fasciculata/reticularis region (Muglia et al., 1995). CRF-R1 (-/-) mice 
confirms that it is the main receptor for mediating the effects of CRF in the pituitary. 
These studies also confirmed that both CRF and CRF-R1 are required for normal 
adrenal development function and stress response (Smith et al., 1998; Timpl et al., 
1998). While the zona fasciculata is markedly decreased in size in CRF-R1 (-/-) mice, 
the zona reticularis appeared relatively normal (Smith et al., 1998). 
CRF-R2 (-/-) mice has normal adrenal function and structure along with normal 
corticosterone secretion. However, they show a more rapid increase in glucocorticoid 
levels in response to stress and a quick decline compared to wild type mice. This 
suggests that these receptors mediate an inhibitory action on adrenal function (Bale et 
al., 2000). However, it has yet to be established whether this effect involves CRF-R2 
receptors locally in the adrenal, or the identity of the endogenous peptide involved in 
mediating this response. 
1.14 Adrenal dysfunction in T2DM: unanswered questions?  
1.14.1 Does the zona reticularis of the adrenal gland play a role in T2DM? 
The key role of the adrenal gland in carbohydrate metabolism was recognised through 
observations of altered blood glucose in adrenalectomised animals. Administration of 
adrenal extracts raised blood sugar levels and glycogen in liver and muscle in both 
adrenalectomised and normal animals (Long et al., 1940). Adrenalectomy in obese 
Zucker rats prevented hyperinsulinaemia (Freedman et al., 1986). Similarly 
adrenalectomy in diabetic (ob/ob) mice reduced plasma insulin and glucose levels 
(Makimura et al., 2000). 
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Intravenous injections of CRF or sauvagine are known to cause hyperglycaemia 
(Brown et al., 1982). This hyperglycaemia was thought to be a glucocorticoid 
response due to pituitary activation. However, while sauvagine and CRF are 
equipotent stimulators of ACTH release through CRF-R1 receptor, sauvagine is more 
potent in causing hyperglycaemia than CRF (Brown et al., 1982). Therefore, it is most 
likely that this effect is due to a CRF-R2 receptor dependent mechanism. Previous 
studies showed that this was an adrenal dependent response (Kaminski 2004), but not 
mimicked by dexamethasone or corticosterone (Barker and Corder, 1996; Kaminski, 
2004). Interestingly, while surgical removal of the adrenal gland blocked the 
response, pharmacological adrenalectomy with metyrapone augments the 
hyperglycaemia produced by sauvagine, and causes hyperglycaemia when 
administered alone in rodents (Kaminski, 2004; Rotllant et al., 2002). These findings 
seriously question the relative contribution of known corticosteroids such as 
corticosterone to adrenal induced hyperglycaemia as well as to the precise 
mechanisms regulating carbohydrate metabolism. This raises the possibility of 
secondary pathways in steroidogenesis. If this hypothesis is correct, then what adrenal 
cells are responsible for the synthesis of these corticosteroids? 
In this respect the location of CRF-R2 receptors in the adrenal may provide some 
insight as CRF-R2 receptors have been localised to the zona reticularis of the adrenal 
cortex (Fukuda et al., 2005). The zona reticularis (ZR) of the adrenal cortex could be 
the major site of production of a novel zona reticularis gluconeogenic factor (ZRGF). 
Moreover, there are marked differences in the zonation of certain enzymes in the 
adrenal gland. Pertinent to observations with metyrapone, there is less 11-β 
hydroxylase activity in the zona reticularis (Hyatt et al., 1983). Indeed, novel steroids 
may have been overlooked in previous analyses because marked synthesis, as a 
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compensatory mechanism may occur only during hypoglycaemia or fasting or in 
disease states such as T2DM when normal regulatory mechanisms are lost. 
Interestingly, in early reports of glucose regulation by synthetic steroids adrenal 
extracts showed a greater activity in adrenalectomised rats. 
1.14.2 Is there a role for a novel adrenal corticosteroid in regulating 
hepatic glucose output? 
Metyrapone is an inhibitor of 11-β hydroxylase and its administration inhibits the 
final conversion of deoxycorticosterone to corticosterone. However, 
aminoglutethimide does not cause a similar hyperglycaemic effect to metyrapone 
(Kaminski 2004). Aminoglutethimide inhibits 20α-hydroxylation preventing the 
conversion of cholesterol to pregnenalone. Unlike metyrapone it also inhibits both 21 
and 18 hydroxylation blocking both aldosterone and corticosterone synthesis 
(Dollery, 1999). These differences in action point to a defective steroid metabolism 
resulting in the production of a novel gluconeogenic corticosteroid. 
 
 
 
 
 
69 
 
Aims of this thesis 
The main aim of this thesis is to test the hypothesis that the adrenal gland produces a 
novel gluconeogenic steroid, which may play a role in physiological or 
pathophysiological regulation of glucose metabolism. 
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CHAPTER 2 
Development of a multi-well format, 
high-throughput-bioluminescent 
methodology for measurement of 
PEPCK activity. 
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2.1 Introduction. 
PEPCK (EC 4.1.1.32) is a gluconeogenic enzyme that catalyses the conversion of 
oxaloacetate (OAA) to phosphoenolpyruvate (PEP) (reaction 1, Figure 2.1). PEPCK 
contains 13 cysteine residues all in the reduced state (Nordlie et al., 2010). The 
purified enzyme needs thiol compounds like DTT or β-mercaptoethanol to maintain 
maximal activity (Ballard et al., 1969). PEPCK has a dual cation requirement: 
millimolar concentrations of Mg
2+
 are associated with the nuclear substrate, and 
micromolar concentrations of a second cation (Mn
2+
 or Fe
2+
) bind to a specific 
enzyme site as an activator (Snoke et al., 1971). 
Extremely sensitive methods are required to determine PEPCK activity in various 
tissues. Four different methods have been employed to measure PEPCK enzyme 
activity: (1) determination of PEPCK activity by coupled fluorimetric method (Burch 
et al., 1978); (2) determination of PEPCK activity using an assay in which the 
coupling enzyme, malate dehydrogenase, which reduces OAA to malate 
concomitantly with the oxidation of NADH to NAD
+
 (Petrescu et al., 1979); (3) 
determination of γ-32 P incorporation in phosphoenolpyruvate from γ-32 P GTP, as a 
phosphate donor (Vandewalle et al., 1981); and (4) bioluminescent assay for the 
determination of PEPCK activity in tissue samples (Wimmer, 1988). 
Methods (1) and (3) are complicated and time consuming. Method (2) is the preferred 
choice by many groups and is in use. But this method is not suitable for the rapid 
analysis of multiple samples required for this project. Method (4) as described by 
Wimmer is not practical for use in cell culture studies and involves performing the 
measurements under oil, which is technically demanding and not easily reproducible. 
However, the principle of Wimmer's bioluminescent method has the potential for 
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highly sensitive measurements with low amounts of sample. Therefore, it was used as 
the basis for developing an optimised multi-well format method for measurements of 
PEPCK activity in cultured cells and tissue samples to meet the needs of this project. 
This method is based on the measurement of ATP generated in three reaction steps. 
The first reaction is the formation of phosphoenolpyruvate (PEP) from oxaloacetate 
and GTP in the PEPCK reaction (reaction 1, Figure 2.1). The PEP generated in this 
reaction is used in the second reaction to generate ATP in the presence of PK and 
ADP (reaction 2, Figure 2.1). ATP generated in reaction 2 is used in the next step in 
which the amount of ATP is quantified by the luminescence produced in the presence 
of luciferin and beetle luciferase (reaction 3, Figure 2.1). The luminescence signal 
produced is proportional to the amount of PEPCK in reaction 1. 
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Reaction1 
 
Reaction2
 
Reaction 3 
 
Figure 2.1 Schematic representations of the three coupled reactions in the PEPCK 
bioluminescent assay. 
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2.1.1 Need for a high-throughput PEPCK assay for screening of a novel 
diabetogenic compound. 
T2DM is characterised by post-prandial and fasting hyperglycaemia. This 
hyperglycaemia at least in part results from increased hepatic glucose production 
through increased gluconeogenesis (Mitrakou et al., 1992; Perriello et al., 1997) and 
in particular increased activity and transcription of PEPCK (Veneziale et al., 1983). 
The main goal of this PhD project was to screen plasma, tissue and cell culture 
medium samples for potential novel gluconeogenic adrenal steroids. Separating and 
purifying a gluconeogenic component from a complex mixture like plasma or 
incubation medium requires the use of purification techniques such as solid phase 
extraction (SPE) and high performance liquid chromatography (HPLC). This requires 
testing intermittent pools and fractions in a bioassay on cultured hepatocytes and 
using a rapid sensitive method to measure PEPCK activity in multiple samples. 
In order to achieve this, the PEPCK activity assay should be cost effective, time 
saving and should be suitable for use in a multi-well format so that HPLC fractions 
collected using different separation techniques can be tested for an effect on the 
PEPCK enzyme activity. 
2.1.2 Overview of the method development. 
This PEPCK method relies on the successful coupling of the initial two reactions 
involving PEPCK and PK (Figure 2.1). The resultant ATP is measured using the 
luciferin/luciferase reaction. 
The success of this assay is in the detection of the final signal, which involves the 
sensitive measurement of ATP using bioluminescence (reaction 3). Therefore this 
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reaction was optimised by determining the luciferase enzyme reaction time course. 
The initial velocity region of the luciferase reaction was determined and in all 
subsequent experiments ATP measurements were conducted in this linear range. 
The second reaction involving PK generates ATP from the dephosphorylation of PEP. 
This reaction was optimised by coupling with luciferin/luciferase reaction (reaction 3) 
to determine the ATP generated. Validation experiments were performed to determine 
the optimal dilution factor of the ATP generated in PEP/PK (reaction 2) so that it was 
in the ideal signal range of reaction 3. 
The initial PEPCK reaction (reaction 1) generates PEP, the substrate for reaction 2. 
This reaction was fully optimised to be coupled with reaction 2. As this method is for 
determination of PEPCK activity in cultured hepatocytes, cell lysis conditions were 
optimised to achieve reproducible protein levels. PEPCK has a very sensitive dual 
cation requirement with Mg
2+
 and Mn
2+
, with
 
Mn
2+ 
also being inhibitory at higher 
concentrations. 
Experiments were performed to establish assay parameters, reagent stability and 
suitability, linearity of enzyme activity, signal window and data analysis. Rat 
hepatocytes (H4-II-E-C3 cell line) were initially used to validate the assay using 
known stimulators and inhibitors of PEPCK activity. Reproducibility, coefficient of 
variance and limit of detection were established. This was further extended to tissue 
samples collected from in vivo animal models. 
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2.2 Materials and Methods 
2.2.1 Materials 
Reagents: 
All dilutions were prepared in H2O (uHQ Elga) unless mentioned. 
Phosphoenolpyruvate (PEP) was purchased from Fluka. Luciferin, luciferase, and 
pyruvate kinase (PK) were purchased from Promega. Adenosine triphosphate (ATP), 
adenosine diphosphate (ADP), oxaloacetate (OAA), inosine triphosphate (ITP), Triton 
X-100 (TX-100), Dulbecco’s Modified Eagle’s Medium (DMEM), phosphate 
buffered saline (PBS), 8-Br-cAMP, insulin, and EGTA were purchased from Sigma-
Aldrich. H4-II-E-C3 cell line was obtained from European collection of animal cell 
cultures (ECACC; ECACC no. 85061112). Unless mentioned, all other reagents and 
chemicals used were purchased from Sigma. 
Equipment: 
Luminescence was measured using a set programme on the Wallac TRILUX 1450 
Microbeta counter using 96-well black Costar plates. Luminescence measured was 
plotted as relative luminescence units (RLU). 
Data Analysis: 
All data are expressed as mean ± SEM. Data were analysed using Graphpad Prism 
and Statview software. Statistical differences were evaluated by one-way (or) two-
way analysis of variance (ANOVA), followed by a Bonferroni’s post-hoc test where 
appropriate. Statistical differences were accepted as P < 0.05. 
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2.3 Determination of ATP 
2.3.1 Reaction 3 Chemistry 
Luciferase (EC 1.13.12.7) catalyzes the oxidative decarboxylation of luciferin (LH2) 
in the presence of ATP,
 
O2, and Mg
2+
, producing yellow-green light (λmax = 560 nm). 
Like all mono-substrate enzyme reactions the initial rate varies hyperbolically with 
ATP concentrations for a fixed concentration of luciferase. 
 
Figure 2.2 Oxidative decarboxylation of luciferin (LH2) by luciferase in the 
presence of ATP,
 
O2, and Mg
2+
, producing yellow-green light (λmax = 560 nm). 
 
2.3.2 Luciferase-Luciferin reaction mix  
Luciferase-luciferin reaction mix (LLRM) reaction buffer (RB) was prepared and 
stored as a 20x stock containing 500 mM tris-HCl buffer (pH 7.8), 100 mM MgSO4, 2 
mM EDTA, and 2 mM sodium azide. LLRM (10 ml) was prepared by adding 8.9 ml 
H2O, 0.5 ml 20x RB, 0.1 ml 0.1 M DTT, 0.5 ml 10 mM D-luciferin and luciferase 
(2.5 µl). 
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2.3.3 Luciferase reaction progress curve 
The reaction was initiated by adding working LLRM (100 µl) to 10 µl of ATP 
standard dilutions (0.01 – 1 mM). Luminescence was measured at 10 min. The 
reaction rate (slope Vo) for each concentration was calculated by ΔY/ΔX and plotted 
against the concentration in a Michaelis-Menten plot. Vmax of ATP was 513 ± 37 and 
the Km =33 ± 8 µM ATP (Figure 2.5A). 
2.3.4 Establishing the linear range of measurable ATP using the initial 
velocity conditions. 
Dilutions of ATP (1 – 10 µM) (10 µl) were incubated with working LLRM (100 µl). 
The reaction was protected from light with an aluminum foil and incubated for 10 min 
at room temperature before measuring luminescence (Figure 2.5.B). The 
luminescence measured is plotted against ATP (µM). The assay produced linear 
regression of r
2
=0.99 up to 10 µM. 
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Figure 2.3 Initial velocity conditions of Luciferase/luciferin reaction with changes 
in ATP. 
Working LLRM (100 µl) was incubated with 10 µl ATP (0 – 200 µM). Slope Vo for 
each concentration is calculated by ∆luminescence/∆time (sec). (A) Michaelis-Menten 
plot of Vo vs ATP (µM) at saturated Luciferin (0.5 mM). (B) ATP standard in the 
linear range (0 – 10 µM). Linear regression was calculated using Graphpad Prism. 
80 
 
 
2.3.5 Optimisation of reaction 3 incubation time. 
LLRM (100 µl) was added to ATP (range 1 – 62 pmol/10 µl) in a 96-well plate. 
Luminescence was measured after 5, 10 and 20 min (Figure 2.4). ATP standard 
curves had a regression of r
2
 =0.99, 0.98 and 0.99 respectively for 5, 10 and 20 min. 
10 min reaction time was chosen for practical reasons when handling large sample 
numbers. 
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Figure 2.4 Reaction 3 incubation time. 
LLRM (100 µl) were incubated with 10 µl of ATP dilutions (1 – 62 pmol). The linear 
regression was calculated using Graphpad Prism. Results are mean from 3 separate 
experiments. 
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2.4 Formation of ATP using Pyruvate kinase. 
2.4.1 Reaction 2 Chemistry 
Pyruvate kinase (EC 2.7.1.40) catalyzes the dephosphorylation of PEP in the presence 
of ADP, K
+
, and Mg
2+
producing pyruvate, and ATP. This reaction is irreversible 
under intracellular conditions. 
 
 
Figure 2.5 Dephosphorylation of PEP by pyruvate kinase in the presence of ADP, 
K
+
, and Mg
2+
producing pyruvate, and ATP  
2.4.2 Pyruvate Kinase reaction buffer. 
A stock solution of phosphoenolpyruvate (PEP) (100 mM) was prepared in H2O. PK 
was diluted (0.5 U/µl) in enzyme dilution buffer containing 50 mM sodium phosphate 
buffer (pH 7.5) and 40% glycerol. Pyruvate kinase reaction buffer (PKRB) was 
prepared from stock solutions to attain the final working concentrations of 5 mM 
MgCl2, 50 mM potassium phosphate buffer, 2 mM ADP and 2.5 mM KCl. 
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2.4.3 ATP formation in reaction 2 
PEP dilutions (2.5 – 25 µM) (10 µl) were incubated with PKRB (40 µl). The reaction 
was incubated on a shaker at room temperature for 40 min. The reaction was then 
stopped and 10 µl of this incubated reaction was transferred to a 96-well plate. ATP 
dilutions (0.01 – 10 µM) were used to determine a control response in order to 
compare the coupling of the two reactions. LLRM (100 µl) was added to each well, 
and the sealed plate was incubated in the dark and luminescence was measured after 
10 min (Figure 2.6). ATP standard curve was linear with little or no background 
signal in the control wells, r
2
= 0.99. PEP standard curve on the other hand had a high 
background noise and resulted in a poor standard curve with r
2
=0.86. Further 
experiments were carried out to find the interference in PKRB that resulted in very 
high background luminescence. 
2.4.4 Interference in reaction 2 
In order to find the interference observed in reaction 2, three conditions were tested: 
(i) 10 μl H2O + 40 μl PKRB (5 mM MgCl2, 50 mM potassium phosphate buffer, 2 
mM ADP and 2.5 mM KCl). (ii) 10 μl of 5 μM ATP dilution + 40 μl H2O, (iii) 10 μl 5 
μM PEP + 40 μl PKRB. All three conditions were incubated at room temperature for 
40 min. Samples (10 µl) of the incubation mix were incubated with LLRM (100 µl) 
and luminescence was measured after 10 min (Figure 2.7). PKRB, ATP, and PEP 
+PKRB gave 96752±6176, 76270±2302, and 160359±10236 RFU (cps) respectively. 
The results confirmed that PKRB contained a source of ATP, which was responsible 
for generating the very high background signal in reaction 3. In order to further 
investigate the main cause of the high background signal, each of the components 
were individually assayed in reaction 3 
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Figure 2.6 ATP formation from PEP using Pyruvate Kinase. 
Reaction 2 sample (10 µl) containing an effective PEP concentration (1 – 10 µM) or 
ATP (1 – 10 µM) were incubated with LLRM (100 µl) and luminescence measured 
after 10 min. n=6. Linear regression r
2
 was 0.99 and 0.89 for ATP and PEP 
respectively. 
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Figure 2.7 Interference in reaction 2 
PKRB (5 mM MgCl2, 50 mM potassium phosphate buffer, 2 mM ADP and 2.5 mM 
KCl) 40 µl was added to 10 µl H2O, 10 µM ATP, and 10 µM PEP. The reaction was 
incubated for 40 min at room temperature and 10 µl of the reactions were assayed for 
luminescence in reaction 3. n=8. 
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2.4.5 Interference in PKRB 
In order to identify the interfering component within PKRB (5 mM MgCl2, 50 mM 
potassium phosphate buffer, 2 mM ADP and 2.5 mM KCl), 10 µl of all the 5 
components of the buffer were incubated with LLRM (100 µl) for 10 min. ADP (10 
µl) alone produced a signal of 75243±476 (Figure 2.8). This indicated that ADP 
purchased from Sigma (catalogue no A5285) was not pure as it contained ATP. 
Further experiments were carried out to purify this ADP and to remove the interfering 
ATP. 
2.4.6 Purification of ADP using ion-exchange chromatography 
Strong anion exchange resin was purchased from Sigma Aldrich (DOWEX 1x8 200) 
and packed in a mini-column (1 cm bed volume). The resin bed was washed with 10 
ml of 2 M KCl and equilibrated with 40 ml of 10 mM KH2PO4. For purification, 2 ml 
of ADP (50 mg/ml) was prepared in 10 mM KH2PO4 and loaded onto the column. 
The eluant was collected into 5 ml tubes and the bound adenosine nucleotides were 
eluted by serial elution with (KH2PO4) with increasing salt concentrations as follows: 
2 ml x 1 (0.1 M KH2PO4), 2 ml x 2 (0.3 M KH2PO4), 2 ml x 3 (0.4 M KH2PO4), 2 ml 
x 5 (0.75 M KH2PO4), 2 ml x 5 (1 M KH2PO4). Adenine content of each fraction 
(1:1000 dilution) was estimated by measuring absorbance at A260. Fractions 
containing ATP were identified by incubating 10 µl of the eluted fraction with LLRM 
(100 µl) for 10 min to measure the luminescence signal. A260 and luminescence signal 
were plotted to identify the fractions containing ADP alone with no interfering ATP 
luminescence with LLRM (Figure 2.9). 
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Figure 2.8 Interference within PKRB. 
Samples (10 µl) of H2O, 5 mM MgCl2, 50 mM phosphate buffer, 2 mM ADP, and 2.5 
mM KCl were incubated with LLRM (100 µl) and luminescence measured after 10 
min. n=4. 
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Figure 2.9 Purification of ADP for use in PKRB. 
Representative chromatogram of fractions collected from Dowex (strong-anion-
exchange resin) by elution with KH2PO4. Fractions assayed for luminescence in 
reaction 3 and plotted against absorbance (A 260 nm) to identify the fractions for use 
in PKRB. 
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2.4.7 Optimisation of reaction 2 incubation time using purified ADP. 
PEP (250 pmol/10 µl) was incubated with PKRB prepared using the purified ADP (5 
mM MgCl2, 50 mM potassium phosphate buffer, 2 mM purified ADP and 2.5 mM 
KCl). The reaction was stopped at 5 min time intervals by addition of 10 µl of 
termination buffer (1 M NaOH) up to 50 min. The terminated reaction was neutralised 
again by addition of 1 M HCl (10 µl). Neutralised reaction (10 µl) was incubated with 
LLRM (100 µl). Luminescence was measured after 10 min and plotted against time to 
determine the optimal incubation time (Figure 2.10). Luminescence signal reached a 
plateau at 20 min but increased slightly to 40 min. The reaction 2 incubation time was 
standardised at 40 min to allow conversion of all the PEP formed in reaction 1 to 
pyruvate and ATP. 
2.4.8 Verification of the coupling of reaction 2 with reaction 3 using 
purified ADP. 
PEP dilutions and ATP dilutions (1 – 10 µM) were prepared. PKRB with purified 
pooled ADP (40 µl) were incubated with PEP dilutions (10 µl) for 40 min at room 
temperature on a shaker. Reaction 2 (10 µl) and ATP dilutions (10 µl) were incubated 
for 10 min with LLRM (100 µl). Luminescence measured at 10 min was plotted 
against concentration to compare the stoicheometric conversion of PEP into ATP 
(Figure 2.11). 
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Figure 2.10 Reaction 2 incubation time. 
PEP samples (25 µM) (10 µl) were incubated with PKRB (5 mM mgCl2, 50 mM 
potassium phosphate buffer, 2 mM purified ADP and 2.5 mM KCl). ATP formed in 10 
µl of the reaction was measured using LLRM in reaction 3 and the luminescence 
plotted against reaction 2 incubation times. 
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Figure 2.11 Coupling of reaction 2 with reaction 3 
PEP (2.5 – 25 µM) was incubated with 40 µl PKRB for 40 min. 10 µl of this reaction 
was incubated with LLRM (100 µl) for 10 min. The bioluminescence was measured 
and compared with that obtained with ATP (1 – 10 µM).n=6. 
2.5 Generation of phosphoenolpyruvate (PEP) with intracellular 
PEPCK. 
2.5.1 Reaction 1 chemistry. 
PEPCK catalyses the conversion of oxaloacetate to phosphoenolpyruvate and has a 
dual cation requirement: millimolar concentrations of Mg
2+
 and micromolar 
concentrations of a second cation (Mn
2+
 or Fe
2+
).  
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Figure 2.12 Decarboxylation of oxaloacetate to phosphoenolpyruvate by PEPCK in 
the presence of divalent cations Mg
2+
 and Mn
2+
. 
2.5.2 Reaction 1 Lysis buffer. 
Reaction 1 lysis buffer (R1LB) was prepared fresh before each experiment. It 
contained 50 mM potassium phosphate buffer, pH 7.5, 10 mM MgSO4, 0.1 mM 
MnSO4, 0.1 mM EGTA, 1 mM mercaptoethanol, 3 mM inosine triphosphate (ITP), 
and 2.5 mM oxaloacetate. 
2.5.3 Choice of non-ionic detergents in reaction 1 lysis buffer 
Detergents break the lipid barrier surrounding cells by solubilising proteins and 
disrupting lipid-lipid, protein-protein and protein-lipid interactions. Detergents like 
lipids, self associate and bind to hydrophobic surfaces. They are comprised of a polar 
hydrophilic head group and a non-polar hydrophobic tail and are categorized by the 
nature of the head group as either ionic (cationic or anionic), non-ionic or 
zwitterionic. Their behaviour depends on the properties of the head group and tail. 
As there is no standard protocol available for selecting a detergent to use for 
membrane lysis. The ideal detergent depends on the intended application. In general, 
non-ionic and zwitterionic detergents are milder and less denaturing than ionic 
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detergents and are used to solubilise membrane proteins where it is critical to 
maintain protein function and/or retain native protein: protein interactions for enzyme 
assays or immunoassays. CHAPS, a zwitterionic detergent, and the Triton-X series of 
non-ionic detergents are commonly used for these purposes. 
H4-II-E-C3cells were seeded in multiwell plates; 6 well (9.5 cm
2
 growth area; 1.2 x 
10
6
 cells) or 24 well (2 cm
2
 growth area; 2.5 x 10
5
 cells) and grown to 100% 
confluence in DMEM with 10% FCS. Cells were washed twice in ice cold PBS and 
stored frozen at -80
o
C for subsequent use. R1LB with varying TX-100 concentrations 
(0 – 1%) was added to the cells on thawing. The cells were incubated for 10 min at 
room temperature and the contents of each well were collected for total protein 
measurement (Figure 2.12 A). R1LB containing 0, 0.01, 0.1, 0.5 and 1% TX-100 
produced 80±15, 90±12, 138±8.5, 175±13.6, 180±15.4 total protein (µg/2x10
5
cells). 
R1LB (0.5% TX-100) was used to compare an equimolar PEP and ATP standard 
(Figure 2.13 B). TX-100 (0.5%) did not interfere in reaction 2 & 3 resulting in PEP 
standard r
2
= 0.996, and ATP r
2
=0.993. For the rest of the experiments R1LB with TX-
100 (0.5%) was used to lyse cells during reaction 1. 
2.5.4 PEPCK progression curve and Km of oxaloacetate in reaction 1. 
R1LB without oxaloacetate (OAA) (50 mM potassium phosphate buffer, pH 7.5, 10 
mM MgSO4, 0.1 mM MnSO4, 0.1 mM EGTA, 1 mM mercaptoethanol, 3 mM ITP) 
was incubated with 50 µl OAA dilutions (0.5 – 20 mM) and 50 µl of H4-II-E-C3 total 
protein (150 µg/ml). For each concentration, the reaction was stopped at 5, 10, 15 and 
20 min with 1 M NaOH (20 µl). 10 µl of each reaction time point were transferred 
into 96 well plate and reaction 2 and reaction 3 were carried out as described in 
section 2.4.8. Luminescence was plotted against time for each OAA concentration and 
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the slope Vo for each concentration was calculated by ∆Y/∆X. Vo of each 
concentration was plotted against the corresponding OAA concentration in a 
Michaelis-Menten plot. Vmax of PEPCK at the given reaction conditions was 11717 ± 
650 and the Km for OAA was 5 ± 1 mM (Figure 2.14). 
2.5.5 Optimisation of Mg2+ and Mn2+ in reaction 1. 
As mentioned earlier, PEPCK has a dual cation requirement and the concentration of 
Mg
2+
 and Mn
2+
 affect the reaction rate and the sensitive determination of enzyme 
activity. Low concentrations of Mn
2+
 are essential for PEPCK activity, but are 
inhibitory at higher concentrations for both PEPCK and PK. Therefore it was 
necessary to optimise the Mn
2+
 concentrations in R1LB to ensure maximum activity 
in reaction 1, and a negligible effect in reaction 2.  
R1LB (50 mM potassium phosphate buffer, pH 7.5, 0.1 mM EGTA, 1 mM 
mercaptoethanol, 3 mM ITP, and 2.5 mM OAA) with varying Mn
2+ 
(0.01 – 10 µM) 
were prepared with and without 10 mM Mg
2+
. Each of these reaction 1 buffer 
conditions (150 µl) was incubated with 50 µl of H4-II-E-C3 total protein (150 µg/ml). 
Reaction 1 was incubated for 20 min and reaction 2 and 3 were carried out as 
described in section 2.4.8. Luminescence was plotted against Mn
2+ 
concentrations 
(Figure 2.15). 
2.5.6 Reaction 1 incubation time 
R1LB (50 mM potassium phosphate buffer, pH 7.5, 0.1 mM EGTA, 1 mM 
mercaptoethanol, 3 mM ITP, and 2.5 mM OAA, 10 mM Mg
2+
, and 0.5 mM Mn
2+
) 
(150 µl) was added to 50 µl of H4-II-E-C3 total protein (150 µg/ml) in Eppendorf 
tubes. The reaction was stopped at 5, 10, 15, 20, 25 and 30 min with 1 M NaOH (20 
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µl). Reaction 2 and 3 were performed as described in section 2.4.8. Luminescence 
was plotted against time (Figure 2.16). Reaction 1 incubation time was optimised at 
10 min to maximise the differences between treatments in PEPCK activity. 
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Figure 2.13 Optimising TX-100 in R1LB. 
(A) 150 µl of R1LB with TX-100 (0.01 – 1%) was added to H4-II-E-C3cells grown to 
confluence in a 24 well plate. After 10 min, the cell lysate was assayed for total 
protein using Bio-Rad detergent compatible assay. n=4 (B) PEP (2.5 – 25 µM) and 
ATP (0 – 10 µM) dilutions were assayed in reaction 2 and 3 in the presence of 0.5% 
TX-100 to test for any interference in the assay. n=4. ** = P < 0.01 vs Freeze thaw 
protein 
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Figure 2.14. PEPCK time course and Km of oxaloacetate in reaction 1 
R1LB (150 µl) without oxaloacetate was incubated with 50 µl OAA dilutions (0.8 – 20 
mM) and 50 µl of H4-II-E-C3 total protein (150 µg/ml). For each concentration, the 
reaction was stopped at 5, 10, 15 and 20 min and the corresponding slope Vo plotted 
against the OAA concentration in a Michaelis-Menten plot. 
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Figure 2.15 Optimisation of the Mg
2+
 and Mn
2+
 concentration in R1LB. 
R1LB was prepared with varying concentrations of Mn
2+
 (0 – 10 µM) with and 
without Mg
2+
 (10 mM). R1LB (150 µl) was incubated with 7.5 µg total protein. 
Reaction 1 was stopped after 10 min and 10 µl assayed in reaction 2. 10 µl of 1:100 
dilution of reaction 2 was assayed in reaction 3 and the luminescence measured. n=3. 
Statistical differences determined by one-way ANOVA. *** = P<0.001 vs control. 
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Figure 2.16 Optimisation of Reaction 1 Incubation time. 
H4-II-E-C3 total cell protein (7.5 µg) was incubated with 150 µl optimised R1LB. The 
reaction was stopped with 1 M NaOH (20 µl) at 5 min time intervals up to 30 min. 
Neutralised reaction 1 was assayed in reaction 2 and 3 as described in section 2.4.8. 
Luminescence is plotted against time. n=6. Statistical differences determined by one-
way ANOVA.* = P< 0.05;  ***= P<0.001 vs 0 min. 
 
 
 
99 
 
2.6 Optimised multi-well format PEPCK activity method. 
For all further PEPCK activity measurements, cells were frozen at -80
o
C after 
treatment. On the day of the assay, the plates were thawed at room temperature. R1LB 
(150 µl/well) (50 mM phosphate buffer, pH 7.5, 0.5 µM MnSO4, 10 mM MgSO4, 0.1 
mM EGTA, 1 mM mercaptoethanol, 3 mM ITP, 2.5 mM OAA and 0.5% TX-100) 
was added to each well and then incubated on an orbital mixer at room temperature 
for 10 min. The reaction was terminated with the addition of 20 µl 1 M NaOH and the 
plates were heated at 75
o
C in a water bath for 10 min before being neutralised with 20 
µl 1 M HCl. Neutralised reaction 1 (10 µl) was incubated with 40 µl PKRB (50 mM 
HEPES buffer, 2 mM purified ADP and 2.5 mM KCl, and PK (0.5 U/µl)) for 40 min 
at room temperature. Reaction 2 was diluted (1 in 50 or 1 in 100) in H2O. Diluted 
reaction 2 (10 µl) was incubated with LLRM (100 µl) for 10 min before measuring 
the luminescence signal generated. Control samples of reaction 1 are taken through 
reaction 2 and 3 without the addition of PKRB. The ATP signal generated from these 
samples in reaction 3 is subtracted from the corresponding values generated with 
PKRB for the same sample. 
2.7 Experimental evaluation of PEPCK activity method 
2.7.1 The effect of 8-Br-cAMP on PEPCK activity. 
H4-II-E-C3 cells were grown to confluence in 10% FCS containing DMEM. Cells 
were washed with PBS and incubated for 6 h with 8-Br-cAMP (75 – 600 µM) in 
EBSS with 10 mM lactate and 2 mM pyruvate. Medium was aspirated and cells were 
frozen at -80°C. PEPCK activity assay was performed on these cells as described in 
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section 2.6. 8-Br-cAMP (75 – 600 µM) caused a concentration dependent increase in 
PEPCK activity with 1.2 ± 0.1, 1.6 ± 0.1, 1.9 ± 0.1, and 2.2 ± 0.1 fold increase from 
untreated cells with 75, 150, 300 and 600 µM cAMP respectively. Insulin (10 ng/ml) 
suppressed the cAMP induced PEPCK activity in all the treatments to below the 
control values (Figure 2.19). 
 
 
Figure 2.19 Effect of cAMP and Insulin on PEPCK activity in H4-II-E-C3cells. 
H4-II-E-C3 cells were treated with 8-Br-cAMP (75 – 600 µM) for 6h with and 
without 100 ng/ml insulin. The cell lysate were assayed for PEPCK activity using the 
optimised method described in section 2.6. Relative PEPCK activity is plotted against 
concentration. n=6. Statistical analysis was performed using a two-way ANOVA with 
a Bonferroni post hoc test. *** = P <0.001 vs 0 cAMP treatments; #=P < 0.05; ## = 
P < 0.01 and ### = P < 0.001 vs the corresponding cAMP treatments. 
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2.8 Discussion 
PEPCK plays an important role in the conversion of pyruvate to glucose and acts as 
the first bypass reaction of gluconeogenesis. It is often referred to as the rate-limiting 
enzyme in gluconeogenesis. The PEPCK assay was optimised to achieve a 
reproducible method capable of measuring multiple samples in a competitive manner 
for gluconeogenic activity. 
Extremely sensitive methods are required to determine PEPCK activity in various 
tissues. The principle of Wimmer's bioluminescent method was used to develop and 
optimise this multi-well format that can be used on cultured cells and mg quantities of 
tissue to suit the needs of this project. 
Reaction 1 buffer was optimised to contain all the substrates and cofactors required by 
PEPCK along with a mild detergent TX-100 to facilitate cell lysis and permit 
reproducible application in multi-well format. Possible interferences were addressed. 
As the initial PEPCK reaction is the rate limiting of all the three reactions the 
incubation time was optimised such that the reaction is terminated during the initial 
velocity conditions such that the signal measured in reaction 3 is a measure of the 
PEPCK enzyme concentration in the lysed cells. 
Reaction 1 is terminated with changes in pH and heating at 70
o
C for 10 min. This 
denatures all enzymes that could interfere in the subsequent reactions. PEP formed in 
reaction 1 is carried into reaction 2 in the presence of optimal conditions for PK. Non 
PEPCK generation of ATP as a contributor to the measurement can be excluded by 
taking control samples of reaction 1 through reaction 2 and 3 without the addition of 
PKRB. The ATP generated from these control samples is subtracted from the 
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corresponding values generated with the samples from the same wells incubated with 
PKRB containing PK. The change in pH and the heating at 70°C denatures all the 
protein in the samples preventing any other way of generating ATP apart from that 
generated due to PK.  Purification of ADP was required to reduce the background 
signal. The ATP generated in reaction 2 is measured in reaction 3. The relative 
luminescence measured is a measure of the PEPCK activity. The ability to measure 
functional differences in PEPCK activity was confirmed using a cell permeable 
cAMP analogue to stimulate PEPCK gene expression. One of the key limitations of 
this assay method is that the reactions have to be carefully optimised for all reactions 
to be coupled in order to yield a quantitative measure. The control samples to subtract 
the background ATP are very important.  
The specificity of the methodology for measurement of PEPCK may be further tested 
by the addition of mercaptopicolinic acid as a PEPCK inhibitor (Wimmer, 1988) or 
the use of cells without PEPCK (siRNA). Other negative controls that can be 
considered as part of the assay are to lyse and heat treat the control samples before 
conducting the PEPCK measurements. Results were comparable with previous reports 
describing cAMP regulation of PEPCK and suppression with insulin. Insulin only 
marginally down regulates PEPCK activity at baseline. This may be due to its ability 
to suppress the mRNA and expression, but the PEPCK protein already present in the 
cell before treatment could be responsible for the activity noticed in these 
experiments. The evaluation of PEPCK responses with the optimised reactions 
conditions confirmed the suitability of this methodology for the studies to be 
undertaken in this project. 
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CHAPTER 3 
 
Definition of experimental conditions 
for studying regulation of 
gluconeogenesis by adrenal 
corticosteroids. 
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3.1 Introduction 
The liver is the major organ for glucose production in vivo. Experimental studies 
using isolated perfused livers or liver slices are difficult to perform and not always 
reproducible. Nevertheless hepatic glucose release has been measured in a liver slice 
culture system. This method may be helpful for characterization of direct insulin 
action and resistance in a complex tissue as the liver. It has been applied for the 
analysis of drug effects on hepatic glucose metabolism (Buettner et al., 2005). This 
method of culturing liver slices is not suitable for the current project as we need a 
robust system to test a lot of samples under highly comparable conditions. 
Hepatocyte cultures allow the detailed investigation of the effect of various 
compounds on hepatic metabolism and secretion. They form an important 
experimental tool for pharmacological, toxicological and metabolic studies. 
Traditionally isolated hepatocytes are cultured as a monolayer on collagen coated 
plates. Primary cultures of adult rat liver hepatocytes have been extensively used in 
studying hepatocyte cell function. The short-term controls of glycogen synthase and 
glycogen phosphorylase by major regulators, such as insulin, glucose, catecholamine, 
and glucagon, were compared in adult rat hepatocytes in primary culture (Nakamura 
et al., 1984). However hepatocytes cultured under such conditions tend to de-
differentiate rapidly and their liver specific functions such as gluconeogenesis are lost 
during the culture process (Kang et al., 2002; Sidhu et al., 2004; Wang et al., 2004b). 
Several laboratories have explored new experimental conditions in order to prevent 
hepatocyte dedifferentiation. There are now accumulating data suggesting that 
culturing cells in a 3D matrix offers an environment that mimics native tissue 
architecture in order to establish hepatocyte integrity (Cho et al., 2008; Yamamoto et 
105 
 
al., 2006). Cultured hepatocytes in a 3D collagen matrix have demonstrated 
advantage over monolayer cells in terms of liver-specific protein expression, glucose 
metabolism, and cytochrome (CYP450) activities (Richert et al., 2002). However, for 
the current study these complex culture systems are time consuming and restrict the 
potential for measurement of rapid changes in protein expression or glucose 
production. 
The human hepatic carcinoma cell line HepG2 is widely used in studying liver 
metabolism in culture. These cells respond to insulin by altering the synthesis and 
secretion of insulin like growth factor binding protein-1 (IGFBP-1) in a manner that 
mimics many of the changes in plasma IGFBP-1 levels observed in vivo. Popular rat 
hepatoma cell lines, such as H4-II-E-C3 from Reuber hepatoma, and H35 and HTC 
from Morris hepatoma 7288C are routinely used in studies of hepatocyte function. 
Glucose uptake and insulin signalling pathways have been studied using H4-II-E-C3 
cell lines (Curran et al., 2010; Dickens et al., 1998). These cell lines have also been 
used to study the effect of various compounds on PEPCK gene expression (Juan et 
al., 2010). H4-II-E-C3 cells have also been used to determine total glucose production 
in culture conditions (de Raemy-Schenk et al., 2006). These studies have evaluated 
the effects of gluconeogenic stimulators, and suppression by insulin and metformin. 
Adrenal corticosteroids have long been known to regulate glucose homeostasis. 
Administration of adrenal cortex extracts to fasted adrenalectomised rats leads to 
increased blood glucose levels and liver glycogen deposition (Long et al., 1940). This 
increase in glucose levels was demonstrated to be due to stimulation of glucose 
production and not an inhibition of glucose utilization (Welt et al., 1952). Actions of 
glucocorticoids in vitro on liver to stimulate gluconeogenesis have also been 
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demonstrated. Cortisol and corticosterone stimulated glucose production in liver 
tissue slices from fasted, adrenalectomised animals (Haynes, 1962; Uete et al., 1963). 
It was proposed that glucocorticoids play a permissive role in the hormonal regulation 
of gluconeogenesis. Livers from adrenalectomized rats were shown to be less 
responsive to glucagon and epinephrine, yet became fully responsive within 60 min of 
dexamethasone addition to the liver perfusions (Friedmann et al., 1967). 
Dexamethasone alone caused no significant stimulation in these studies.  
A physiologically relevant increase in serum cortisol levels alone does not 
significantly increase the rate of glucose production. Although infusion of cortisol 
alone had no effect on glucose production, the addition of cortisol markedly 
accentuated hyperglycaemia produced by glucagon and (or) epinephrine primarily by 
sustaining the increases in glucose production produced by these hormones. These 
data indicate that changes in glucose metabolism in circumstances in which several 
counter regulatory hormones are elevated (e.g., "stress hyperglycaemia") are a 
consequence of synergistic interactions among these hormones (Eigler et al., 1979). 
This synergistic effect with glucagon was also shown in vitro in isolated hepatocytes 
using dexamethasone (Allan et al., 1984).  
The adrenal glands have been studied since the 1870s in relation to blood glucose. In 
the 1900’s many studies reported that subcutaneous or intravenous administration of 
adrenal extracts caused glycosuria (Blum, 1901). Production of corticosteroids by 
adrenal glands in vitro has been extensively used in assay methods for corticotrophin 
(ACTH) (de Wied et al., 1969; Saffran et al., 1952; Vinson, 1966). 
Different approaches have been preferred to investigate in vitro steroidogenesis using 
adrenal glands. Adrenal slices and homogenates have been found to produce steroids, 
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incorporate radioactive precursors and respond to ACTH (Cooper et al., 1958; 
Vinson, 1966). Adrenal slices were used to study aldosterone and corticosterone 
production in vitro (Kaplan, 1965; Laplante et al., 1966). Adrenal glands were 
perfused to study the response of ACTH stimulation on cortisol release (Madill et al., 
1973). Guinea pig adrenal segments were used to study the effects of ACTH effect on 
adrenal glands (Chayen et al., 1976). 
Pathways of corticosteroid biosynthesis from 
3
H-pregnenolone and 
14
C-progesterone 
have been studied in vitro using duck (Whitehouse et al., 1967), sheep (Vinson, 1967) 
and human (Whitehouse et al., 1968) adrenal tissue. Many groups have studied in 
vitro steroid metabolism using adrenal cells obtained by trypsin or collagenase 
digestion. However, it was observed that in vitro studies using adrenal quarters 
produced reliable results (Hofmann et al., 1954). 
Previous studies have shown that sauvagine and metyrapone infusions cause long 
lasting hyperglycaemia in rats. This was an adrenal dependent response that could not 
be reproduced by corticosterone alone (Kaminski, 2004). The hyperglycaemic effect 
of metyrapone strongly suggested that perturbation of corticosterone synthesis led to 
the production of an adrenal steroid with even greater gluconeogenic activity. Despite 
more than 100 years of research on adrenal regulation of glucose homeostasis, there is 
a lack of studies describing comparative data for the gluconeogenic activity of 
different adrenal steroids. Therefore, this chapter describing optimisation of the 
conditions to study the relative gluconeogenic activity of adrenal steroids on cultured 
hepatocytes. In addition, solid phase extraction methods were optimised to recover the 
steroids from adrenal incubations, and initial bioassays of extracts from adrenal 
incubations with sauvagine and metyrapone are included. 
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3.2 Aims of this chapter. 
1. Optimisation of cell culture conditions for studying gluconeogenesis in vitro. 
2. Characterisation of H4-II-E-C3 cell responses to standard stimuli (8-Br cAMP, 
glucagon, insulin and corticosterone) 
2. Extraction of steroids from isolated adrenal gland incubations with sauvagine and 
metyrapone, and evaluation of their biological activity on cultured hepatocytes. 
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3.3 Methods 
3.3.1 Cell Culture 
The rat liver hepatoma cell line, H4-II-E-C3 (European collection of animal cell 
cultures; ECACC no. 85061112) was used for all experiments. The cell line was 
originally derived from Ruber H-35 hepatoma, which was induced in an AXC rat by 
the carcinogen N-2 fluorenyldiacetamide (Weinstein, 1972). Cells were cultured in 
Dulbecco’s modified Eagle medium (DMEM) containing 5 mM glucose, non-
essential amino acids and 10% (v/v) foetal calf serum (FCS), and incubated at 37°C in 
a humidified CO2 incubator (92% air, 8% CO2). Cells were passaged using 0.05% 
trypsin in phosphate buffered saline (PBS) containing 0.02% EDTA. Cells were 
seeded in multi-well plates: 6 well (9.5 cm
2
 growth area; 1.2 x 10
6
 cells) or 24 well (2 
cm
2
 growth area; 2.5 x 10
5
 cells) and grown to 100% confluence. Treatments were 
carried out in either glucose-free Earl’s balanced salt solution (EBSS; 0.264 g/L 
CaCl2, 0.4 g/L KCl, 0.2 g/L MgSO4.7H2O, 6.8 g/L NaCl, 2.2 g/L NaHCO3, 0.158 g/L 
NaH2PO4.2H2O) or DMEM containing 5 mM glucose. 
3.3.2 Glucose assay 
Glucose was assayed using a protocol adapted from the method described by Hugget 
and Nixon (Bergmeyer, 1963). Media samples (50 µl) were added to reaction buffer 
(100 µl) containing 0.12 M sodium phosphate (pH 7), 9 U/ml glucose oxidase, 6 U/ml 
horseradish peroxidase (HRP), 1 mM Amplex red® and incubated in the dark for 10 
min. The assay is based on two sequential enzymatic reactions. Initially, glucose 
oxidase catalyses the conversion of glucose to gluconic acid and hydrogen peroxide 
(H2O2) and secondly, H2O2 is reduced by HRP and in turn reacts with Amplex Red® 
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to form resorfin which is highly fluorescent. Amplex red reacts with H2O2 in a 1:1 
stoichiometry. Thus, the presence of glucose is indicated by the measure of 
fluorescence. Measurements were made in a 96 well plate using a Cytofluor II 
fluorescent plate reader (Ex: 560; Em: 590 nm) (Perspective Biosystems, US). Data 
were analysed by linear regression using Graph Pad prism software. 
3.3.3 PEPCK Activity assay 
PEPCK activity was measured using the bioluminescent method described in section 
2.10. At the end of each cell experiment media samples were collected for glucose 
measurement and the cells were frozen at -80
o
C for subsequent PEPCK activity assay. 
3.3.4 Adrenal incubations in vitro. 
Male Wistar rats (250 – 300 g; Charles River, UK) were used in all experiments. Rats 
were killed using an approved method and their adrenal glands were removed. The 
peri-capsular fat was carefully removed and each adrenal gland was cut into 4 
quarters in a Petri dish. These adrenal sections were washed twice in 2 ml PBS and 
then incubated in phenol red free DMEM (5 mM glucose) with treatment compounds 
(sauvagine 3 µM, metyrapone 30 µM, or ACTH 1 nM) for 6 hours at 37°C in a CO2 
incubator. The incubation media were collected and stored at -20°C for extraction and 
bioassay. 
3.3.5 Corticosterone measurements. 
Corticosterone concentrations in the adrenal incubation media were measured by 
using an EIA corticosterone kit (Assay Designs, Inc USA). The kit uses a polyclonal 
antibody to corticosterone to bind in a competitive manner. All the reagents were 
allowed to warm to room temperature before performing the experiment. Standards 
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were prepared in glass tubes.  Assay buffer was prepared by diluting 10 ml of the 
buffer provided with 90 ml of deionised water. Wash buffer was prepared by diluting 
5 ml of the supplied concentrate with 95 ml of deionised water. Standards and 
samples (100 µl) were dispensed into the appropriate wells in the strips provided. 
Conjugate (50 µl) was added to each well except the total activity well and the blank 
well, and antibody (50 µl) was added to each well except the blank, TA and NSB 
wells. The plate was incubated on a plate shaker for 2h. The contents of the plate were 
emptied and the wells washed three times with 400 µl of wash solution. Conjugate (5 
µl) was added to the TA well, and pNpp substrate (200 µl) was added to every well. 
The plate was then incubated for 1 h at room temperature.  Stop solution (50 µl) was 
added to each well and the plate was read immediately at 405 nm.  
The % crossreactivity of the assay to deoxycorticosterone (28.6%), progesterone 
(1.7%), aldosterone (0.18%) and cortisol (0.046%). 
3.3.7 Extraction of steroids using Sep-pak C18 cartridges. 
Media samples were acidified with 10% 1 M HCl and extracted on Sep-pak® 1 cc 
(100 mg) C18 cartridges (Waters). The cartridges were initially equilibrated with 
methanol (2 x 1 ml) followed by a wash step with water (1 x 1 ml). The cartridges 
were further acidified with 50 mM HCl (1 x 1 ml) before loading the acidified 
samples. After loading samples the columns were washed with 50 mM HCl (1 x 1 ml) 
and water (1 x 1 ml). Bound steroids were eluted with 80% methanol (2 x 0.5 ml) into 
glass tubes and dried with a stream of N2 at 40°C on a heated block. The dried 
extracts were reconstituted in 200 µl 50% ethanol and stored for further analysis on 
cells and for HPLC analysis. 
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3.3.8 Extraction of steroids using Strata-X Cartridges. 
The media samples were acidified with 10% 1 M HCl and extracted on Strata-X 
cartridges (Phenomenex). The Strata-X matrix is described by the manufacturer as a 
mixed anion-exchange hydrophobic interaction resin. The cartridges were initially 
equilibrated with methanol (2 x 1 ml) followed by a wash step with water (1 x 1 ml). 
The cartridges were further acidified with 50 mM HCl (1 x 1 ml) before loading the 
acidified samples. The columns were washed with 50 mM HCl (1 x 1 ml) and water 
(1 x 1 ml). The steroid conjugates were eluted following the manufacturer’s 
recommended elution conditions with 5% ammonia in methanol (2 x 0.5 ml) into 
glass tubes and dried under N2 gas at 40°C on a heated block. The dried extracts were 
reconstituted in 200 µl 50% ethanol and stored for further analysis on cells and for 
HPLC analysis. 
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3.4 Results 
3.4.1 Optimisation of cell culture conditions for studying gluconeogenesis. 
3.4.1.1 Effect of Lactate/Pyruvate ratio on hepatocyte glucose production 
H4-II-E-C3 cells were treated with increasing concentrations of lactate (2 – 20 mM) 
and 2 mM pyruvate in EBSS. Control cells were treated with EBSS alone with no 
substrates. The cells were incubated for 6 h in a CO2 incubator at 37
o
C. Significant 
increases in glucose production were observed with 5, 10 and 20 mM lactate forming 
4.6 ± 0.6, 8.4 ± 0.7, and 10.4 ± 1.2 (nmol/2x10
5
 cells) respectively (Figure 3.1).  
3.4.1.2 Time course of glucose production in fed and fasted H4-II-E-C3 cells. 
H4-II-E-C3 cells were grown to confluence in DMEM (5 mM glucose) supplemented 
with 10 % FCS. Cells were then maintained for 18 h in serum-free DMEM (5 mM 
glucose). 
For the fed cell experiments, cells were treated without any prior fasting for 6 h in 
EBSS with and without gluconeogenic substrates (20 mM lactate/2 mM pyruvate). 
Glucose production in cells without substrates increased with time up to 180 min 
producing 9.0 ± 1.2 (nmol/2x10
5
 cells) and subsequently decreased to 3.2 ± 1.3 
(nmol/2x10
5
 cells) at 360 min. Glucose production in cells incubated with substrates 
reached a maximum at 240 min (15.9 ± 4 nmol/2x10
5
 cells) and decreased by 30 – 
40% at 360 min (10 ± 2 nmol/2x10
5
 cells) (Figure 3.2 A).  
For the fasted cell experiments, cells were starved in DMEM (0 mM glucose) for 4 h 
and then incubated for 6 h in EBSS with and without gluconeogenic substrates (20 
mM lactate/2 mM pyruvate). Glucose production in cells without substrates did not 
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increase in the 360 min. With the substrates the glucose production increased 
significantly with time up to 240 min when steady state glucose levels were reached 
(13 ± 2 nmol/2x10
5
 cells) (Figure 3.2 B). 
3.4.1.3 cAMP mediated glucose production in H4-II-E-C3 cells. 
Fasted H4-II-E-C3 cells were incubated for 6 h in EBSS (20 mM lactate/2 mM 
pyruvate) containing 8-Br-cAMP (75 – 600 µM) with and without insulin (10 ng/ml). 
Media samples were collected for glucose measurements and the cells were frozen at -
80
o
C for PEPCK activity measurements. 
Glucose production increased significantly with 300 µM and 600 µM cAMP to 25 ± 4 
and 35 ± 6 glucose (nmol/2x10
5
 cells) respectively. Insulin (10 ng/ml) suppressed this 
glucose production to below basal levels (Figure 3.3 A). The corresponding PEPCK 
activities in cells treated with 300 µM and 600 µM cAMP were increased 1.8 ± 0.1 
and 2.2 ± 0.5 fold basal values (Figure 3.3 B). 
3.4.1.4 Effect of glucagon on hepatocytes 
Fasted H4-II-E-C3 cells were incubated for 6 h in EBSS (20 mM lactate/2 mM 
pyruvate) containing glucagon (1 – 1000 nM) with and without insulin (10 ng/ml). 
Media samples were collected for glucose measurements and the cells were frozen at -
80
o
C for PEPCK activity measurements. 
Glucose production increased significantly with 100 nM and 1000 nM glucagon to 18 
± 3 and 24 ± 3 glucose (nmol/2x10
5
 cells) respectively. Insulin (10 ng/ml) suppressed 
this glucose production to basal levels (Figure 3.4 A). The corresponding PEPCK 
activities in cells treated with 100 nM and 1000 nM glucagon were increased to 1.4 ± 
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0.2 and 1.7 ± 0.5 fold basal values. The PEPCK activity was suppressed in cells 
treated with insulin (10 ng/ml) (Figure 3.4 B). 
3.4.2 Effect of adrenal corticosteroids on gluconeogenesis. 
3.4.2.1 Effect of corticosterone on hepatic glucose production and PEPCK activity. 
Fasted H4-II-E-C3 cells were incubated for 6 h in EBSS (20 mM lactate/2 mM 
pyruvate) containing corticosterone (0 – 10,000 nM) with and without insulin (10 
ng/ml). Media samples were collected for glucose measurements and the cells were 
frozen at -80
o
C for PEPCK activity measurements. 
Glucose production increased significantly with 1000 nM and 10,000 nM 
corticosterone to 23 ± 3 and 30 ± 6 glucose (nmol/2x10
5
 cells) respectively. Insulin 
(10 ng/ml) suppressed this glucose production to basal levels of 9 ± 1 and 11 ± 3 
glucose (nmol/2x10
5
 cells) respectively (Figure 3.5 A). The corresponding PEPCK 
activities in cells treated with 1000 nM and 10000 nM corticosterone were increased 
to 1.9 ± 0.1 and 2.2 ± 0.2 fold basal values. These increases in PEPCK activity were 
blocked in cells treated with insulin (10 ng/ml) (Figure 3.5 B). 
3.4.2.2 Effect of DHEA, pregnenolone, allopregnenolone and their sulphated 
conjugates on hepatic glucose production. 
Fasted H4-II-E-C3 cells were incubated for 6 h in EBSS (20 mM lactate/2 mM 
pyruvate) containing corticosterone, DHEA, PREG, ALPREG, DHEA-S, PREG-S, 
and ALPREG-S (1 µM). Untreated cells produced 12 ± 1 glucose (nmol/2x10
5
 cells). 
In the presence of corticosterone (1 µM) glucose production was significantly 
increased to 22 ± 3 glucose (nmol/2x10
5
 cells). The same concentrations of DHEA, 
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PREG, ALPREG, DHEA-S, PREG-S and ALPREG-S did not cause any significant 
increase in glucose production. A trend for decreased glucose production was 
observed in the DHEA and PREG incubations (Figure 3.6). 
3.4.2.3 SPE extraction of corticosterone. 
DMEM was spiked with corticosterone to obtain a final concentration of 1 µM. 
Extraction with Sep-pak® 1cc (100 mg) C18 cartridges resulted in recovery of 84 ± 
3% of corticosterone.  
3.4.2.4 Adrenocorticotropic hormone induced corticosterone production in vitro. 
Adrenal gland sections were incubated in DMEM (5 mM glucose) with and without 
adrenocorticotropic hormone (ACTH; 1 nM). Incubation media was collected at 1 h 
time intervals for 6 h and corticosterone was measured by enzyme immunoassay. The 
Corticosterone values for untreated adrenal sections were 7.2 ± 3, 28 ± 6, 72 ± 9, 74 ± 
6 (ng/100 mg tissue), and for ACTH stimulated adrenals 6 ± 1, 171 ± 23, 256 ± 16, 
and 281 ± 23 (ng/100 mg tissue) at 0, 2, 4 and 6 h respectively (Figure 3.8). 
3.4.2.5 Adrenal Incubations with sauvagine and metyrapone. 
Adrenal sections were incubated for 6 h with DMEM (5 mM glucose) under basal (B) 
conditions or with sauvagine (S, 3µM), metyrapone (M, 30 µM), sauvagine and 
metyrapone (S, 3 µM; M, 30 µM). There were no significant increases in 
corticosterone production compared to basal secretions. The corticosterone 
measurements of the incubation medium were 93 ± 10, 105 ± 9, 43 ± 5, and 53 ± 6 
(ng/100 mg) for B, S, M and SM respectively (Figure 3.9) 
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3.4.2.6 Comparison of the effect of SPE extracts of adrenal incubations on total 
glucose production and PEPCK activity. 
SPE extracts were prepared using Sep-pak C18 cartridges and Strata-X AW columns 
from adrenal incubations collected after 6 h basal (B) conditions or with sauvagine (S, 
3µM), metyrapone (M, 30µM), sauvagine and metyrapone (S, 3 µM; M, 30 µM). The 
extracts were reconstituted in EBSS (20 mM lactate/2 mm pyruvate) and incubated 
with fasted H4-II-E-C3 cells for 6 h. Corticosterone (C, 1 µM) was also used to 
compare the glucose production. Glucose production was 11 ± 3, 20 ± 3, 29 ± 4, 62 ± 
9, 66 ± 12 and 48 ± 5 (nmol/2x10
5
 cells) for Sep-pak C18 extracts from U, C, B, S, M, 
and SM incubations respectively. The corresponding glucose levels were 11 ± 3.3, 
14.2 ± 2.7, 17 ± 3.4 and 17.6 ± 4 (nmol/2x10
5
 cells) for extracts prepared with Strata-
X AW columns for B, S, M and SM incubations respectively (Figure 3.11A). Relative 
PEPCK activity measurements showed that corticosterone and the Sep-pak extracts of 
B, S, M and SM incubations produced significant increases in PEPCK activity, which 
were 1.7 ± 0.2, 1.8 ± 0.1, 2.1 ± 0.4, 2 ± 0.3, and 2.3 ± 0.4 times the levels of untreated 
cells respectively. PEPCK activity did not increase significantly in the cells incubated 
with extracts obtained from Strata-X AW columns (Figure 3.11B). 
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Figure 3.1 Concentration dependent increases in glucose output with lactate. 
H4-II-E-C3 cells were incubated for 6 h with lactate (2 – 20) mM in addition to 
pyruvate (2 mM). Results are mean ± SEM. n= 8. Statistical differences were 
determined by ANOVA (** = p<0.01, *** = p<0.001, vs pyruvate alone) 
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Figure 3.2 Time course of glucose production by fed and fasted cells. 
(A) Fed cells; (B) fasted cells, incubated with (dark circles) and without (dark 
squares) substrates (20 mM lactate/2 mM pyruvate) in EBSS for 6h with glucose 
measured at the indicated time points. Results are mean ± SEM. n= 8. Statistical 
differences were determined by ANOVA (* = p<0.05, *** = p<0.001, vs the 
corresponding time points without substrates.) 
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Figure 3.3 cAMP stimulated hepatic glucose production in vitro. 
Fasted H4-II-E-C3 cells were incubated for 6 h in EBSS (20 mM lactate/2 mM 
pyruvate) containing 8-Br-cAMP without (dark bars) and with (white bars) insulin 
(10 ng/ml). (A) Glucose measurements at 6 h. (B) PEPCK activity measurements in 
cells at 6 h. n=8. Statistical differences were determined by two-way ANOVA 
followed by Bonferroni post test (**=P<0.01; ***=P<0.001 vs control; # = P<0.05; 
###=P<0.001 vs the corresponding cAMP treatment without insulin) 
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Figure 3.4 Effect of glucagon on hepatic glucose production. 
Fasted H4-II-E-C3 cells were incubated for 6 h in EBSS (20 mM lactate/2 mM 
pyruvate) containing glucagon (1 – 1000 nM) without (dark bars) and with (white 
bars) insulin (10 ng/ml). (A) Glucose measurements at 6 h. (B) PEPCK activity 
measurements in cells at 6 h. n=8. Statistical differences were determined by two-way 
ANOVA followed by Bonferroni post test (**=P<0.01; ***=P<0.001 vs control;# = 
P < 0.05, ##= P<0.01, ###=P<0.001 vs the corresponding cAMP treatment without 
insulin) 
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Figure 3.5 Effect of corticosterone on glucose production and PEPCK activity in 
H4-II-E-C3 cells 
Fasted H4-II-E-C3 cells were incubated for 6 h in EBSS (20 mM lactate/2 mM 
pyruvate) containing corticosterone (10 – 10,000 nM) without (dark bars) and with 
(white bars) insulin (10 ng/ml). (A) Glucose measurements at 6 h. (B) PEPCK activity 
measurements in cells at 6 h. n=8. Statistical differences were determined by two-way 
ANOVA followed by Bonferroni post test (*=P<0.05; ***=P<0.001 vs control; # = P 
< 0.05, ###=P<0.001 vs the corresponding cAMP treatment without insulin) 
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Figure 3.6 Effect of some common adrenal steroids on H4-II-E-C3 glucose 
production. 
Starved H4-II-E-C3 cells were incubated for 6 h in EBSS (20 mM lactate/2 mM 
pyruvate) containing corticosterone (C, 1 µM), dehydroepiandrosterone (DHEA 1 
µM), pregnenolone (PREG 1 µM), Allo-pregnenolone (ALPREG 1 µM), DHEA 
sulphate (DHEA-S 1 µM), PREG sulphate (PREG-S 1 µM), and ALPREG sulphate 
(ALPREG-S 1 µM). n=6. Statistical differences were determined by one-way ANOVA 
(***=P<0.001 vs untreated cells). 
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Figure 3.7 ACTH induced corticosterone production by adrenal sections. 
Adrenal sections were incubated in DMEM for 6h. Medium was collected and 
assayed for corticosterone levels. The clear bars show corticosterone (ng/100mg 
tissue) production by untreated adrenal gland sections and the dark bars show 
corticosterone production from adrenal sections stimulated with ACTH (10 nM). 
Statistical differences were determined by two-way ANOVA followed by Bonferroni 
post test. (***=P<0.001 compared to the corresponding incubation time without 
ACTH). 
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Figure 3.8 Secretion of corticosterone from adrenal sections incubated with 
sauvagine and metyrapone. 
Adrenal sections were incubated for 6 h in DMEM (5 mM glucose) under basal 
conditions (B), sauvagine (S, 3µM), metyrapone (M, 30 µM), or sauvagine and 
metyrapone (S, 3 µM; M, 30 µM). n=6. Statistical analysis was performed using one-
way ANOVA (###=P<0.001 vs B). 
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Figure 3.9 Comparison of biological activity of SPE extracts of adrenal 
incubations. 
SPE extracts from Sep-pak C18 cartridges (dark bars) and Strata-X AW columns 
(white bars) were reconstituted in EBSS (20 mM lactate/2 mM pyruvate) and 
incubated on fasted H4-II-E-C3 cells for 6 h. U= control EBSS. C=corticosterone (1 
µM), B, S, M and SM correspond to adrenal incubation conditions described in figure 
3.9. (A) Total glucose production was measured in media samples. (B) PEPCK 
activity is measured in cell lysate. n=6. Statistical differences were determined by 
two-way ANOVA followed by Bonferroni post test. (***=P<0.001 vs U). 
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3.5 Discussion 
Optimisation of conditions for studying hepatic glucose production used lactate and 
pyruvate as gluconeogenic substrates. In this study the ratio of lactate/pyruvate were 
optimised to maximize total glucose production in cell culture using H4-II-E-C3 cells. 
A lactate/pyruvate ratio of (10:1) in EBSS produced the maximal glucose in 6 h and 
was standardised as the substrate concentrations for this study. This ratio has 
previously been shown to be optional in hepatocytes isolated from starved rats 
(Rigoulet et al., 1987). 
Total glucose production is a result of both glycogenolysis and gluconeogenesis. 
Experiments were performed to observe the difference in glucose production during 
fed and fasted sates. Gluconeogenic genes are up-regulated during fasted states and 
should result in increased glucose production in the presence of gluconeogenic 
substrates (Owen et al., 1969). Results in this chapter show that in the fasted states 
H4-II-E-C3 cells produce more glucose at any given time for the same substrate 
concentrations. These glucose release assays include both glucose uptake and release 
simultaneously. The net glucose release into the media in the presence of 
gluconeogenic substrates such as lactate and pyruvate and during starving is mostly 
attributed to increased gluconeogenic genes (Rigoulet et al., 1987).  
All further experiments with treatment conditions were carried out on starved cells. 
Well known gluconeogenic stimulators (Liu et al., 2008) were initially tested under 
these experimental conditions. 8 Br-cAMP, glucagon and corticosterone produced a 
concentration dependent increase in glucose production and PEPCK activity which 
was suppressed to below control/untreated levels in the presence of insulin (10 
ng/ml). 
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In order to study the role of adrenal corticosteroids in hepatic glucose production, in 
vitro adrenal incubations were performed. Adrenal glands were removed from male 
Wistar rats and the peri-capsular fat was quickly removed and the gland was chopped 
into four quarters, which were washed in PBS to minimise background levels of 
steroids due to any stress response occurring during animal handling. In order to 
confirm adequate responses in the adrenal incubations, initial experiments were 
performed to measure corticosterone production in the presence of ACTH (1x10
-9 
M). 
The adrenal glands produced 4 fold more corticosterone with ACTH stimulation 
compared to un-stimulated adrenal glands. The corticosterone levels produced by the 
adrenal glands under basal conditions were comparable with published results (White 
et al., 1992). 
Adrenal incubation media collected from adrenal glands incubated with sauvagine and 
metyrapone were tested for biological activity. SPE of the steroids present in the 
adrenal incubation media was performed using two different columns. Sep-pak C18 
columns were used to extract all steroids. This extraction was optimised using DMEM 
spiked with corticosterone. The optimised method provided >80% recovery of 
corticosterone. 
Strata-X columns contain a weak anion exchange resin and are used to extract steroid 
conjugates from the adrenal incubation media. Initial experiments with spiked DMEM 
provided less than 10% recovery of corticosterone. This extraction was essential to 
determine the nature of the biological activity observed in hepatocyte incubations 
with adrenal media extracts. Sep-pak extracts of sauvagine and metyrapone caused a 
significant increase in total glucose production and relative PEPCK activity compared 
to untreated, corticosterone (1μM) and basal extracts. The corresponding Strata-X 
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extracts did not cause any significant change in glucose production or in PEPCK 
activity.  
The corticosterone levels present in the adrenal incubations varied according to the 
different treatments. Basal and sauvagine incubations had maximum values that 
approximated to 100 nM corticosterone. Metyrapone incubations had significantly 
low corticosterone levels of around 40 nM. Despite these low levels of corticosterone 
present in the metyrapone incubations, the Sep-pak extracts increased glucose 
production to 2 fold the level of extracts from basal adrenal incubations, and to 
approximately 3.5 times the level of glucose production of cells incubated with 
corticosterone (1 µM). Even the extracts from adrenal incubations under basal 
conditions, with corticosterone levels below 100 nM produced 1.5 times the glucose 
output compared to that of cells incubated with corticosterone (1 µM). These results 
raise an important question as to the exact role of corticosterone in hepatic glucose 
production and the importance of the other steroid components in the extracts that are 
responsible for this gluconeogenic effect.  Even under extreme stress conditions the 
circulating blood corticosterone levels never increase over (0.5 µg /mL) (Dugovic et 
al., 1999). This implies that other endogenous factors are likely critical for a stress-
induced hyperglycaemic response. 
The results in this chapter conclude that adrenal incubations contain gluconeogenic 
steroids in addition to corticosterone, which are unlikely to be conjugated. Whether 
these steroids act in synergy with corticosterone or have an effect on their own is yet 
to be determined.  
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CHAPTER 4 
Characterisation of gluconeogenic 
adrenal steroids 
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4.1 Introduction 
The preliminary studies to evaluate the conditions for bioassay of secreted 
gluconeogenic steroids showed that despite low levels of corticosterone in extracts 
prepared from adrenal incubations with sauvagine and metyrapone, they had 
significant glucose producing activity. This chapter describes the investigations by 
high performance liquid chromatography used to characterise the steroids present in 
the conditioned media samples. 
The historically important, initial experiments of extraction and characterisation of 
steroids from adrenal extracts involved complex chemical methods. Only six of the 
twenty-eight crystalline compounds that were isolated could prolong the life of 
adrenalectomised animals (Reichstein et al., 1938). Paper–partition chromatography 
was one of the earliest methods used to isolate and characterise the adrenal steroids 
(Zafforoni et al., 1951). 
Gas chromatography coupled to mass spectrometry (GC–MS) is now considered the 
gold standard for quantification of steroids. It is highly specific and has been applied 
to quantify a large number of steroids (Ichimura et al., 1986; Shackleton, 1993). 
However, this technique requires complicated and time-consuming sample 
preparation procedures which are not suitable for the needs of this project. 
Liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS) is a 
better alternative to quantify steroids. Methods have been described for the 
determination of cortisol and cortisone (Taylor et al., 2002), 17-hydroxyprogesterone 
(Etter et al., 2006), 11-desoxycortisol (Guo et al., 2006) and corticosterone (Ghulam 
et al., 1999). Derivatisation is often necessary to achieve the required sensitivity to 
quantify endogenous levels of steroids.  
132 
 
Although all these methods are suitable to simultaneously quantify and study the 
steroid profiles under different conditions, a simple HPLC method was used in this 
study. Fractions were collected and dried and reconstituted in incubation media to test 
the activity on cells. 
 
AIMS of this chapter: 
1. Define a HPLC separation method to identify specific gluconeogenic steroids 
that are secreted during adrenal incubations with sauvagine and metyrapone. 
2. Characterise the activity of potential gluconeogenic steroids. 
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4.2 Experimental 
4.2.1 Chemicals and reagents 
Corticosterone, 11-deoxycorticosterone (DOC) and 11-deoxycorticosterone acetate 
(DOCA) were obtained from SIGMA (Dorset, UK). 18-OH-DOC was purchased 
from Steraloids, UK. 
4.2.2 Chromatography 
HPLC was performed with a MERCK HITACHI L-6200 dual piston pump. 
Corticosteroids were detected at 240 nm using a Shimadzu SPD-6A UV detector. 
Chromatographic data was collected and processed by PRIME software. 
Chromatography was undertaken using a reverse phase Hichrom H5ODS H3724 
column (4.6 x 150 mm). 
A number of HPLC conditions were evaluated for their potential to separate the 
steroid components in extracts for identification of gluconeogenic activity. The flow 
rate for all these gradient conditions was 1.5 ml/min. A blank run was always 
conducted between steroid standards and test samples. For test samples, fractions (1 
min duration) were collected automatically on a fraction collector throughout each 
HPLC run. 
4.2.2.1 Conditions set 1: The column was equilibrated with a solvent mixture consisting 
of 7.7% methanol, 7.7 mm H3PO4 and 30% CH3CN and eluted with a linear gradient 
over 20 min to 6.6% methanol, 6.6 mM H3PO4 and 40% CH3CN. The column was 
further eluted with a gradient over 40 min to 0% methanol, 0 mM H3PO4 and 100% 
CH3CN. The elution conditions were maintained at 100% CH3CN for 5 min and the 
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column was then re-equilibrated to 7.7% methanol, 7.7 mM H3PO4 and 30% CH3CN 
for 5 min. 
4.2.2.2 Conditions set 2: The column was equilibrated with a solvent mixture consisting 
of 7.7% methanol, 7.7 mm HCl and 30% CH3CN and eluted with a linear gradient 
over 20 min to 6.6% methanol, 6.6 mM HCl and 40% CH3CN. The column was 
further eluted with a gradient over 40 min to 0% methanol, 0 mM HCl and 100% 
CH3CN. The elution conditions were maintained at 100% CH3CN for 5 min and the 
column the re-equilibrated to 7.7% methanol, 7.7 mM HCl and 30% CH3CN for 5 
min. This method was adapted from condition set 1 to overcome incompatibility for 
bioassay purposes of fractions containing H3PO4. 
4.2.2.3 Conditions set 3: The column was equilibrated with a solvent mixture consisting 
of 8.5% methanol, 8.5 mM HCl and 15% CH3CN and eluted with a linear gradient 
over 25 min to 6.0% methanol, 6.0 mM HCl and 40% CH3CN. The column was 
further eluted with a gradient over 40 min to 0% methanol, 0 mM HCl, 90% CH3CN 
and 0.01% tri-fluoro acetic acid (TFA). The elution conditions were maintained at 
90% CH3CN and 0.01% TFA for 5 min and the column was then re-equilibrated to 
8.5% methanol, 8.5 mM HCl and 15% CH3CN for 5 min. 
4.2.2.4 Conditions set 4: The column was equilibrated with a solvent mixture consisting 
of 8.5% methanol, 8.5 mM HCl and 15% CH3CN and eluted with a linear gradient 
over 30 min to 7.0% methanol, 7.0 mM HCl and 30% CH3CN. The column was 
further eluted with a gradient over 40 min to 0% methanol, 0 mM HCl, 90% CH3CN 
and 0.01% TFA. The elution conditions were maintained at 90% CH33CN and 0.01% 
TFA for 5 min and the column then re-equilibrated to 8.5% methanol, 8.5 mM HCl 
and 15% CH3CN for 5 min. 
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4.2.2.5 HPLC condition set 5 
The column was equilibrated with a solvent mixture consisting of 8.0% H20, 8.0 mM 
HCl and 20% CH3CN and eluted with a linear gradient over 25 min to 5.8% 
methanol, 5.8 mM HCl and 42% CH3CN. The column was further eluted with a 
gradient over 40 min to 0% methanol, 0 mM HCl, 90% CH3CN and 0.01% TFA. The 
elution conditions were maintained at 90% CH33CN and 0.01% TFA for 5 min and 
the column then re-equilibrated to 8.0% H20, 8.0 mM HCl and 20% CH3CN for 5 
min. 
4.2.2.6 HPLC condition set 6 
The column was equilibrated with a solvent mixture consisting of 8.5% H20 , 8.5 mM 
HCl and 15% CH3CN and eluted with a linear gradient over 30 min to 7.0% H20, 7.0 
mM HCl and 30% CH3CN. The column was further eluted with a gradient over 40 
min to 0% H20, 0 mM HCl, 90% CH3CN and 0.01% TFA. The elution conditions 
were maintained at 90% CH33CN and 0.01% TFA for 5 min and the column then re-
equilibrated to 8.5% H20, 8.5 mM HCl and 15% CH3CN for 5 min. 
4.2.3 Method for DOCA hydrolysis. 
DOCA solution was incubated with 1M NaHCO3 solution overnight in a 37°C water 
bath. The incubated solution was centrifuged and the steroids in the supernatant were 
extracted using Sep-pak C18 cartridges as described in section 3.3.7. 
4.2.4 Bioassay of HPLC fractions 
HPLC fractions were dried down with a stream of N2 at 40°C, reconstituted in EBSS 
and incubated with H4-II-E-C3 cells in 24 well plates for 6 h. Media was collected 
and assayed for total glucose as described in section 3.3.2. 
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4.2.5 In vivo studies of the effect of sauvagine and metyrapone on blood 
glucose. 
Male Wistar rats (220 – 300 g; Charles River, UK) were used. In the days prior to the 
experiment, rats were given standard chow and water ad libitum and subjected to a 12 
h dark/light cycle. On the day of the experiment the rats were anaesthetised by i.p 
injection of thiopentone sodium (Intraval sodium; 100 mg/kg). Rats were 
tracheotomised and catheters were inserted in the carotid artery and jugular vein using 
polyethylene catheters of tubing size PP50 and PP25 respectively (Portex, UK). 
Experiments were conducted after a 30 min stabilisation period. Sauvagine treated 
rats were initially given an i.p injection of saline (200 µl) 60 min prior to sauvagine 
infusion for 25 min with sauvagine at the rate of 20 pmol/kg/min. For control rats, an 
initial i.p injection of saline was given 60 min prior to saline infusion for 25 min. For 
sauvagine and metyrapone treatments, rats were given an i.p injection of metyrapone 
(200 mg/kg) 60 min prior to sauvagine infusion for 25 min at the rate of 20 
pmol/kg/min. 
Blood glucose measurements were made using Accu-chek Aviva (Roche Ltd) by 
placing a drop of blood collected by pricking the tail vein at 15 min time intervals. At 
the end of the experiment 3 ml of arterial blood was collected to prepare plasma. 
Liver sections were snap frozen in liquid nitrogen for PEPCK activity measurements. 
Adrenals removed and subjected to incubation in DMEM for 6 h as described in 
section 3.3.4. 
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4.3 Results and discussion 
Each experiment results discussed in this section is a representative of one or two 
experiments for the given condition. Mean ± SEM was not derived for the peak areas, 
but a comparison to the respective control under the same chromatographic condition 
was made. The main goal of these experiments was to generate fractions from the 
adrenal incubations to test for gluconeogenic activity on hepatocytes. 
4.3.1 Initial evaluation of the HPLC methodology and comparison of 
adrenal incubation extracts. 
Gradient elution was performed using the HPLC condition set 1 described in section 
4.2.2.1. Corticosterone eluted at 6.1 min under these conditions.  
4.3.2 Bioassay of the HPLC fractions collected using condition set 1. 
Five consecutive fractions (0.5 ml) were pooled and dried under a stream of N2. The 
dried fractions were reconstituted in EBSS (20 mM lactate/2 mM pyruvate) and tested 
on H4-II-E-C3 cells as described in section 3. 
The cells incubated with the reconstituted fractions did not survive the 6 h incubation 
time period. This was assumed to be due to the high phosphate concentrations arising 
from H3PO4 used in the elution buffer, even though fractions were neutralised with 
NaHCO3 prior to cell incubation. 
4.3.3 Comparison of HPLC results for media extracts from basal 
incubations with sauvagine and metyrapone. 
As the reconstituted fractions from condition set 1 containing H3PO4 were toxic to the 
cells, it was replaced by 10 mM HCl as described in HPLC condition set 2 in section 
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4.2.2.2 as this would be readily neutralised after drying down. Fractions were 
collected at 1 min time intervals. The collected fractions (0.5 ml) were pooled in 
series of five, dried under a stream of N2 gas and reconstituted in EBSS (20 mM 
lactate/2 mM pyruvate). These fractions were used for bioassay. 
The HPLC method was first evaluated using corticosterone. A representative 
chromatogram for corticosterone is shown in Figure 4.1. The retention time (RT) for 
corticosterone was 5.9 min under the given conditions. Sep-pak extracts of the adrenal 
incubations collected from basal (B), sauvagine (S) and metyrapone (M) treatments 
were reconstituted in equilibration mix (1.5 ml) and injected into the HPLC system 
under the same conditions. The differences between the chromatograms of the adrenal 
extracts from the three conditions are shown in Figure 4.2.  
A corticosterone peak was present on all three chromatograms eluting at 6.1 min 
(RT).  The corticosterone peak for the sauvagine sample had a relatively similar peak 
area to that of the basal extract. The metyrapone extract showed a 41% reduction in 
peak area compared to basal corticosterone levels. Various peaks were consistently 
found in all three media extracts. Of interest were the peaks at RTs of 5.2, 6, 8.5, 11.5 
and 24.6 min (Figure 4.2). The peak areas and the relative changes are shown in table 
4.1. The peak at 5.2 min was unchanged in the sauvagine extract compared to basal 
extract, while there was a 31% decrease in the metyrapone extracts. The identity of 
this peak is unknown. Another observed change was in the peak at 8.5 min. This peak 
was markedly increased in the sauvagine extract while minimal in the basal and 
metyrapone extracts. The peak at 11.5 min, which was subsequently identified as 
DOC, increased in both the sauvagine and metyrapone extracts. The small peak at 
24.6 min was relatively constant in all extracts. 
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Figure 4.1 Representative chromatogram of corticosterone separation. 
Column: Hypersil ODS (4.6 x 150 mm); Injection (0.6 nmol corticosterone); gradient: HPLC condition set 2 (section 4.2.2.2). 
Corticosterone RT is 5.9 min. Chromatogram integration and data analysis was done using PRIME software. 
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Figure 4.2 Representative chromatograms of extracts of Basal, Sauvagine and Metyrapone adrenal incubations. 
Column: Hichrom ODS Hypersil (4.6 x 150 mm); Injection (1.5 ml of reconstituted adrenal extract in equilibration mix). Gradient 
setting: HPLC condition set 2 (section 4.2.2.2). Flow rate (1.5 ml/min). Peaks: (A) unknown 1 (4.7 min), (B) unknown 2 (5.2 min), (C) 
corticosterone (6.1 min), (D) unknown 3 (8.5 min), (E) unknown 4 (11.7 min), and (F) unknown 5 (24.6 min). Chromatogram 
integration and data analysis was done using PRIME software. 
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Table 4.1 Comparison of HPLC peak areas for extracts from adrenal 
incubations with basal, sauvagine and metyrapone. 
 
Peak (RT) Basal extract 
Peak Area 
Sauvagine extract 
Peak Area 
Metyrapone extract 
Peak Area 
A (4.7 min) 82.4 156.5 120.3 
B (5.2 min) 231.3 217.4 159.6 
C (6.1 min) 470.0 505.0 277.1 
D (8.5 min) 6.1 130.4 11.5 
E (11.7 min) 87.6 117.7 337.08 
F (24.6 min) 28.5 41.2 37.5 
 
4.3.4 Bioassay of HPLC fractions. 
HPLC fractions (0.5 ml) were pooled in series of 5 and dried under a stream of N2 gas. 
The dried fractions were reconstituted in EBSS (1ml) containing 20 mM lactate and 2 
mM pyruvate. Reconstituted fractions (300 µl) were then incubated on fasted H4-II-E-C3 
cells in a 24 well plate for 6 h. Medium was collected and assayed for glucose (Figures 
4.1, 4.2 and 4.3) 
Untreated cells incubated with substrates produced 8 ± 1 glucose (nmol/2 x 10
5
 cells). 
Glucose production with basal adrenal extract (containing 33 ng/ml ~ 0.1 µM 
corticosterone) and corticosterone (1 µM) was 31 ± 2 and 19 ± 1 nmol glucose/2 x 10
5
 
cells respectively. Direct incubation of the reconstituted fraction pools did not stimulate 
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any significant glucose production apart from the fraction pool (6 – 10) which produced 
13 ± 1 nmol glucose/2 x 10
5
 cells compared to control untreated cells (Figure 4.3). 
Glucose production with the fractions incubated along with corticosterone (1 µM) did not 
differ significantly from incubations with corticosterone alone (Figure 4.3). Sauvagine 
extracts (containing corticosterone ~ 0.1 µM) produced 58 ± 4 (nmol/2 x 10
5
 cells) 
glucose (Figure 4.4). None of the collected fraction pools showed any significant glucose 
production compared to the untreated cells. To test whether gluconeogenic activity was 
facilitated by corticosterone, fractions were also incubated in its presence. However, 
fractions incubated with corticosterone (1 µM) did not show any significant increases in 
glucose production from the incubations with corticosterone alone (Figure 4.4). 
Although, there was a tendency towards increased glucose production with fraction pools 
6 – 10 and 11 – 15 producing 22 ± 1 and 29 ± 9 glucose (nmol /2 x 105 cells) 
respectively. Similarly, metyrapone extracts (containing corticosterone ~ 0.04 µM) 
produced 73 ± 3 glucose (nmol /2 x 10
5
 cells), but none of the fraction pools showed any 
significant glucose production compared to the untreated cells. Fractions incubated along 
with corticosterone did not show any significant increases in glucose production from 
incubations with corticosterone alone. Fraction pool (11 – 15) showed slight increases 
with 22 ± 4 glucose (nmol /2 x 10
5
 cells). These values were not significantly greater 
compared to incubations with corticosterone alone which produced 21 ± 1 (nmol 
glucose/2 x 10
5
 cells). 
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Figure 4.3 Effect of HPLC fractions obtained from adrenal medium from basal 
incubations on hepatocyte glucose production. 
Starved H4-II-E-C3 cells were incubated for 6 h with the pooled samples of HPLC 
fractions in EBSS (20 mM lactate/2 mM pyruvate) with (dark bars) and without (white 
bars) corticosterone (1 µM). Corticosterone alone (C), extract of basal adrenal media 
(B), untreated cells with EBSS and substrates (U). Glucose was measured in the 
conditioned media samples. Results are mean ± SEM (n=6). Statistical differences were 
determined by ANOVA (*** = P<0.001 vs U). 
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Figure 4.4 Effect of HPLC fractions obtained from adrenal medium from sauvagine 
incubations on hepatocyte glucose production. 
Starved H4-II-E-C3 cells were incubated for 6 h with the pooled samples of HPLC 
fractions in EBSS (20 mM lactate/2 mM pyruvate) with (dark bars) and without (white 
bars) corticosterone (1 µM). Corticosterone alone (C), extract of sauvagine adrenal 
media (S), untreated cells with EBSS and substrates (U). Glucose was measured in the 
conditioned media samples. Results are mean + SEM (n=6). Statistical differences were 
determined by ANOVA (*** = P<0.001 vs U). 
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Figure 4.5 Effect of HPLC fractions obtained from adrenal medium from metyrapone 
incubations on hepatocyte glucose production. 
Starved H4-II-E-C3 cells were incubated for 6 h with the pooled samples of HPLC 
fractions in EBSS (20 mM lactate/2 mM pyruvate) with (dark bars) and without (white 
bars) corticosterone (1 µM). Corticosterone alone (C), extract of metyrapone adrenal 
media (M), untreated cells with EBSS and substrates (U). Glucose was measured in the 
conditioned media samples. Results are mean + SEM (n=6). Statistical differences were 
determined by ANOVA (*** = P<0.001 vs U). 
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4.4 Impurities in the commercially available corticosterone and their effect on 
glucose production. 
In the initial characterisation of the HPLC methodology it was observed that there were 
secondary peaks at 11.9 min similar to those observed in the adrenal extracts. In order to 
understand the importance of the contribution of the impurities found in the commercially 
available corticosterone on the hepatocyte glucose production a large scale purification of 
25 mg of corticosterone (SIGMA; catalogue number C2505 Lot 109H0949) was carried 
out to obtain sufficient pure corticosterone for further studies of cell responses in the 
presence and absence of corticosterone (Figures 4.6 & 4.7). 
For the large scale purification APEX hypersil C18 column (25 cm, 8 µ) was used with 
HPLC condition set 2 (section 4.2.2.2), with a flow rate of 2 ml/min. Absorbance was 
measured at 240 nm. Fractions were collected at 1 min time intervals. 
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Figure 4.6 A typical chromatogram showing impurities in commercially available corticosterone. 
Column: APEX prepsil ODS (10 x 250 mm); flow (2 ml/min); Gradient setting: HPLC condition set 2 (section 4.2.2.2).  Peaks: 
Corticosterone (24.2 min), unknown 1 (33.3min), unknown 2 (36.7 min), unknown 3 (38.8 min). Chromatogram integration and data 
analysis was done using PRIME software. 
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Figure 4.7 Representative chromatogram of large scale corticosterone purification. 
Column: APEX prepsil ODS (10 x 250 mm); flow (2 ml/min); Gradient setting: HPLC condition set 2 (section 4.2.2.2). Fractions (1 
min) were collected; Injection: Corticosterone (25 mg) in equilibration mix. Data integrated using PRIME software. Fraction 23 – 28 
were collected to obtain pure corticosterone. UV detection at 240 nm. 
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Figure 4.8 Representative chromatograms of DOCA and DOC. 
Column: APEX prepsil ODS (10 x 250 mm); flow (2 ml/min); Gradient setting: HPLC condition set 2 (section 4.2.2.2). UV detection 
at 240 nm. 
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4.6 Identification of unknown peaks in commercially available 
corticosterone. 
Deoxycorticosterone acetate (DOCA) was injected into the HPLC system under the same 
chromatographic conditions as used previously (section 4.2.2.2). DOCA eluted at 38.1 
min (Figure 4.8) corresponding with one of the impurity peaks (unknown 3) eluted from 
commercially available corticosterone (Figure 4.6). Hydrolysis of DOCA produced DOC, 
which eluted at 33.1 min (Figure 4.8). This also corresponded to an impurity peak 
(unknown 1) observed in the corticosterone chromatogram (Figure 4.6). 
4.7 Purification of media samples from adrenal incubations by higher 
resolution HPLC. 
The HPLC method was changed to condition set 3 as described in section 4.2.2.3 to 
improve the resolution of the peaks before corticosterone in the chromatograms. This was 
the main part of the chromatogram showing some bioactivity, but it was unclear whether 
this was due to corticosterone or other undefined adrenal steroids. Under these new 
HPLC conditions DOC eluted at 19.8 min (Figure 4.9), 18-OH DOC eluted at 12.5 min 
(Figure 4.10), and corticosterone eluted at 13.6 min (Figures 4.11) (Table 4.2). Sep-pak 
extracts of the adrenal incubations under basal (B), sauvagine (S) and metyrapone (M) 
treatment conditions were reconstituted in equilibration mix (1.5 ml) and injected into the 
HPLC system under the same conditions. Other differences between the chromatograms 
of the adrenal extracts from the three conditions are shown in Figure 4.12.  
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Similar to previous observations DOC increased with sauvagine and metyrapone 
treatments. However, it was also observed that there was a double peak at 13.3 min and 
13.6 min respectively that were not fully resolved (Figure 4.12) suggesting that a second 
peak (13.3 min) with similar elution characteristics to corticosterone was being resolved 
under these conditions. 
4.8 Bioassay of fractions from higher resolution HPLC of adrenal media 
samples. 
HPLC fractions (8 – 28) collected at 1 min time intervals were dried under a stream of N2 
gas and reconstituted in EBSS (1 ml) containing 20 mM lactate and 2 mM pyruvate. 
Reconstituted fractions (300 µl) were then incubated on fasted H4-II-E-C3 cells in a 24 
well plate for 6 h. Media samples were collected and assayed for glucose (Figures 4.13, 
4.14 and 4.15) 
Untreated cells incubated with substrates produced 9 ± 1 glucose (nmol/2 x 10
5
 cells). 
Glucose production with extract from basal incubation of adrenal sections and purified 
corticosterone (1 µM) was 31 ± 2 and 14 ± 1 glucose (nmol /2 x 10
5
 cells) respectively. 
Direct incubation of the reconstituted fraction pools did not stimulate any significant 
glucose production in any of the fractions compared to control untreated cells (Figure 
4.13). Glucose production with the fractions incubated together with purified 
corticosterone (1 µM) did not vary significantly from the incubations with corticosterone 
alone (Figure 4.14). Extracts of sauvagine stimulated adrenal media produced 57 ± 3 
glucose (nmol/2 x 10
5
 cells) (Figure 4.14). The collected fractions did not show any 
significant glucose production compared to the untreated cells. Fractions incubated with 
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purified corticosterone (1 µM) did not show any significant increases in glucose 
production compared to incubations with corticosterone alone (Figure 4.14). Extracts of 
media from metyrapone treated adrenals produced 69 ± 4 glucose (nmol /2 x 10
5
 cells). 
But none of the fractions showed any significant glucose production compared to the 
untreated cells. Fractions incubated together with corticosterone did not show any 
significant increases in glucose production compared to incubations with corticosterone 
alone (Figure 4.15).  
Standard compound Retention time (RT min) 
Corticosterone 13.6 min 
18-OH 11-deoxycorticosterone 12.5 min 
11-deoxycorticosterone 19.8 min 
Table 4.2 Standard retention time with HPLC condition set 3 
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Figure 4.9 Representative chromatograms of DOC under HPLC condition set 3. 
Column: Hichrom ODS Hypersil (4.6 x 150 mm); Gradient setting: HPLC condition set 3 (section 4.2.2.3). Flow rate (1.5 ml/min). 
DOCretention time 19.9 min. Chromatogram integration and data analysis was done using PRIME software.
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Figure 4.10 Representative chromatograms of 18-OH DOC under HPLC condition set 3. 
Column: Hichrom ODS Hypersil (4.6 x 150 mm); Gradient setting: HPLC condition set 3 (section 4.2.2.3). Flow rate (1.5 ml/min). 
18-OH DOC retention time 12.5 min. Chromatogram integration and data analysis was done using PRIME software.
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Figure 4.11 Representative chromatograms of corticosterone under HPLC condition set 3. 
Column: Hichrom ODS Hypersil (4.6 x 150 mm); Gradient setting: HPLC condition set 3 (section 4.2.2.3). Flow rate (1.5 ml/min). 
Corticosterone retention time 13.6 min. Chromatogram integration and data analysis was done using PRIME software.
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Figure 4.12 Representative chromatograms of extracts of adrenal from incubations under basal, sauvagine or sauvagine 
with metyrapone treatment conditions. 
Column: Hichrom ODS Hypersil (4.6 x 150 mm); Injection (1.5 ml of reconstituted adrenal extract in equilibration mix). Gradient 
setting: HPLC condition set 3 (section 4.2.2.3). Flow rate (1.5 ml/min). Peaks: (A) unknown 1 (9.8 min), (B) unknown 2 (12.0 min), 
(C) 18-OH DOC (12.6 min), (D) unknown 3 (13.2 min), (E) Corticosterone (13.6 min), (F) unknown 4 (16.7 min) and (G) DOC (19.9 
min). Chromatogram integration and data analysis was done using PRIME software. 
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Figure 4.13 Effect of HPLC fractions obtained from adrenal medium from basal 
incubations on hepatocyte glucose production. 
Starved H4-II-E-C3 cells were incubated for 6 h with the reconstituted samples of HPLC 
fractions in EBSS (20 mM lactate/2 mM pyruvate) with (dark bars) and without (white 
bars) corticosterone (1 µM). Corticosterone alone (C), extract of basal adrenal media 
(B), untreated cells with EBSS and substrates (U). Glucose was measured in the 
conditioned media samples. Results are mean of 3 experiments. Statistical differences 
were determined by ANOVA (* = P < 0.05; *** = P <0.001 vs U). 
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Figure 4.14 Effect of HPLC fractions obtained from adrenal media from sauvagine 
incubations on hepatocyte glucose production. 
Starved H4-II-E-C3 cells were incubated for 6 h with the reconstituted samples of HPLC 
fractions in EBSS (20 mM lactate/2 mM pyruvate) with (dark bars) and without (white 
bars) corticosterone (1 µM). Corticosterone alone (C), extract of sauvagine adrenal 
media (S), untreated cells with EBSS and substrates (U). Glucose was measured in the 
conditioned media samples. Results are mean of 3 experiments. Statistical differences 
were determined by ANOVA (* = P < 0.05; *** = P<0.001 vs U). 
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Figure 4.15 Effect of HPLC fractions obtained from adrenal media from incubation 
with sauvagine and metyrapone on hepatocyte glucose production. 
Starved H4-II-E-C3 cells were incubated for 6 h with the reconstituted samples of HPLC 
fractions in EBSS (20 mM lactate/2 mM pyruvate) with (dark bars) and without (white 
bars) corticosterone (1 µM). Corticosterone alone (C), extract of sauvagine and 
metyrapone adrenal media (SM), untreated cells with EBSS and substrates (U). Glucose 
was measured in the conditioned media samples. Results are mean of 3 experiments. 
Statistical differences were determined by ANOVA (* = P < 0.05; *** = P<0.001 vs U) 
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4.10 Further improvements to the HPLC method to compare the 
adrenal extracts. 
The HPLC method was changed to further improve the resolution of the peaks before 
corticosterone in the chromatograms. HPLC condition set 4 (section 4.2.2.4) was used in 
further HPLC separations. 
Under these new HPLC conditions DOC eluted at 30.0 min (Figure 4.16), 18-OH DOC 
eluted at 17.6 min (Figure 4.17), and corticosterone eluted at 19.0 min (Figure 4.16) 
(Table 4.3). Sep-pak extracts of the adrenal incubations from basal (B), sauvagine (S) or 
metyrapone (M) treatment conditions were reconstituted in equilibration mix (1.5 ml) and 
injected into the HPLC system under the same conditions. The differences between the 
chromatograms of the adrenal extracts from these three conditions are shown in Figure 
4.18.  
Fractions were collected at 1 min time intervals. Similar to previous observations DOC 
increased with sauvagine and metyrapone treatments (Figure 4.18). But the double peak 
at the corticosterone retention time was not observed. 
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Figure 4.16 Representative chromatograms of corticosterone and DOC under HPLC condition set 4. 
Column: Hichrom ODS Hypersil (4.6 x 150 mm); Gradient setting: HPLC condition set 4 (section 4.2.2.4). Flow rate (1.5 ml/min). 
Corticosterone retention time (19.0 min); DOC retention time 29.9 min. Chromatogram integration and data analysis was done using 
PRIME software. 
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Figure 4.17 Representative chromatograms of 18-OH DOC under HPLC condition set 4. 
Column: Hichrom ODS Hypersil (4.6 x 150 mm); Gradient setting: HPLC condition set 4 (section 4.2.2.4). Flow rate (1.5 ml/min). 
18-OH DOC retention time 17.6  min. Chromatogram integration and data analysis was done using PRIME software. 
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Figure 4.18 Representative chromatograms of extracts of adrenal incubations from basal, sauvagine, and sauvagine 
with metyrapone. 
Column: Hichrom ODS Hypersil (4.6 x 150 mm); Injection (1.5 ml of reconstituted adrenal extract in equilibration mix). Gradient 
setting: HPLC condition set 4 (section 4.2.2.4). Flow rate (1.5 ml/min). Peaks: (A) unknown 1 (9.8 min), (B) unknown 2 (16.2 min), 
(C) 18-OH DOC (17.6 min), (D) Corticosterone (19.0 min), (E) DOC (29.9 min). Chromatogram integration and data analysis was 
done using PRIME software. 
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4.11 Further analysis of the incubation extracts with modified elution 
conditions replacing methanol with acetonitrile. 
Because of the possibility of methanol affecting the elution of a few steroids more 
adrenal incubation extracts was analysed using HPLC condition set 5, which does not use 
methanol.  
Under these new HPLC conditions DOC eluted at 19.3 min (Figure 4. 19), 18-OH DOC 
eluted at 10.7 min (Figure 4.19) and corticosterone eluted at 12.2 min (Figure 4.19). Sep-
pak extracts of corticosterone and DOC spiked in DMEM showed 100% recovery (Figure 
4.20). Adrenal incubations from basal (B), sauvagine (S) or metyrapone (M) treatment 
conditions were prepared under the same conditions and reconstituted in equilibration 
mix (1.5 ml) and injected into the HPLC system under these conditions. The differences 
between the chromatograms of the adrenal extracts from these three conditions are shown 
in Figure 4.21. It was interesting to note that 18-OH DOC now is in much higher 
concentrations in these samples when methanol was replaced with acetonitrile suggesting 
that methanol was not a good choice of eluent in the previous chromatographic 
conditions. It does seem to co elute with another steroid suggesting that the method still 
needs improvement. Corticosterone eluting at 12.3 min showed consistent changes as 
before with lower levels in the metyrapone treated samples. Increased DOC levels were 
found in sauvagine and sauvagine and metyrapone treated incubations consistent with 
previous observations (Figure 4.21). 
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Figure 4.19 Representative chromatograms of 18-OH DOC, corticosterone and DOC  under HPLC condition set 5. 
Column: Hichrom ODS Hypersil (4.6 x 150 mm); Gradient setting: HPLC condition set 4 (section 4.2.2.4). Flow rate (1.5 ml/min). 
18-OH DOC retention time 10.7  min. Corticosterone eluted at 12.3 min and DOC eluted at 19.3 min. Chromatogram integration and 
data analysis was done using PRIME software. 
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Figure 4.20 Representative chromatograms of corticosterone and DOC extracts from DMEM under HPLC condition set 5. 
Column: Hichrom ODS Hypersil (4.6 x 150 mm); Gradient setting: HPLC condition set 4 (section 4.2.2.4). Flow rate (1.5 ml/min).  
Corticosterone eluted at 12.3 min and DOC eluted at 19.3 min. Chromatogram integration and data analysis was done using PRIME 
software. 
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Figure 4.21 Representative chromatograms of extracts of adrenal incubations from basal, sauvagine, and sauvagine with 
metyrapone. 
Column: Hichrom ODS Hypersil (4.6 x 150 mm); Injection (1.5 ml of reconstituted adrenal extract in equilibration mix). Gradient 
setting: HPLC condition set 5 (section 4.2.2.5). Flow rate (1.5 ml/min). Peaks: 18-OH DOC (10.7 min), Corticosterone (12.3 min) and 
DOC (19.3min). Chromatogram integration and data analysis was done using PRIME software. 
A
b
so
rb
a
n
ce
 a
t 
2
4
0
 n
m
 (
m
V
) 
168 
 
4.12 Comparison of the effects of purified and unpurified corticosterone 
on hepatic glucose production.  
Purified corticosterone (section 4.5), and commercially available corticosterone with 
impurities (SIGMA; catalogue number C2505) were compared on their ability to 
stimulate glucose production in H4-II-E-C3 cells. Control cells incubated with EBSS (20 
mM lactate/2 mM pyruvate) produced 9 ± 3 glucose (nmol/2x10
5
 cells). Cells incubated 
with the unpurified corticosterone (1 µM) produced 20 ± 2 glucose (nmol/2x10
5
 cells). 
Insulin (10 ng/ml) suppressed this glucose production to below control levels. However, 
cells incubated with purified corticosterone (1 µM) produced only 12 ± 3 glucose 
(nmol/2x10
5
 cells) (Figure 4.22). 
4.13 Sauvagine and metyrapone infusions cause hyperglycaemia in the 
anaesthetised rat. 
Control rats had a blood glucose level of 5 ± 0.2 mM before saline infusion and the levels 
did not change significantly after. Sauvagine infusions (40 pmol/kg/min) caused an 
increase in the blood glucose concentrations from 5.5 ± 0.5 to 9.2 ± 0.3 at 90 min. Rats 
pre-treated with metyrapone (100 mg/kg) for 60 min prior to sauvagine infusion showed 
a marked increase in blood glucose concentrations. Initial blood glucose levels were 6 ± 
0.5 mM which steadily rose to 9 ± 0.5 mM in the first 1 hr and to 10.6 ± 0.6 mM by 90 
min (Figure 4.23). Livers collected from sauvagine treated rats had a 0.2 ± 0.16 fold 
increase in PEPCK activity compared to control rat livers (Figure 4.24). Pre-treatment 
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with metyrapone for 60 min prior to sauvagine infusions increased the PEPCK activity by 
0.4 ± 0.15 fold compared to control livers (Figure 4.24). 
4.13 Plasma extracts from sauvagine and metyrapone treatments. 
Plasma extracts were prepared from arterial blood collected from control rats (C), 
sauvagine-infused rats (S) and sauvagine-infused rats pre-treated with metyrapone (SM). 
Reconstituted extracts in EBSS were incubated on cells to test the effect on total glucose 
production. S and SM extracts produced 43 ± 2 and 68 ± 3 glucose (nmol/2 x 10
5
 cells) 
respectively. C extracts produced 22 ± 2 glucose (nmol/2 x 10
5
 cells). This glucose 
production was suppressed by insulin (10 ng/ml) (Figure 4.25). 
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Figure 4.22 Comparison of purified and unpurified corticosterone on hepatocyte 
glucose production. 
Starved H4-II-E-C3 cells were incubated for 6 h in EBSS (20 mM lactate/2 mM pyruvate) 
containing substrate alone (U), unpurified corticosterone (C, 1 µM), purified 
corticosterone (Cp, 1 µM) with (white bars) and without (dark bars) insulin (10 ng/ml). 
Results are mean ± SEM, (n=6). Statistical differences were assessed by ANOVA (* = P 
< 0.05; *** = P < 0.001 vs control U). 
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Figure 4.23 Blood glucose concentrations for rats under basal conditions or after 
treatment with sauvagine alone or with metyrapone. 
Tail vein blood was collected every 15 min from anaesthetized Wistar rats that were 
treated with sauvagine (40 pmol/kg/min) with or without metyrapone (100 mg/kg). 
Glucose was measured using Accu-chek® Aviva (Roche Ltd). Results are mean values 
from four animals for each time point. Statistical differences were determined by ANOVA 
(** = P <0.01, *** = P < 0.001, sauvagine + metyrapone vs control; +++ = P < 0.001, 
sauvagine vs control). 
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Figure 4.24 Relative levels of liver PEPCK activity in rats treated with sauvagine alone 
or with metyrapone. 
Liver sections (≈ 3 x 200 mg) were collected from each animal at the end of the 100 min 
treatment with sauvagine (40 pmol/kg/min) with or without metyrapone (100 mg/kg). 
PEPCK activity was measured in extracted liver protein. Results are means of 8 liver 
samples for each condition collected from 4 animals (2 sections per animal). Statistical 
analyses were performed using ANOVA (***=P<0.001 vs B). Control (C); sauvagine 
(S); sauvagine with metyrapone pre-treatment (SM). 
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Figure 4.25 Effect of plasma extracts on hepatocyte glucose production. 
Plasma was prepared from arterial blood collected after 90 min from rats treated with 
sauvagine (40 pmol/kg/min) with and without metyrapone (200 mg/kg). Reconstituted 
extracts in EBSS (20 mM lactate/2 mM pyruvate) were incubated on fasted H4-II-E-C3 
cells for 6 h. Glucose was measured in the medium. Dark bars represent treatment 
without and white bars indicate response in the presence of insulin (10 ng/ml). n=8. 
Statistical analysis was performed using a two-way ANOVA followed by a Bonferroni 
post test (*** = P < 0.001 vs B; ### = P < 0.001 vs the respective treatments without 
insulin). 
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4.14 Discussion 
In the previous chapter it was established that extracts prepared from incubations of 
adrenal sections with sauvagine alone or with metyrapone caused an increase in total 
glucose production from cultured rat hepatocytes. In order to further characterise the 
gluconeogenic steroids within these extracts HPLC separation methods were defined.  
Initially, HPLC condition (set 1) included H3PO4. Under these conditions 
corticosterone eluted at 6 min and the chromatograms of the extracts from adrenal 
incubations with treatments showed good separation. However, H4-II-E-C3 cells died 
with the reconstituted fractions. It was likely this was a cytotoxic effect due to high 
phosphate concentrations. Therefore H3PO4 was replaced by HCl in HPLC condition 
set 2. Under the new HPLC conditions corticosterone eluted at 6 min and the 
collected fractions were not toxic on the hepatocytes. Comparison of chromatograms 
of extracts from adrenal incubations with sauvagine or metyrapone with that of 
extracts from adrenal incubations under basal conditions showed relative changes in 6 
peaks with retention times 4.7, 5.2, 6.0, 8.5, 11.7 and 24.6 min. Peaks areas at 
retention times 4.7, 11.7 and 24.6 increased with sauvagine and metyrapone 
treatments. The peak area at 6 min decreased in the metyrapone treatment compared 
to the basal and sauvagine treatments in accordance with the corticosterone 
measurements in the extracts. However, none of the collected fractions had any 
significant effect on hepatocyte glucose production either alone or in combination 
with corticosterone. 
It was interesting to note that the peak eluting at 11.5 min in the chromatograms of 
adrenal incubation extracts (Figure 4.2), was also present as an impurity in the 
commercially available corticosterone (Figure 4.6). To identify the impurities in 
175 
 
corticosterone and the peaks obtained from adrenal incubation extracts, DOCA was 
analysed with HPLC condition set 2. It was found to elute at 24.6 min. When DOCA 
was hydrolysed to DOC a second peak eluted at 11.7 min which correlates with the 
peak that increases in the chromatograms of the extracts of adrenals with sauvagine 
and metyrapone. The increase in DOC with metyrapone is consistent with its 
inhibitory action on 11-beta-hydroxylase. The sauvagine-stimulated increase in DOC 
was not expected. 
The HPLC conditions were further altered with HPLC condition set 3 to increase 
resolution of the earlier peaks. Under these conditions corticosterone, DOC and 18-
OH DOC eluted at 13.6, 19.8 and 12.5 min respectively. Chromatograms of extracts 
from adrenal incubations with sauvagine and metyrapone showed changes in at least 
20 different peaks compared to that from extracts of adrenal incubation under basal 
conditions. As previously observed DOC peak areas increased with the treatment 
conditions compared to basal incubations. Of particular interest was the double peak 
that was unresolved at 13.2 and 13.6 min respectively. The relative peak areas of 
these two peaks changed with the treatment conditions, with the peak at 13.2 min 
increasing in the extracts from adrenal incubations with sauvagine and metyrapone. 
The peak at 13.6 min which corresponds to the corticosterone decreased in these two 
extracts compared to extracts prepared from adrenal incubations under basal 
conditions. The reconstituted fractions did not have any significant effect on 
hepatocyte glucose production alone or in combination with corticosterone. However, 
it was consistently observed that the total extract had a significant effect on 
hepatocyte glucose production compared to untreated cells and to the cells incubated 
with corticosterone (1 µM). HPLC condition set 4 was used to further resolve the 
double peak at 13 min. Under these new HPLC conditions corticosterone, DOC, 18-
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OH DOC eluted at 19.0, 30.0, and 17.6 min respectively. As previously observed 
peak areas of DOC increased in the extracts obtained from adrenal incubations with 
sauvagine and metyrapone. Changes were observed in a peak eluting at 16.2 min that 
was not observed before in earlier comparisons (Figure 4.12). But no improvement in 
resolution of corticosterone was observed. 
More studies of these fractions under different elution conditions will provide more 
insights into weather each of these peaks represent a single steroid. The lack of 
responses to corticosterone indicates that other factors in the adrenal extracts are 
important. The real test would be to combine a pooled sample of all the fractions 
collected and test for biological activity if different from the starting material. If there 
a novel steroid, it might have unknown or poor stability under the conditions used as 
demonstrated by the modification of 18-OH DOC by methanol in the eluting buffer. 
More careful evaluation of the appropriate extraction and HPLC conditions would be 
necessary to ensure that a pool of all HPLC fractions had the same activity as the 
starting material. Under such a set up, we can further investigate individual fractions 
for biological activity.  
In vivo studies confirmed earlier observations (Kaminski 2004) that sauvagine 
infusions caused hyperglycaemia in the anaesthetised rats. Rats treated with 
metyrapone prior to sauvagine infusions had a more profound hyperglycaemic 
response. Plasma extracts from rats treated with sauvagine alone or with metyrapone 
had a more than 2 fold greater effect on stimulating glucose production in H4-II-E-C3 
cells. Liver samples collected from these treatments showed an increase in PEPCK 
activity in the animals treated with sauvagine and metyrapone compared to control rat 
livers. A group of animals treated with metyrapone alone would have been a useful 
addition to the experiment. It would have been desirable to have measured plasma 
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corticosterone and insulin levels to obtain a clear insight into the hyperglycaemia 
observed in the sauvagine and metyrapone treated rats. 
The results in this chapter show that there are significant differences in the steroids 
secreted by the adrenal glands incubated with sauvagine alone or with metyrapone 
compared to adrenals incubated under basal conditions. DOC is increased in the 
treatment conditions compared to basal incubations. There are several unknown peaks 
that change and are not consistent in the relative increases or decreases. This could be 
due to the differences in the stress levels of the rats or due to differences in handling 
of samples such that adrenal corticosteroids were modified by the extraction process. 
Sauvagine infusions in rats pre-treated with metyrapone have increased blood glucose 
levels due to increased hepatic glucose output, which is confirmed with the increases 
in PEPCK activities in the livers. 
Extracts obtained from adrenal incubations with sauvagine and metyrapone are very 
potent in stimulating hepatic glucose production when used as a whole extract even 
with very low corticosterone levels (~ 0.04 µM). But the individual fractions did not 
show any significant effect on the hepatocyte glucose production. This could be due 
to loss of sample or the need for more than one or two combinations of steroid to have 
a synergistic effect. However, plasma extracts may be confounded by the presence of 
other factors that are co-extracted on Sep-pak but not recovered under the HPLC 
conditions being used. 
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CHAPTER 5 
Investigation of the role of 11-
deoxycorticosterone in hepatic 
glucose metabolism. 
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5.1 Introduction 
It is well established that hepatic glucose regulation is tightly regulated by insulin, 
glucocorticoids, glucagon and epinephrine (Pilkis et al., 1992). Glucocorticoids 
normally stimulate hepatic gluconeogenesis and antagonise the action of insulin 
(Ruzzin et al., 2005). In the previous chapter commercial synthetic corticosterone was 
found to produce a greater increase in glucose than pure corticosterone in fasted 
hepatocytes. The major contaminants of the commercial synthetic product had HPLC 
elution characteristics of DOC, suggesting that these contaminants contributed to the 
biological activity of the unpurified commercial product. Studies of stress related 
adrenal corticosteroid secretion often show a concomitant increase in DOC and 
corticosterone (Gallant et al., 1979). This suggests that DOC may have a 
physiological role in modulating or enhancing the actions of corticosterone. 
For more than fifty years the two most commonly investigated adrenal corticosteroids 
in experimental studies have been corticosterone and DOC, mainly as the acetyl ester 
DOCA. Corticosterone is considered as a glucocorticoid, whereas DOC is considered 
as a weak mineralocorticoid. The extent to which these definitions are true remains an 
area for discussion and experimentation. Recent studies have now shown that DOC is 
a potent glucocorticoid (Brookes et al., 2011). The glucocorticoid potential of a 
steroid largely depends on what is perceived to be the “glucocorticoid potential”. Is it 
the ability to (1) increase liver gluconeogenesis, (2) increase liver glycogen 
deposition, (3) act as an anti-inflammatory, or (4) all the above? Recent detailed 
appraisals of the actions of corticosteroids have concluded that experimental data 
comparing DOC with corticosterone fails to distinguish between their actions 
(Vinson, 2009; Vinson, 2011). 
180 
 
Insulin normally increases hepatic glycogen deposition by increasing glycogen 
synthase (GS) activity and decreasing glycogen phosphorylase (GP) activity. 
Conversely, resistin induces insulin resistance in hepatocytes by disturbing glycogen 
metabolism (Yang et al., 2009). Glycogen formation is determined by GS activity. GS 
activity is determined by both its covalent phosphorylation and the intracellular 
presence of glucose-6-phosphate (G6P). Resistin does not affect GS covalent 
phosphorylation, but has an effect on the G6P levels. It has also been observed that 
resistin affects glycogen metabolism in two different ways depending on the presence 
or absence of insulin. In the presence of insulin, resistin decreases the glucose uptake 
without changing hexokinase1 (HK) activity. In the absence of insulin resistin reduces 
HK activity (Niederwanger et al., 2007). 
Similarly, the effects of DOC in the presence and absence of insulin need to be 
investigated as it has been observed to improve insulin sensitivity in animal models 
(Dai et al., 1992). It was found that, in non-diabetic rats, DOCA-induced hypertension 
was associated with normal glucose levels and glucose tolerance but with 
significantly lower levels of plasma insulin. DOCA-treated diabetic animals showed 
significantly lower levels of plasma glucose, but their plasma insulin concentrations 
were not significantly different from those of the DOCA vehicle treated diabetic rats. 
This suggests that DOCA may have either a direct or indirect action on the 
assimilation, production, or utilisation of glucose. 
Aims of this chapter 
 To characterise the effects of DOC on hepatic glucose production. 
 To evaluate whether RU-486 (glucocorticoid antagonist) or eplerenone 
(mineralocorticoid antagonist) alter the response to DOC. 
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5.2 Methods 
The methods used in this chapter are described in sections of early chapters – cell 
culture (3.3.1), glucose assay (3.3.2), PEPCK activity assay (2.10). H4-II-E-C3 cells 
were grown to confluence in DMEM (5 mM glucose) supplemented with 10% FCS. 
Cells were then maintained for 18 h in serum-free DMEM (5 mM glucose). 
For fed cell experiments cells were treated for 6 h in EBSS (20 mM lactate/2 mM 
pyruvate). For fasted cells experiments cells were further incubated in DMEM (0 mM 
glucose) for 4 h and then incubated for 6 h in EBSS (20 mM lactate/2 mM pyruvate). 
5.2.1 Glycogen measurements 
For glycogen synthesis experiments, H4-II-E-C3 cells were incubated for 24 h in 
DMEM (5 - 25 mM glucose) with and without insulin in the presence of treatment 
compounds. The medium was aspirated and the cells were washed with PBS before 
being analysed for glycogen. 
The plates were frozen at -80°C until the time of the assay. On the day of the assay 
the cells were scraped off the plate in ice cold PBS (300 µl), and the well contents 
were transferred into Eppendorf tubes. The cell contents were sonicated for 10 
seconds and the sonicated cell suspension was heated at 75°C for 10 min to inactivate 
any enzyme activity that might interfere in the assay. The heat-treated samples were 
centrifuged to remove the cell debris. The supernatant was collected in fresh tubes and 
stored for glycogen assay.  
Glycogen standards were prepared (2 – 10 µg/ml). Standards and samples (50 µl) 
were transferred into a 96 well plate. 100 µl of hydrolysis buffer containing 2U 
glucoamylase was added into each well. For glucose control of each sample, 100 µl of 
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the buffer without the hydrolysing enzyme was added. The plate was incubated at 
room temperature for 60 min for the hydrolysis to take place. The hydrolysed samples 
were heated at 75°C for 10 min to inactivate the enzyme, and then subjected to 
glucose assay (3.3.2) to measure the amount of glucose in each well. The glucose 
concentrations of the unhydrolysed samples from each well were subtracted from the 
hydrolysed concentrations to give the corrected value for the amount of glycogen in 
each well containing 2 x 10
5
 cells. 
5.3 Results 
5.3.1 DOC causes a concentration dependent decrease in hepatic glucose 
production and PEPCK activity in the fed state. 
Incubation of DOC (1 µM) with H4-II-E-C3 cells in the fed state decreased glucose 
production of control cells from 9.5 ± 0.6 to 7.7 ± 0.5 (nmol/2 x 10
5
 cells). 
Corticosterone significantly increased glucose production to 18.5 ± 0.7 (nmol/2 x 10
5
 
cells), and this increase was significantly reduced in a concentration dependent 
manner to 16.6 ± 0.6, 13.8 ± 0.9, and 10.5 ± 0.7 when DOC concentrations of 0.1, 0.5 
and 1 µM respectively were co-incubated with corticosterone (Figure 5.1 A). These 
changes in glucose production correlated with corresponding decrease in PEPCK 
activity in these cells. DOC (1 µM) on its own decreased relative PEPCK activity by 
0.2 ± 0.06 fold compared to control untreated cells. It also significantly reduced 
corticosterone induced PEPCK activity in a concentration dependent manner from 1.8 
± 0.2 to 1.5 ± 0.09, 1.4 ± 0.04 and 1.2 ± 0.08 of the control values with DOC 
concentrations of 0.1, 0.5 and 1 µM respectively (Figure 5.1 B). Glycogen 
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concentrations under the same treatment conditions did not show any significant 
changes between the treatments (Figure 5.2). 
5.3.2 The effect of RU-486, eplerenone and insulin on DOC mediated 
suppression of corticosterone induced hepatic glucose production and 
PEPCK activity in the fed state.  
Insulin (10 ng/ml) suppressed total glucose production due to DOC (1µM), C (1 µM) 
and DOC + C (1 µM) from 8.5 ± 0.6, 18.7 ± 0.9 and 9.5 ± 0.6 to 6.5 ± 0.6, 7.5 ± 0.6 
and 5.7 ± 0.8 glucose (nmol/2 x 10
5
 cells) respectively (Figure 5.3 A). The 
corresponding PEPCK activity was also suppressed from 1 ± 0.04 to 0.8 ± 0.06 for 
untreated cells, 1.9 ± 0.1 to 0.7 ± 0.04 for corticosterone (1 µM) treated cells, 0.8 ± 
0.08 to 0.62 ± 0.04 for DOC (1 µM) treated cells and 1.4 ± 0.09 to 0.47 ± 0.05 for 
corticosterone and DOC treated cells (Figure 5.3 B) 
RU-486 (10 µM) suppressed total glucose production due to DOC (1µM), C (1 µM) 
and DOC + C (1 µM) from 8.5 ± 0.6, 18.7 ± 0.9 and 9.5 ± 0.6 to 7.8 ± 0.9, 7.7 ± 0.8 
and 8 ± 0.5 glucose (nmol/2x10
5
 cells) respectively (Figure 5.3 A). The corresponding 
PEPCK activity was not significantly changed for untreated cells and DOC (1µM) 
treatments. However, with RU-486 treatment PEPCK activity was suppressed from 
1.9 ± 0.1 to 0.93 ± 0.06 for corticosterone (1 µM) treated cells, and 1.4 ± 0.09 to 0.92 
± 0.06 for corticosterone and DOC treated cells (Figure 5.3 B). 
Eplerenone (1 µM) did not have any significant effects on either the total glucose 
production or the relative PEPCK activity observed with the different treatments 
(Figure 5.3 A & B).  
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5.3.3 DOC causes a concentration dependent increase in hepatic glucose 
production but does not affect the relative PEPCK activity in fasted H4-II-
E-C3 cells. 
Incubation of H4-II-E-C3 cells in the fasted state with DOC (1 µM) alone did not 
affect glucose production when compared to control cells (12.3 ± 0.8 versus 11.5 ± 
0.6 nmol/2 x 10
5
 cells). However, it significantly increased corticosterone induced 
glucose production in a concentration dependent manner from 20.5 ± 0.6 to 24 ± 0.7, 
33 ± 1.6, and 39 ± 0.9 with DOC concentrations of 0.1, 0.5 and 1 µM respectively 
(Figure 5.4 A). These changes in glucose production occurred without a parallel 
increase in the corresponding PEPCK activity in these cells. DOC (1 µM) on its own 
did not cause any significant change in the relative PEPCK activity compared to 
control untreated cells. In addition, DOC treatment did not reduce the corticosterone 
induced increase in PEPCK activity at any of the test concentrations (Figure 5.4 B). 
Glycogen concentrations did not show any significant changes compared to the 
control untreated wells with either corticosterone, DOC, or the combination (Figure 
5.5) 
5.3.4 The effect of RU-486, eplerenone and insulin on DOC modulation of 
corticosterone induced hepatic glucose production and PEPCK activity in 
the fasted state.  
Insulin (10 ng/ml) suppressed total glucose production due to DOC (1µM), C (1 µM) 
and DOC + C (1 µM) from 11 ± 1, 18.8 ± 0.9 and 36.5 ± 1 to 8 ± 0.4, 9.7 ± 0.5 and 
8.2 ± 0.5 glucose (nmol/2 x 10
5
 cells) respectively (Figure 5.6 A). The corresponding 
PEPCK activity was also suppressed from 1 ± 0.04 to 0.75 ± 0.06 for untreated cells, 
0.9 ± 0.04 to 0.6 ± 0.02 for DOC (1 µM) treated cells, 1.9 ± 0.08 to 0.7 ± 0.04 for 
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corticosterone (1 µM) treated cells and 1.7 ± 0.1 to 0.75 ± 0.06 for corticosterone and 
DOC treated cells (Figure 5.6 B) 
RU-486 (10 µM) suppressed total glucose production due to DOC (1µM), C (1 µM) 
and DOC + C (1 µM) from 11 ± 1, 18.8 ± 0.9 and 36.5 ± 1 to 8.2 ± 0.7, 8.5 ± 0.6 and 
10.7 ± 0.5 glucose (nmol/2 x 10
5
 cells) respectively (Figure 5.6 A). The 
corresponding PEPCK activity was also suppressed from 1 ± 0.04 to 0.85 ± 0.06 for 
untreated cells, 1.9 ± 0.1 to 0.75 ± 0.06 for corticosterone (1 µM) treated cells, 0.9 ± 
0.04 to 0.8 ± 0.05 for DOC (1 µM) treated cells and 1.7 ± 0.1 to 0.97 ± 0.04 for 
corticosterone and DOC treated cells (Figure 5.6 B) 
Eplerenone (1 µM) did not cause any significant effects on either the total glucose 
production or the relative PEPCK activity (Figure 5.6 A & B). 
5.3.5 The effect of DOC on insulin stimulated glycogen formation in 
hepatocytes in vitro. 
DOC had a varied effect on hepatocytes glycogen levels depending on the glucose 
concentrations. In the presence of 5 mM glucose concentrations untreated (U), 
corticosterone 1µM (C), and 11-deoxycorticosterone 1µM (D) treated cells had  
glycogen concentrations of 0.11 ± 0.03, 0.09 ± 0.01, and 0.22 ± 0.04 without insulin 
and 0.19 ± 0.03, 0.19 ± 0.04 and 0.15 ± 0.03 ug/2x10
5
 cells with insulin (Figure 5.7 
A).  In the presence of 7 mM glucose the glycogen concentrations for U, C and D 
were 0.13 ± 0.03, 0.12 ± 0.03 and 0.12 ± 0.01 without insulin and 0.26 ± 0.02, 0.17 ± 
0.03 and 0.24 ± 0.07 ug/2x10
5
 cells with insulin (Figure 5.7 B). In the presence of 15 
mM glucose the glycogen concentrations for U, C and D were 0.14 ± 0.03, 0.09 ± 
0.03 and 0.12 ± 0.03 without insulin and 0.38 ± 0.04, 0.27 ± 0.01 and 0.42 ± 0.01 
ug/2x10
5
 cells with insulin (Figure 5.7 C). All the glycogen concentrations in the 
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presence of insulin at this glucose (15 mM) concentrations were significantly (P < 
0.001) increased compared to the corresponding non-insulin treatments. When the 
cells were incubated with 25 mM glucose concentrations, the glycogen concentrations 
for U, C and D were 0.15 ± 0.04, 0.26 ± 0.04 and 0.29 ± 0.02 without insulin and 0.43 
± 0.06, 0.48 ± 0.01 and 0.63 ± 0.02 ug/2x10
5
 cells with insulin (Figure 5.7 D). All the 
glycogen concentrations with insulin were significantly increased compared to the 
corresponding non-insulin treatments. The DOC treatments with insulin were 
significantly increased (P < 0.05) compared to insulin alone at 25 mM glucose 
concentrations (Figure 5.7 D).   
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Figure 5.1 Effect of DOC on corticosterone induced glucose production and 
PEPCK activity in fed cells. 
H4-II-E-C3 cells were incubated for 6 h in EBSS (20 mM lactate/2 mM pyruvate) with 
deoxycorticosterone (D, 1 µM), corticosterone (C, 1 µM), and corticosterone (1 µM) 
with 0.1, 0.5 or 1 µM deoxycorticosterone (C + D). Results are mean ± S.E.M., n=6.  
*** = P < 0.001 vs U (untreated) conditioned media samples; # = P < 0.05 and ### 
= P < 0.001  vs C. One-way ANOVA with Bonferroni post hoc test was used to 
compare all columns. 
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Figure 5.2 Effect of DOC and corticosterone on glycogen concentrations in fed H4-
II-E-C3 cells. 
H4-II-E-C3 cells were incubated for 6 h in EBSS (20 mM lactate/2 mM pyruvate) with 
deoxycorticosterone (D, 1 µM), corticosterone (C, 1 µM), and corticosterone (1 µM) 
with 0.1, 0.5 or 1 µM deoxycorticosterone (C + D). Results are mean ± S.E.M., n=6.  
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Figure 5.3 The effect of Insulin, RU486 and eplerenone on hepatic glucose 
production and PEPCK activity in the presence of DOC and corticosterone in fed 
H4-II-E-C3 cells.  
H4-II-E-C3 cells were incubated for 6 h in EBSS (20 mM lactate/2 mM pyruvate) with 
deoxycorticosterone (D, 1 µM), corticosterone (C, 1 µM), or corticosterone (1 µM) 
with deoxycorticosterone (C + D, both 1 µM) alone or combined with insulin (10 ng 
/ml), RU486 (10 µM), or eplerenone (1 µM). (A) glucose measurements in medium. 
(B) Relative PEPCK activity in the corresponding cells. Results are mean ± S.E.M., 
n=6.  *** = P < 0.001 vs U. ### = P < 0.001 vs the corresponding control 
treatments under each group. Statistical differences were determined by two-way 
ANOVA with Bonferroni post hoc test. 
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Figure 5.4 Effect of DOC on corticosterone induced glucose production and 
PEPCK activity in fasted cells. 
H4-II-E-C3 cells were incubated for 6 h in EBSS (20 mM lactate/2 mM pyruvate) with 
deoxycorticosterone (D, 1 µM), corticosterone (C, 1 µM), and corticosterone (1 µM) 
with 0.1, 0.5 or 1 µM deoxycorticosterone (C + D). Results are mean ± S.E.M., n=6.  
*** = P < 0.001 vs U (untreated) conditioned media samples. One-way ANOVA with 
Bonferroni post hoc test was used to compare all columns. 
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Figure 5.5 Effect of DOC and corticosterone on glycogen concentrations in fasted 
H4-II-E-C3 cells. 
H4-II-E-C3 cells were incubated for 6 h in EBSS (20 mM lactate/2 mM pyruvate) with 
deoxycorticosterone (D, 1 µM), corticosterone (C, 1 µM), and corticosterone (1 µM) 
with 0.1, 0.5 or 1 µM deoxycorticosterone (C + D). Results are mean ± S.E.M., n=6. 
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Figure 5.6 The effect of Insulin, RU486 and eplerenone on hepatic glucose 
production and PEPCK activity in the presence of DOC and corticosterone in fasted 
H4-II-E-C3 cells.  
H4-II-E-C3 cells were incubated for 6 h in EBSS (20 mM lactate/2 mM pyruvate) with 
deoxycorticosterone (D, 1 µM), corticosterone (C, 1 µM), and corticosterone with 
deoxycorticosterone (C + D, both 1 µM) with insulin (10 ng /ml), RU486 (10 µM), 
and eplerenone (1 µM).(A) glucose measurements in medium. (B) Relative PEPCK 
activity in the corresponding cells. Results are mean ± S.E.M., n=6.  *** = P < 0.001 
vs U. # = P < 0.05, ### = P < 0.001 vs the corresponding control treatments for each 
group. Statistical differences were determined by two-way ANOVA with Bonferroni 
post hoc test. 
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Figure 5.7 The effect of corticosterone, DOC and insulin on hepatic glycogen 
concentrations in H4-II-E-C3 cells under different glucose concentrations.  
H4-II-E-C3 cells were incubated for 24 h in DMEM containing (A) 5 mM (B) 7 mM 
(C) 15 mM and (D) 25 mM glucose with untreated (U), DOC (1 µM) (D), and 
Corticosterone 1 µM (c) both in the presence (black bars) and absence (Clear bars) 
of insulin (10 ng/ml). Results are mean ± S.E.M., n=6. *** = P < 0.001 vs the 
corresponding treatments without insulin. + = P < 0.05 vs Insulin alone. Statistical 
differences were determined by two-way ANOVA with Bonferroni post test. 
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5.4 Discussion 
In this chapter it was observed that DOC had effects on hepatocyte glucose 
production which varied according to the incubation conditions. DOC had a markedly 
different effect on hepatic glucose production under different energy states of the 
cells. In the fed state with glycogen reserves and surplus gluconeogenic substrates, 
DOC suppressed hepatic glucose production induced by corticosterone. It is 
interesting to observe that DOC suppresses PEPCK activity under these conditions. 
Further studies measuring mRNA and protein levels by western blot would be 
required to substantiate this finding. This would require specific PCR primers for 
measuring cytosolic and mitochondrial PEPCK, and selective antibodies for PEPCK1 
and PEPCK2, to assess whether these changes were entirely due to altered cytosolic 
PEPCK1.  However, intracellular glycogen concentrations under these experimental 
conditions were low and did not vary significantly between the different treatments. 
In the fed state, RU486 blocked corticosterone-stimulated increases in total glucose 
production and PEPCK activity. Whereas eplerenone did not modify corticosterone 
responses under these conditions, which supports the established opinion that these 
gluconeogenic actions of corticosterone are mediated through GR rather than MR. 
DOC alone had no effect on glucose production or PEPCK activity in the fed state, 
but when co-incubated with corticosterone it suppressed the corticosterone induced 
increase in glucose production and attenuated the increase in PEPCK activity (Figure 
5.3). The inhibitory effect of DOC was not reversed by the use of eplerenone, which 
tends to exclude an action mediated through MR, and suggests that suppression of 
corticosterone responses by DOC could be due to other metabolic changes in the cell. 
Whether this involves receptors other than GR or MR is difficult to determine with 
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currently available antagonists. RU486 completely blocks responses to corticosterone 
and DOC, however RU486 is not a specific GR antagonist, so it cannot be used to rule 
out the possibility of other receptors that might be involved in mediating the actions 
of DOC. 
In the fasted state, with increased glycogenolysis and gluconeogenic enzymes, DOC, 
acted in synergy with corticosterone increasing total glucose production into the 
external medium. There is constant glucose uptake and release in these conditions and 
the source of this glucose cannot be determined from these experiments. The PEPCK 
suppression by DOC was not observed during the fasted state indicating a different 
regulation (probably due to the increased gluconeogenic substrates) in the fasted state. 
The glycogen concentrations in these cells were low compared to the fed state, but 
again there were not significant differences between the treatments. This is not 
surprising as it was shown that for maximal effects on glycogen production in the 
presence of insulin the hepatocytes have to be co incubated with a low concentration 
of a glucocorticoid such as dexamethasone (Lopez et al., 1984). In order to 
distinguish the true effect of DOC on these cells future investigations should include 
comparisons of the responses to dexamethasone in the presence . 
In the fasted state the cells are geared to increased gluconeogenesis, with other 
metabolites helping to overcome potential suppressors of glucose production. Under 
these conditions the combination of DOC with corticosterone increased glucose 
production compared to corticosterone alone. PEPCK activity with the combination 
was not different from corticosterone alone. Like the studies in the fed state, RU486 
completely blocked the actions of corticosterone when used alone or combined with 
DOC. Eplerenone did not modify the corticosterone responses or the synergistic 
effects of DOC, indicating that MR are not involved in these responses. While the 
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results of these studies are in agreement with GR rather than MR mediating the 
actions of glucocortiocids, non-genomic actions of DOC through membrane receptors 
or intracellular actions that are still unknown could be contributing to the increased 
flux for gluconeogenesis and glycogen turnover in these cells.  
The concentration of RU486 (10 µM) may be too high to notice more finite 
differences between these treatments. Further work with lower concentrations of 
RU486 or other specific GR antagonists, including confirmation of changes in the 
gluconeogenic genes using western blots and PCR, is needed to elucidate the 
mechanism of this interaction between DOC and corticosterone.  
However, when hepatocytes were incubated with different glucose concentrations, 
with and without corticosterone and deoxycorticosterone, the differences in glycogen 
stores were measurable and significant only in the presence of insulin at higher 
glucose concentrations above 15 mM. The overall glycogen measures were low 
probably due to the lack of a fasting step and the inclusion of dexamethasone (10 nM) 
in all treatment conditions in the experiment. Literature suggests that fasting for 24 h 
prior to the treatments significantly enhances glycogen synthesis (Boyd et al., 1981).  
DOC is considered to have no effect on carbohydrate metabolism or on glycogen 
deposition in the livers of fasted adrenalectomised animals (Kendall, 1941; Ingle et 
al., 1945). However, others concluded that the difference in action on carbohydrate 
metabolism of these two corticosteroids is only in the time and rate at which they act, 
DOC acting more slowly (Montigel et al., 1943). It was also shown that DOC was 
capable of restoring the liver and muscle glycogen content to normal in 
adrenalectomised rats (Wang et al., 1949) confirming that in longer term experiments 
the differences between corticosterone and DOC are not marked. Large doses of 
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DOCA have been reported to have a glycogenic effect in adrenalectomised mice 
(Nissim, 1952). A later study to compare the different effects of corticosterone and 
DOC showed that in adrenalectomised rats both DOC and corticosterone restored the 
hexose phosphate levels to the levels of normal rats, with corticosterone being more 
potent (Conway et al., 1953). The differences observed in these studies are likely due 
to the differences in the metabolic state of the animal models, which could influence 
the effect of DOC on carbohydrate metabolism. 
There are no studies so far that describe the effect of DOC on glucose production 
using cultured hepatocytes. But there have been observations of an unknown 
mechanism or abnormalities in carbohydrate metabolism in animal studies with 
DOCA. A study investigating the metabolic changes in DOCA hypertensive rats 
showed that these animals had increased glycogen stores and hyperinsulinaemia but 
decreased blood glucose levels (Hernandez et al., 2000). However, DOCA treated 
Wistar rats had significant increases in blood glucose levels compared to control rats 
(Campion et al., 1998). The differences in these observations could be due to the 
strains of animals used and the fed and fasted states. So far, no explanation has been 
provided for these DOCA induced changes in blood glucose levels. 
DOC has recently been shown to be both a potent mineralocorticoid and 
glucocorticoid (Brookes et al., 2012). Previous studies have shown that DOC had no 
effect on a glucose tolerance test (Soffer et al; 1940), which was considered as 
indirect evidence of a lack of effect on insulin sensitivity (Vinson, 2011). In contrast, 
DOCA has also been shown to enhance insulin sensitivity (Cheng et al., 1949). In this 
study it was observed that DOC significantly increased the glycogen stores when used 
in combination with insulin compared to insulin alone at higher glucose 
concentrations or when compared to insulin with corticosterone. This suggests that 
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DOC is an insulin sensitiser. It has yet to be determined whether DOC improves 
glucose disposal in hepatocytes or in skeletal muscle in the in vivo models. The 
finding that DOC suppresses PEPCK activity, suggests a role similar to that of 
insulin. DOC suppression of PEPCK activity was not found when cells were fasted. 
Under these circumstances based on the cells energy needs there is increased 
gluconeogenesis and DOC may not be a potent suppressor to override the regulatory 
mechanisms in the fasted state. The increased hepatic glucose output in the fasted 
state when DOC is used in combination with corticosterone probably reflects 
increased glycogen turnover.  
There is increasing interest in the potential role of Ang II, mineralocorticoids 
(aldosterone and deoxycorticosterone) and the mineralocorticoid receptor (MR) in the 
pathogenesis of insulin resistance. High fat fed diabetic mice exhibiting phenotypic 
characteristics of the metabolic
 
syndrome, including insulin resistance, hypertension, 
dyslipidemia,
 
and fatty liver showed improved glucose and insulin tolerance tests 
when co-treated with spironolactone, a mineralocorticoid antagonist. Interestingly, 
PEPCK mRNA levels were suppressed by spironolactone suggesting a MR dependent 
signalling mechanism for regulation of gluconeogenic genes. These results indicate 
that inhibition
 
of mineralocorticoid receptor might be a beneficial therapeutic
 
approach for diet-induced phenotypes of metabolic syndrome and
 
fatty liver (Wada et 
al., 2010). In addition, aldosterone causes hyperglycaemia in fasted mice (Yamashita 
et al., 2004). Consistent with this, it is reported that in cultured mouse hepatocytes, 
aldosterone produced a concentration dependent increase in gluconeogenic enzymes 
such as G6Pase, PEPCK and F1,6Pase (Yamashita et al., 2004). However, because 
this response was blocked by RU486, the authors concluded that the effect of 
aldosterone was mediated via a GR dependent mechanism. 
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Interestingly, the liver specific analogue of RU486 (a bile acid conjugate), A-348441 
decreased hepatic glucose output in fasted dogs and fasted fa/fa rats. In freely feeding 
ob/ob mice chronic administration of very high doses of A-348441 reduced glucose 
levels without influencing the elevated insulin levels. This treatment had no effect on 
post-prandial glucose levels in ob/ob mice, suggesting that RU486 interferes with GR-
dependent regulation of gluconeogenesis only in the fasted state (Jacobson et al., 
2005). However, RU486 shows a poor degree of receptor selectivity being both a 
progesterone receptor and a glucocorticoid receptor antagonist at nM concentrations 
(Attardi et al., 2004). So, given this lack of receptor selectivity, RU486 could 
conceivably block the actions of corticosteroids mediated through other mechanisms 
not involving either GR or MR. 
These observations along with the results in this chapter suggest the interplay between 
glucocorticoids, mineralocorticoids and 11-deoxycorticosteroids in the regulation of 
hepatic glucose metabolism merits further investigation. A greater degree of 
understanding of the receptors and signalling pathways participating in these 
responses could identify new targets for regulating gluconeogenesis in T2DM.  
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Chapter 6 
General discussion 
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Regulating blood glucose concentrations within tightly controlled limits is very 
important for maintaining health. In this respect, the ability to increase or decrease 
gluconeogenesis is of fundamental importance. Although gluconeogenesis has been 
studied for around 80 years, many key regulatory mechanisms are only now being 
elucidated. 
Previous experiments leading to the current project showed that intravenous 
administration of corticotropin releasing factor or CRF family peptides such as 
sauvagine cause a marked hyperglycaemia (Barker & Corder, 1996; Brown et al., 
1982). This hyperglycaemia could be a glucocorticoid response due to ACTH release. 
However, CRF and sauvagine are equipotent stimulators of ACTH release through the 
pituitary CRF-R1 receptor. Yet sauvagine is at least two fold more potent in inducing 
the observed hyperglycaemia. Therefore it was considered more likely to be via a 
CRF-R2 receptor. 
Earlier attempts to characterise this hyperglycaemic response showed that it was 
adrenal-dependent (Kaminski, 2004). However, consistent with other in vivo studies 
of glucocorticoids, acute administration of large pharmacological doses of 
dexamethasone or corticosterone could not mimic this response. Interestingly, 
although adrenalectomy blocked the response, metyrapone augmented the 
hyperglycaemia. Others have also reported metyrapone to cause hyperglycemia in rats 
(Rotllant et al., 2002). These findings raise important questions about the role of 
known adrenal corticosteroids and indicate the existence of secondary pathways in 
adrenal steroidogenesis that result in corticosteroids with greater hyperglycaemic 
activity. 
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The goal of this project was to identify corticosteroids secreted by the adrenal gland 
responsible for the abnormal hyperglycaemia observed after treatment with sauvagine 
or metyrapone as these may play a role in T2DM and other diseases exhibiting 
hyperglycaemia or insulin resistance. 
6.1 PEPCK activity measurements 
PEPCK is reconsidered as a crucial rate-limiting enzyme in this process (Ballard et 
al., 1969). One of the main aims of this project was to screen cell culture media 
samples for potential novel gluconeogenic corticosteroids. In order to achieve this, a 
rapid and sensitive method to measure the effect of extracted fractions (HPLC and 
SPE) on hepatocyte PEPCK activity was required. 
Chapter 2 describes the optimisation of the PEPCK assay to achieve a reproducible 
method capable of measuring multiple samples in a comparative manner for 
gluconeogenic activity. The current methods available do not allow this flexibility and 
certainly cannot be used in a multi-well format. The cell lysis conditions were 
optimised to obtain reproducible protein quantities from each well without affecting 
PEPCK activity. The coupling of reaction 1 with reaction 2 required careful 
optimisation of the Mg
2+
 and Mn
2+
 concentrations as PEPCK required millimolar 
concentrations of Mg
2+
 and micromolar concentrations of Mn
2+
. The final reaction 
required optimisation of the dilution of reaction 2 sufficiently, so that the ATP levels 
generated in the reaction 2 fall within the linear range of reaction 3. Agents known to 
regulate PEPCK expression such as 8-Br-cAMP, and insulin were used to validate the 
reproducibility of the method. The method has been successfully used in this project 
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and in studies of the effect of endotoxin and fructose on hepatic regulation of PEPCK 
(Caton et al., 2009; Caton et al., 2010; Caton et al., 2011). 
6.2 Experimental conditions for regulation of gluconeogenesis. 
The ATP/ADP ratios, NAD/NADH ratios dictate which metabolic pathways are 
favoured. In the fasted state, there is increased expression of gluconeogenic enzymes 
including PEPCK (Vegiopoulos et al., 2007). Glycogen stores in the liver cell also 
contribute to glucose production. In the fed state, the total glucose produced over 6 h 
is a combination of both gluconeogenesis from substrates, and also from glycogen 
reserves. These conditions were found to be unsuitable to study the differences 
between the gluconeogenic potential of the various steroids (Chapter 3). However, 
when cells are fasted for 4 h, more glucose is produced by the cells in the presence of 
lactate/pyruvate. The glucose produced by the cells is mainly due to gluconeogenesis 
and these conditions can differentiate the effects of the various steroids.  
The levels of corticosterone in the metyrapone incubations were 40% lower compared 
to basal incubations. This is consistent with inhibition of 11-β hydroxylase. However, 
C18 Sep-pak extracts from adrenal incubations with sauvagine and metyrapone had a 
significantly greater effect on the total glucose productions despite lower 
corticosterone levels.  
6.3 Characterisation of the glucocorticoid potential of adrenal 
steroids. 
Chapter 4 showed that there are significant differences in the steroid extracts prepared 
from the incubation media from adrenal glands treated with sauvagine and 
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metyrapone compared to those incubated under basal conditions. Corticosterone 
levels measured by immunoassay in these extracts when diluted for incubation with 
hepatocytes were below 0.05 µM. Despite the low levels of corticosterone in extracts 
from adrenal incubations, these extracts had a stimulatory effect on total glucose 
production which was 3 times that produced by 1 µM corticosterone. This has not 
been previously observed under these cell culture conditions, but is consistent with 
observations that corticosterone on its own does not cause hyperglycaemia in vivo 
(Barker & Corder, 1996; Kaminski 2004). 
However, when these extracts were subjected to HPLC none of the fractions collected 
showed any significant biological activity. It is possible that there were not sufficient 
quantities of the isolated corticosteroid to have an effect on its own. But the 
observation that impure corticosterone containing small quantities of DOC, is more 
potent as an inducer of glucose production compared to purified corticosterone raised 
questions about the glucocorticoid potential of physiologically secreted 
corticosteroids. In particular, the possibility that gluconeogenesis is regulated by a 
combination of corticosteroids with different potencies exerted via a number of 
distinct mechanisms such that the secreted combination in a given metabolic state 
might cause a maximal response that is insulin resistant. 
It is therefore interesting to note that many of the in vivo studies of the effect of 
corticosterone or other steroids on carbohydrate metabolism have been done in fasted, 
adrenalectomised animals (McMahon et al., 1988). The effects observed under these 
experimental conditions do not actually tell us the true story, as they do not consider 
the possibility of complex interactions of the various steroids and other hormones. 
The actions of corticosteroids are often complexly related to the functions of other 
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hormones. The permissive actions of corticosterone has been widely remarked and 
observed (Ingle, 1961; Vinson, 2009). 
Basal levels of corticosterone/cortisol are necessary to allow the effects of other 
hormones that otherwise can go unnoticed. The results in this thesis show that extracts 
from adrenal incubations composed of a combination of steroids along with basal 
levels of corticosterone have a greater effect on hepatocyte glucose production 
compared to individual fractions or incubation with a high concentration of 
corticosterone alone. 
A detailed study of the synergistic effects of the adrenal steroids without classifying 
them as mineralocorticoids or glucocorticoids does not appear to have ever been 
undertaken. It seems likely that the many steroid products that are released into the 
blood from the adrenal gland have an important role, rather than just representing an 
overflow of unwanted steroids.  
6.4 The importance of glycogen regulation in HGP. 
Immunosuppressive doses of prednisolone significantly lower liver glycogen content 
in normal rats (Riegel et al., 1990), but increase liver glycogen in adrenalectomised  
and fasted rats (Lee et al., 1983). Administration of 0.1 or 1 mg of prednisolone to fed 
mice caused a 5-fold activation of glycogen synthase in the liver after 3 h, without 
significant changes in the circulating levels of glucose or insulin, or in the hepatic 
concentration of cyclic AMP. But this was not observed in adrenalectomised rats. 
However, cortisol (10 mg) increased hepatic liver glycogen synthase in 
adrenalectomised fasted mice (Vanstapel et al., 1982). 
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Although it has been known for some time that glucocorticoids increase endogenous 
glucose production, the exact mechanism is still not clear. Glucocorticoids regulate a 
large number of genes involved in hepatic carbohydrate metabolism (Vegiopoulos et 
al., 2007). However, it has been suggested that the diabetogenic effects of 
glucocorticoids were more pronounced in the fasted states of healthy individuals 
(Wajngot et al., 1992). Glucocorticoid induced hepatic glucose production is currently 
explained by at least five different mechanisms. First, glucocorticoids induce the 
expression of key regulatory enzymes like PEPCK and G6Pase (Jin et al., 2004; 
Vander Kooi et al., 2005). Second, long term exposure to glucocorticoids leads to 
break down of protein and fat, thus increasing alanine and glycerol as gluconeogenic 
substrates for the liver (Zimmerman et al., 1989). Thirdly, glucocorticoids facilitate 
metabolite transport across the mitochondrial membrane enhancing gluconeogenesis 
in the liver (McMahon et al., 1988). Fourth, glucocorticoids potentiate the effects of 
other glucoregulatory hormones like glucagon (Dirlewanger et al., 2000). Fifth, 
glucocorticoid induced increases in hepatic glucose production are dependent on 
PPAR-α expression. The list of mechanisms is increasing with more and more 
research on glucocorticoids being performed with fresh perspectives.  
It is now well established that 11-β HSD1 amplifies the glucocorticoid 
(cortisol/corticosterone) signal in the liver and adipose tissue. Selective inhibitors of 
11-β HSD1 improved insulin resistance and glucose tolerance in rodent models 
(Stimson et al., 2007). 11-β HSD1 knockout mice have reduced gluconeogenesis and 
glycogenolysis suggesting that local corticosterone levels play a very important role 
in hepatic glucose regulation (Kotelevtsev et al., 1997).  
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Starvation and stress causes increases in corticosterone levels (Johnstone et al., 2004). 
It is not entirely clear if these increases in corticosterone alone are responsible for the 
observed increases in glucose production as similar or even greater (10 µM) 
concentrations of purified corticosterone in vitro fail to achieve the same effect on 
hepatocytes. The sensitivity of different tissues or cell types to a given level of 
cortisol/corticosterone varies and the synergistic effect of 11-deoxycorticosteroids in 
fasted states could play an important role in this general observation in all 
laboratories. 
It was shown that cortisol regeneration significantly increases glycogen turnover in 
both healthy and T2DM subjects (Andrews et al., 2003; Walker et al., 1995). There is 
already substantial evidence of increased liver glycogen in patients with T2DM 
(Krssak et al., 2004). During fasting breakdown of glycogen reserves is expected with 
subsequent production of glucose by gluconeogenesis, as explained classically. 
However, some studies have surprised scientists with paradoxical results. In a study 
involving patients with T2DM, glycogen stores in the liver were assessed by 
measuring the increases in glucose responses to glucagon after a three-day fast (Clore 
et al., 1992). Measurements were taken after one day and three days of fasting. 
Results were compared to
 
those of lean and obese non-diabetic patients. In obese 
diabetic patients significantly greater glucose responses to glucagon were observed 
after a three day fast compared to lean and obese control subjects and also compared 
to the same subjects after a one day fast. This accumulation of glycogen during the 
fast in the
 
patients with T2DM occurred despite basal rates of hepatic
 
glucose output 
on the third day of the fast being greater than those
 
of obese non-diabetic subjects 
(Clore et al., 1992). It was later shown that hepatic glycogen content influences both 
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the absolute rate of endogenous glucose production and the percentage contribution of 
gluconeogenesis to total glucose production (Wise et al., 1997). 
Animal studies have also found similar surprising results relating to glycogen 
synthesis and storage. The rate of glycogen synthesis was higher in hepatocytes from 
fasted obese Zucker rats compared with hepatocytes from lean Zucker rats (McCune 
et al., 1981). In the Zucker rats, hepatic glycogen content was higher after a six day 
fast than that found in animals after a two day fast (Triscari et al., 1980). Glycogen 
synthesis in adrenalectomised animals seems to be different from normal. Liver 
sections from fasted normal rats showed limited dispersed glycogen synthase activity 
in both periportal and centrilobular regions. In contrast, activity for glycogen synthase 
in hepatocytes from fasted adrenalectomised rats appeared as large aggregates in 
random hepatocytes throughout the lobule (Michaels et al., 1993). 
The rate of glycogenolysis among T2DM patients is also controversial. It was 
reported to be reduced (Boden et al., 2001), unchanged (Gastaldelli et al., 2000), and 
increased (Basu et al., 2004). These controversies can only be attributed to differences 
in methods for assessing glycogenolysis and gluconeogenesis. The reason for an 
increased and preserved glycogen stores in humans and rats during a prolonged fast is 
completely unexplained. Increased glycogen synthesis by GS activation has been 
proposed (van de Werve, 1990). Increased gluconeogenesis was put forward as an 
alternative explanation (Clore et al., 1992), and other studies have indeed 
demonstrated active glycogen synthesis through gluconeogenic pathways (Jin et al., 
2007). The same group also showed that obese Zucker rats had higher fluxes of 
hepatic pyruvate cycling, PEPCK flux and TCA cycle compared to age-matched 
controls. 
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Figure 6.1 The metabolic control of G6P. 
Schematic representation of the G6P formed from gluconeogenic precursors and 
glycogen. The fate of G6P is determined by many regulatory pathways and the energy 
state of the cell. The key enzymes involved are in red. 
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Figure 6.2 An overview of the insulin signalling pathways and various ways of 
increasing glycogen and suppressing gluconeogenesis. 
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6.5 A new role for DOC in hepatic carbohydrate regulation.  
DOC is generally considered to be a weak mineralocorticoid. A recent review has 
clearly revealed the mislabelling of this steroid making it more of a universal steroid 
with both mineralocorticoid and glucocorticoid activities (Vinson, 2011).  
The studies described in this thesis bring a new perspective to the role of DOC on 
hepatic glycogen stores. Two major findings in the studies performed so far are that 
DOC suppresses the activity of gluconeogenic enzyme PEPCK in fed rat hepatocytes 
and enhances insulin stimulated glycogen stores in cultured hepatocytes at higher 
glucose concentrations over a 24 h period. The finding that DOC suppresses PEPCK 
is novel and brings a new perspective to the role of DOC in the control of 
gluconeogenesis (Figure 6.2). DOC has recently been shown to have the potential to 
bind the glucocorticoid receptor and has significant glucocorticoid activity by 
inducing liver glycogen deposition in adrenalectomised rats and also inducing TAT 
activity in hepatocytes (Brooks et al., 2011). Whether the binding of glucocorticoid 
receptor leads to increases in PEPCK or a gluconeogenic flux resulting in glycogen 
deposition is not clear. However, these two observations may not be related. 
Glucocorticoids such as corticosterone and dexamethasone increase hepatic 
gluconeogenic flux and subsequently regulate glycogen synthesis by increasing the 
G6P pool. DOC might act differently to this mechanism in activating the GS via the 
GSK3 phosphorylation and in turn cause a mass pull of the G6P resulting in diverting 
the gluconeogenic pathway and glucose phosphorylation into glycogen synthesis. It 
was previously shown that DOC induces phosphorylation of glycogen synthase kinase 
3 (GSK3) in the heart (Wyatt et al., 2006). Such effects have yet to be investigated in 
the liver. GSK3 is a protein kinase, which phosphorylates GS, thus inactivating it. 
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GSK3 is elevated in diabetic and obese mice (Eldar-Finkelman et al., 1999). 
Inhibition of GSK3 leads to increase in glycogen synthesis and increase in insulin 
sensitivity (Henriksen et al., 2006). More recent studies using knockout mice have 
shown that GSK3α regulates glycogen metabolism in the liver and not in the muscle 
(MacAulay et al., 2007). 
Whether DOC phosphorylates GSK3 in liver is yet to be determined. If one can prove 
the signalling pathway of DOC in hepatocytes, it could activate GS in similar fashion 
to insulin. This would then fit with our observation that DOC is insulin sensitizing in 
the fed state both by increasing glycogen levels and also by decreasing PEPCK levels. 
This effect is not observed in the fasted state, which suggests other mechanisms are 
able to override this effect in the fasted state. This is not surprising as there is an 
absolute requirement for extra cellular glucose. These observations highlight the need 
for a detailed investigation of the signalling pathways and regulatory actions of DOC 
on GK, GS and G6Pase and PEPCK. 
In the fasted H4-II-E-C3 cells, glycogen reserves have been depleted. Under these 
conditions the cells would be expected to have decreased cellular ATP levels, with 
metabolism geared towards glucose production (increased TCA cycle and PEPCK 
flux through mitochondrial enzymes). Treatment of cells under these metabolic 
conditions with corticosterone and DOC caused a significant increase in glucose 
release into the external media. This contrasted with observations from fed cells. It 
can be explained by an increase in the gluconeogenic flux both due to the cells energy 
state (ATP/ADP; NAD/NADH ratios) and increased GS activation due to the 
inactivation of GSK3 as a result of the phosphorylation induced by DOC. Under these 
conditions the increased GSK3 inactivation by DOC causes a pull of the 
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gluconeogenic flux through glycogen synthesis and eventual glycogenolysis and 
glucose release by the activation of G6Pase. 
6.6 A case for the role of DOC in insulin mediated hepatic glycogen 
regulation 
Insulin affects HGP directly by binding to the insulin receptor thus activating the 
insulin signalling pathways and suppressing gluconeogenic genes (Claus et al., 1976; 
Fisher et al., 2003), or indirectly by reducing glucagon secretion and decreasing 
lipolysis and proteolysis (Gupta et al., 2002) (Figure 6.3). Glycogen synthesis and 
breakdown seems to be very complex and varies in different energy states and also in 
culture (Figure 6.2). Not all glycogen made by the hepatocytes is made directly from 
the extracellular glucose (Bergman et al., 1982) and the presence of gluconeogenic 
substrates play a very important role in the indirect process of glyconeogenesis (Boyd 
et al., 1981; Parniak et al., 1985). The direct route is preferred in cells isolated from 
fed rats (Parniak et al., 1985), whereas, the indirect route dominates in cells from 
fasted rats (Spence et al., 1985). This raises a lot of questions about our interpretation 
of liver glycogen deposition and gluconeogenic ability of steroids in fasted ADX rats. 
It has to be noted that both these studies indicate that the carbon in glycogen 
assimilated via the indirect path way can be derived from the glucose which has been 
through the glycolysis pathway until the triose-phosphate level.  
Despite reduced insulin receptor content in certain knockout mice, a normal Akt 
phosphorylation is seen in the liver suggesting other compensatory mechanisms for 
insulin signalling pathway (Okamoto et al., 2005). DOC’s effect on hepatocytes 
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(hypothetic diagram Figure 6.1) could play an important role in insulin signalling 
pathways and is subject to further confirmatory studies.  
Fructose on the other hand is a potent stimulator of glycogen synthesis (Woods et al., 
1982) and enters the glycolytic/gluconeogenic pathways at the level of triose-
phosphate and its metabolite fructose-1-phosphate inhibits phosphorylase and 
activates GK promoting both the indirect and direct glycogen synthetic pathways 
(Youn et al., 1987). One wonders if glucocorticoids (such as dexamethasone) and 
other corticosteroids such as DOC enhance insulin’s ability to restore hepatic 
glycogen stores similar to fructose by affecting the GK and phosphorylase a activities, 
especially when hepatic glycogenolysis, but not gluconeogenesis is sensitive to acute 
changes in insulin and glucose (Edgerton et al., 2006).  
Amino acids markedly stimulate glycogen accumulation in hepatocytes, but this effect 
was not reversed when PEPCK was inhibited by mercaptopicolinic acid in 
hepatocytes prepared from fed rats (Okajima et al., 1979). Did these amino acids 
somehow increase the flux from glucose to glycogen? However, in fasted intact rats, 
the use of the same PEPCK inhibitor (mercaptopicolinic acid) virtually abolished 
hepatic glycogen accumulation (Sugden et al., 1983).  This shows the importance of 
gluconeogenic flux in the contribution to glycogen synthesis in the fasted state. As a 
homeostatic mechanism it seems logical for new glycogen molecules to be made after 
a fast before releasing glucose molecules from hepatocytes. This would work even 
better if there is simultaneous glycogenolysis and glyconeogenesis. This was in fact 
shown to happen both in vivo and in vitro (Barrett et al., 1988; Shulman et al., 1987). 
This would be an ideal scenario during fasting. This also means that glycogenolysis is 
a significant contributor to HGP. 
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6.7 The importance of the regulation of G6Pase in hepatic glucose 
regulation. 
Free glucose outside the liver indirectly leads to the activation of GS by a prior 
inactivation of phosphorylase. Over expression of GK in primary cultures greatly 
enhances glycogen accumulation and improves glucose utilisation and storage in 
culture hepatocytes in diabetic rats (O'Doherty et al., 1996; Seoane et al., 1999). 
Another confirmatory study showed that the G6P arising from gluconeogenesis is as 
effective as G6P produced by GK in activating GS (Gomis et al., 2003). This suggest 
that both gluconeogenesis and glucose uptake releases the G6P to the same pool. 
However, G6P from this pool can also be hydrolysed by G6Pase as shown in the 
studies where over expression of the gluconeogenic enzyme reduced glycogen 
deposition (Seoane et al., 1997). 
It is quite surprising that glucocorticoids increase hepatic glycogen levels in the fasted 
adrenalectomised rats also increase G6Pase expression. One can assume that the 
increased gluconeogenesis is diverted to glycogen synthesis before being released as 
glucose. It should be noted that the allosteric inhibition of GS by GP only works when 
the concentration of the G6P pool remains constant. An increase in this pool overrides 
the inhibition in the culture hepatocytes. GK has a high positive coefficient in 
glycogen deposition (Agius et al., 1996) and on the other hand G6Pase catalyses the 
reverse reaction of GK and has a high negative coefficient of glycogen deposition. In 
other words, hepatic glycogen deposits from glucose are under the control of activated 
GS, which is in turn controlled by GK, GK reactive protein (GKRP) and G6Pase.   
In (H6PDH) knockout mice models, glycogen storage is increased in the fed state 
reflecting increased flux of G6P through to glycogen (Lavery et al., 2007). These 
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knockout animals have less G6Pase compared to wild type controls despite the 
increased concentrations of G6P (substrate for G6Pase). On the other hand PEPCK 
levels are relatively the same in both groups.  It appears that the regulation of G6Pase 
in the fed and fasted states might be key in understanding hepatic carbohydrate 
metabolism in diseased states such as diabetes, as well as providing new insights into 
the metabolic effects of adrenal corticosteroids. 
6.8 Future work to characterise the role of GR and MR in 
gluconeogenesis. 
This project showed that corticosterone and DOC in combination resulted in a 
synergistic increase in glucose production. Future work needs to investigate in more 
detail the steroid ligands that are able to induce this synergistic interaction. This will 
enable an assessment as to whether it is a DOC-specific effect, define the relative 
importance of GR in this response, and confirm lack of importance of MR relative to 
other yet to be defined receptors. Initial experiments should define the minimum 
concentration of DOC required to potentiate the corticosterone-induced glucose 
responses of hepatocytes (H4-II-E-C3 and primary hepatocytes). This concentration 
of DOC should be evaluated in combination with dexamethasone to assess whether 
the response to a more selective GR ligand is also enhanced. Further studies should 
also be conducted to confirm that MR is not involved in this response by testing the 
combinations of aldosterone with dexamethasone, and aldosterone with 
corticosterone. 
In addition studies are required to define the minimal concentration of RU486 
required to block the actions of corticosterone and DOC, as this may enable greater 
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insights into whether additional receptors besides GR are involved in these responses. 
To complement these investigations gluconeogenic enzyme activities with protein 
levels should be determined with DOC and corticosterone combinations at different 
concentrations, with and without the minimum effective concentration of RU486 to 
block the corticosterone response. These experiments will give a greater insight into 
the exact mechanism of action of the increased glucose production observed in the 
fasted state due to DOC and corticosterone combinations. 
Experiments on hepatocytes in the fed state need to further investigate the inhibitory 
effect of DOC to get a complete picture of its role in hepatic carbohydrate 
metabolism. More experiments are required to establish the minimum concentration 
of corticosterone that causes a maximum increase in glucose output. Under these 
conditions a range of DOC concentrations should be investigated to study the 
inhibitory effect of DOC.  Measurement of mRNA levels for PEPCK, G6Pase and GS 
will help elucidate the mechanism underlying DOC inhibition of corticosterone-
induced glucose production.  
6.9 Conclusions 
Studies in this thesis indicate that insulin induced glycogen synthesis is potentiated 
when incubated along with DOC. Further evaluation of this effect should be done in 
in fed and fasted states with the inclusion of lactate and fructose to observe significant 
glycogen synthesis. Other studies have reported similar effects after DOCA 
administration to diabetic animals, which caused an improvement in glucose levels 
and a decrease in insulin levels (Dai et al., 1992). Future work should investigate 
whether DOC induces GSK3 phoshorylation and GS activation, as this would create a 
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metabolic torque at the G6P level. Such actions would support the hypothesis that 
DOC plays a crucial in glycogen uptake during re-feeding following a fast. 
We now know that DOC has glucocorticoid potential (Brookes et al., 2011) such that 
the detailed signalling and biochemical studies in both cultured hepatocytes and 
animal models warrant immediate attention. In addition, an investigation of DOC 
levels in patients with T2DM patients compared to controls is needed.  Further studies 
investigating the effect of various corticosteroids on GK, phosphorylase a, G6Pase 
and PEPCK will give us a better understanding of the regulatory mechanisms in place 
during fasting and re-feeding. 
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